Attorney Docket No. DYO-024WO PCT CAPSID VARIANTS AND METHODS OF USING THE SAME CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No.63/406,157, filed September 13, 2022, and U.S. Provisional Application No.63/483,197, filed February 3, 2023, each of which is hereby incorporated by reference in its entirety. REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on September 13, 2023, is named “DYO024WO_SeqList.XML” and is 156,790 bytes in size. BACKGROUND Dependoparvoviruses, e.g. adeno-associated dependoparvoviruses, e.g. adeno- associated viruses (AAVs), are of interest as vectors for delivering various payloads to cells, including in human subjects. SUMMARY The present disclosure provides, in part, improved variant dependoparvovirus capsid polypeptides (e.g. variants of AAV2), such as VP1, methods of producing a dependoparvovirus, compositions for use in the same, as well as viral particles comprising such capsid polypeptides. In some embodiments, the viral particles that comprise the capsid polypeptides have increased ocular transduction as compared to viral particles without the mutations in the capsid proteins. In some embodiments, the disclosure is directed, in part, to a nucleic acid comprising a sequence encoding a variant capsid protein as provided for herein. In some embodiments, the dependoparvovirus is an adeno-associated dependoparvovirus (AAV). In some embodiments, the AAV is an AAV2 variant. In some embodiments, the disclosure is directed, in part, to a capsid polypeptide described herein. In some embodiments, the disclosure is directed, in part, to a dependoparvovirus particle comprising a capsid polypeptides described herein. 1 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the disclosure is directed, in part, to a vector, e.g., a plasmid, comprising a nucleic acid described herein. In some embodiments, the disclosure is directed, in part, to a dependoparvovirus particle comprising a nucleic acid described herein (e.g., a nucleic acid comprising a sequence encoding a capsid polypeptide, such as VP1, wherein the encoding sequence comprises a change or mutation as provided herein. In some embodiments, the disclosure is directed, in part, to a dependoparvovirus particle comprising a variant capsid polypeptide described herein, for example, comprising a polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 46. In some embodiments, the disclosure is directed, in part, to a dependoparvovirus particle comprising a variant capsid polypeptide described herein, for example, comprising a polypeptide that is a VP1, VP2, or VP3 sequence of SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 46. In some embodiments, the capsid polypeptide comprises a mutation selected from a mutation associated with any of VAR-1 to VAR-13. In some embodiments, the capsid polypeptide comprises more than one, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of the mutations selected from a mutation associated with any of VAR-1 to VAR-13. In some embodiments, the capsid polypeptide comprises an amino acid sequence that is 95% or more amino acid sequence identity to an amino acid sequence of one of SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 46 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises an amino acid sequence that is less than 95% amino acid sequence identity to an amino acid sequence of one of SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 46, and has at least 80% of the mutations in one of SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 2 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 46 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises an amino acid sequence that is 95% or more amino acid sequence identity to an amino acid sequence of one of SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 46, and has less than 80% of the mutations in one of SEQ ID NO: 17, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 46 as compared to SEQ ID NO: 1. In some embodiments, the disclosure is directed, in part, to a nucleic acid molecule comprising SEQ ID NO: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 47, a fragment thereof, or a variant thereof having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity thereto. In some embodiments, the disclosure is directed, in part, to a vector comprising a nucleic acid described herein, e.g., a nucleic acid comprising a sequence encoding a capsid polypeptide, e.g. a VP1 polypeptide, wherein the encoding sequence comprises a change or mutation as provided for herein. In some embodiments, the disclosure is directed, in part, to a cell, cell-free system, or other translation system comprising a nucleic acid or vector described herein, e.g., comprising a sequence encoding capsid polypeptide, such as VP1, wherein the capsid polypeptide encoding sequence comprises a change or mutation as provided for herein in the encoding sequence. In some embodiments, the cell, cell-free system, or other translation system comprises a dependoparvovirus particle described herein, e.g., wherein the particle comprises a nucleic acid comprising a sequence encoding a capsid polypeptide, such as a VP1 polypeptide, wherein the encoding sequence comprises a change or mutation as provided for herein. In some embodiments, the disclosure is directed, in part, to a cell, cell-free system, or other translation system comprising a polypeptide described herein, wherein the polypeptide encoding sequence comprises a change or mutation as provided for herein. In some embodiments, the cell, cell-free system, or other translation system comprises a 3 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT dependoparvovirus particle described herein, e.g., wherein the particle comprises a nucleic acid comprising a sequence encoding a VP1 polypeptide, wherein the VP1 encoding sequence comprises a change or mutation corresponding such as provided for herein. In some embodiments, the disclosure is directed, in part, to a method of delivering a payload to a cell comprising contacting the cell with a dependoparvovirus particle comprising a nucleic acid described herein. In some embodiments, the disclosure is directed, in part, to a method of delivering a payload to a cell comprising contacting the cell with a dependoparvovirus particle comprising a capsid polypeptide described herein. In some embodiments, the disclosure is directed, in part, to a method of making a dependoparvovirus particle, comprising providing a cell, cell-free system, or other translation system, comprising a nucleic acid described herein (e.g., a nucleic acid comprising a sequence encoding an AAV2 capsid variant as provided for herein); and cultivating the cell, cell-free system, or other translation system, under conditions suitable for the production of the dependoparvovirus particle, thereby making the dependoparvovirus particle. In some embodiments, the disclosure is directed, in part, to a method of making a dependoparvovirus particle described herein. In some embodiments, the disclosure is directed, in part, to a method of making a dependoparvovirus particle, comprising providing a cell, cell-free system, or other translation system, comprising a polypeptide described herein; and cultivating the cell, cell-free system, or other translation system, under conditions suitable for the production of the dependoparvovirus particle, thereby making the dependoparvovirus particle. In some embodiments, the disclosure is directed, in part, to a method of making a dependoparvovirus particle described herein. In some embodiments, the disclosure is directed, in part, to a dependoparvovirus particle made in a cell, cell-free system, or other translation system, wherein the cell, cell-free system, or other translation system comprises a nucleic acid encoding a dependoparvovirus comprising a capsid variant as provided for herein. In some embodiments, the disclosure is directed, in part, to a method of treating a disease or condition in a subject, comprising administering to the subject a dependoparvovirus particle described herein in an amount effective to treat the disease or condition. The invention is further described with reference to the following numbered embodiments. 4 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT BRIEF DESCRIPTION OF THE DRAWINGS FIG.1. Diagram of tissues collected in each region of the eye. In the retina (left and center figures), peripheral and central retina samples from each of the superior, nasal, inferior and temporal regions of the retina were separately collected, macula was also separately collected. In each region, neural retina and choroid/RPE layers (center figure) were separately collected. In the trabecular meshwork/Schlemm’s canal (TM/SC) region (right figure), superior, temporal, nasal and inferior samples were separately collected. FIG.2A - 2C. Multisequence alignment of representative reference capsid VP1 polypeptides. Such alignment can be used to determine the amino acid positions which correspond to positions within different reference capsid polypeptides. FIG.3A – 3E. Single nuclear RNA sequencing results for AAV2 wild-type (FIG.3A) and VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-8, VAR-10, VAR-11, and VAR-12 (FIG.3B-3E) from eye tissue samples from intravitreal (“IVT”) administration of the medium throughput study (Example 3), reporting number of unique transduction events for each of AAV2 wild-type and VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-8, VAR-10, VAR-11, and VAR-12, respectively. All results are normalized to the amount of each variant in the input test article. FIG.4A – 4E. Single nuclear RNA sequencing results for AAV2 wild-type (FIG.4A) and VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-8, VAR-10, VAR-11, VAR-12 and VAR-13 (FIG.4B-4E) from retina tissue samples from intravitreal (“IVT”) administration of the medium throughput study (Example 3), reporting the number of unique transduction events for each of AAV2 wildtype and VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-8, VAR-9, VAR-10, VAR-11, VAR-12 and VAR-13, respectively. All results are normalized to the amount of vector genome (vg) in the input test article. Results indicate zero transduction of VAR-9 for any of the listed cell types (not shown). FIG.5A-5D. Single nuclear RNA sequencing results for VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-8, VAR-10, VAR-11, VAR-12 and VAR-13 from macula tissue samples from intravitreal (“IVT”) administration of the medium throughput study (Example 3), reporting the number of unique transduction events for each of the variants. All results are normalized to the amount of vector genome (vg) in the input test article. Results indicate zero transduction of AAV-2 wild-type and VAR-9 for any of the listed cell types (not shown). 5 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT FIG.6A-6B. Single nuclear RNA sequencing results for VAR-1, VAR-2, VAR-6, VAR-7, and VAR-11 from trabecular meshwork tissue samples from intravitreal (“IVT”) administration of the medium throughput study (Example 3), reporting the number of unique transduction events for each of the variants. All results are normalized to the amount of vector genome (vg) in the input test article. Results indicate zero transduction of AAV-2 wild-type, VAR-3, VAR-5, VAR-8, VAR-9, VAR-10, VAR-12 and VAR-13 for any of the listed cell types (not shown). FIG.7. Neural retina transduction and biodistribution from retina tissue samples from intravitreal (“IVT”) administration of the medium throughput study (Example 3) for VAR-1, VAR-3, VAR-5, and VAR-13. ENUMERATED EMBODIMENTS 1. A variant capsid polypeptide comprising a polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 46. 2. The variant capsid polypeptide of embodiment 1, wherein the polypeptide comprises: a mutation selected from a mutation associated with any of VAR-1 to VAR- 13. 3. The variant capsid polypeptide of embodiment 2, wherein: the mutation associated with any of VAR-1 to VAR-13 comprises mutations at positions corresponding to residues 551-597 as compared to SEQ ID NO: 1. 4. The variant capsid polypeptide of any one of the preceding embodiments, wherein the polypeptide comprises a sequence having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identity to SEQ ID NO: 1 and comprises a mutation selected from a mutation associated with any of VAR-1 to VAR-13. 5. The variant capsid polypeptide of any one of the preceding embodiments, wherein the polypeptide comprises a sequence having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identity to SEQ ID NO: 1 and wherein the variant capsid polypeptide comprises a mutation that corresponds to a mutation at position 551, 575, 584, 586, 587, 589, 591, or 597, or any combination thereof, an insertion between positions 584 and 585, 586 and 587, or 587 and 6 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 588, or any combination thereof according to SEQ ID NO: 1, optionally wherein the mutation comprises an insertion, a deletion or a substitution. 6. The variant capsid polypeptide of any one of the preceding embodiments, wherein the polypeptide comprises an insertion between positions 584 and 585, 586 and 587, or 587 and 588 or any combination thereof, according to SEQ ID NO: 1. 7. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 551, 586 (e.g., an insertion of one or more amino acids after position 586), 587, 589, and 597 as compared to SEQ ID NO: 1. 8. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 584 (e.g., an insertion of one or more amino acids after position 584), 586, and 587 as compared to SEQ ID NO: 1. 9. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 586 (e.g., an insertion of one or more amino acids after position 586) and 587 as compared to SEQ ID NO: 1. 10. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 586 (e.g., an insertion of one or more amino acids after position 586), 587, and 597 as compared to SEQ ID NO: 1. 11. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 575, 586 (e.g., an insertion of one or more amino acids after position 586), and 587 as compared to SEQ ID NO: 1. 12. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 584 (e.g., an insertion of one or more amino acids after position 584) and 587 as compared to SEQ ID NO: 1. 13. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587 (e.g., an insertion of one or more amino acids after position 587) as compared to SEQ ID NO: 1. 7 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 14. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587 (e.g., an insertion of one or more amino acids after position 587) and 591 as compared to SEQ ID NO: 1. 15. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises an insertion, e.g., an insertion of 1 or more amino acids, e.g., 1 amino acid, e.g., 1-2 amino acids, that corresponds to an insertion between positions 584 and 585, 586 and 587, or 587 and 588, as compared to SEQ ID NO: 1. 16. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N551, N587A, Q589A, and T597N, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of LAKGETMRP (SEQ ID NO: 36), or a fragment of at least 4, at least 5, at least 6, at least 7, or at least 8 amino acids thereof. 17. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of G586P and N587A, and an insertion between positions 584 and 585 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of RARLDETA (SEQ ID NO: 37) or a fragment of at least 4, at least 5, at least 6, or at least 7 amino acids thereof. 18. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of LAKGETMRP (SEQ ID NO: 36), or a fragment of at least 4, at least 5, at least 6, at least 7, or at least 8 amino acids thereof. 19. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A and T597W, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of GVRAETTRP (SEQ ID NO: 38) or a fragment of at least 4, at least 5, at least 6, at least 7, or at least 8 amino acids thereof. 20. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A and T597N, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of GVRAETTRP (SEQ ID NO: 38) or a fragment of at least 4, at least 5, at least 6, at least 7, or at least 8 amino acids thereof. 8 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 21. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of ANLAIEQTRP (SEQ ID NO: 39) or a fragment of at least 5, at least 6, at least 7, at least 8, or at least 9 amino acids thereof. 22. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of PNLALGATARP (SEQ ID NO: 40) or a fragment of at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acids thereof. 23. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of Q575S and N587A, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of QNLALGNTTRQ (SEQ ID NO: 41) or a fragment of at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acids thereof. 24. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A, and an insertion between positions 584 and 585 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of RASNDT (SEQ ID NO: 42) or a fragment of at least 3, at least 4, or at least 5 amino acids thereof. 25. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A and T597L, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of INMAKGETARP (SEQ ID NO: 43) or a fragment of at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acids thereof. 26. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises an insertion between positions 587 and 588 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of LNISPQTKPA (SEQ ID NO: 44) or a fragment of at least 5, at least 6, at least 7, at least 8, or at least 9, amino acids thereof. 27. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of A591I, and an insertion between positions 587 and 588 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of 9 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT RQAGETARPA (SEQ ID NO: 45) or a fragment of at least 5, at least 6, at least 7, at least 8, or at least 9 amino acids thereof. 28. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises a mutation of N587A, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises a polypeptide of GVRAETTRP (SEQ ID NO: 38) or a fragment of at least 4, at least 5, at least 6, at least 7, or at least 8 amino acids thereof. 29. A variant capsid polypeptide, comprising (a) a polypeptide of any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 46, (b) the VP2 or VP3 sequence of any one of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 46, (c) a polypeptide comprising a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto, wherein said sequence comprises at least one (e.g., one, two, three or more, e.g., all) of the mutation differences associated with any of SEQ ID NO: 12 through SEQ ID NO: 23 and SEQ ID NO: 46, relative to SEQ ID NO: 1; or (d) a polypeptide having at least 1, but no more than 20, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 3, or no more than 2 amino acid mutations relative to the polypeptide of (a) or (b), wherein said polypeptide comprises at least one (e.g., one, two, three or more, e.g., all) of the mutation differences associated with any of SEQ ID NO: 12 through SEQ ID NO: 23 and SEQ ID NO: 46, relative to SEQ ID NO: 1. 30. The variant capsid polypeptide of any one of the preceding embodiments, wherein the variant capsid polypeptide is a VP1 polypeptide, a VP2 polypeptide or a VP3 polypeptide. 31. A variant capsid polypeptide comprising: an amino acid sequence that has 95% or more amino acid sequence identity to an amino acid sequence of one of SEQ ID NOs: 12-23 and 46, and has at least 80% of the mutations in the amino acid sequence of one of SEQ ID NOs: 12-23 and 46 as compared to SEQ ID NO: 1. 32. A variant capsid polypeptide comprising: 10 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of one of SEQ ID NOs: 12-23 and 46, and has at least 80% of the mutations in the amino acid sequence of one of SEQ ID NOs: 12-23 and 46 as compared to SEQ ID NO: 1. 33. A variant capsid polypeptide comprising: an amino acid sequence that has 95% or more amino acid sequence identity to an amino acid sequence of one of SEQ ID NOs: 12-23 and 46, and has less than 80% of the mutations in the amino acid sequence of one of SEQ ID NOs: 12-23 and 46 as compared to SEQ ID NO: 1. 34. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-1 (e.g., comprises all of N551H, N587A, Q589A, T597N, and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 35. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more (e.g., all) of the mutation differences associated with VAR-1 (e.g., comprises all of N551H, N587A, Q589A, T597N, and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 36. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-1 (e.g., comprises all of N551H, N587A, Q589A, T597N, and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 37. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 11 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). 38. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 39. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 40. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-3 (e.g., comprises all of N587A and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 41. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more (e.g., all) of the mutation differences associated with VAR-3 (e.g., comprises all of N587A and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 12 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 42. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-3 (e.g., comprises all of N587A and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 43. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-4 (e.g., comprises all of N587A, T597W, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 44. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more (e.g., all) of the mutation differences associated with VAR-4 (e.g., comprises all of N587A, T597W, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 45. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-4 (e.g., comprises all of N587A, T597W, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 46. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 13 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-5 (e.g., comprises all of N587A, T597N, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 47. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-5 (e.g., comprises all of N587A, T597N, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 48. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-5 (e.g., comprises all of N587A, T597N, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 49. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1, with all numbering according to SEQ ID NO: 1). 50. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 14 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 51. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 52. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-7 (e.g., comprises all of N587A and an insertion of PNLALGATARPP (SEQ ID NO: 40) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 53. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-7 (e.g., comprises all of N587A and an insertion of PNLALGATARPP (SEQ ID NO: 40) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 54. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-7 (e.g., comprises all of N587A and an insertion of PNLALGATARPP (SEQ ID NO: 40) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 55. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-8 (e.g., comprises all of Q575S, 15 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT N587A, and an insertion of QNLALGNTTRQ (SEQ ID NO: 41) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 56. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-8 (e.g., comprises all of Q575S, N587A, and an insertion of QNLALGNTTRQ (SEQ ID NO: 41) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 57. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-8 (e.g., comprises all of Q575S, N587A, and an insertion of QNLALGNTTRQ (SEQ ID NO: 41) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 58. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-9 (e.g., comprises all of N587A and an insertion of RASNDT (SEQ ID NO: 42) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). 59. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-9 (e.g., comprises all of N587A and an insertion of RASNDT (SEQ ID NO: 42) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 60. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-9 (e.g., comprises all of N587A and an insertion of RASNDT (SEQ ID NO: 42) between position 584 and position 585, with all numbering according to SEQ ID 16 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 61. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-10 (e.g., comprises all of N587A, T597L, and an insertion of INMAKGETARP (SEQ ID NO: 43) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 62. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-10 (e.g., comprises all of N587A, T597L, and an insertion of INMAKGETARP (SEQ ID NO: 43) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 63. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-10 (e.g., comprises all of N587A, T597L, and an insertion of INMAKGETARP (SEQ ID NO: 43) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 64. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-11 (e.g., comprises an insertion of LNISPQTKPA (SEQ ID NO: 44) between position 587 and position 588, with all numbering according to SEQ ID NO: 1). 17 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 65. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-11 (e.g., comprises an insertion of LNISPQTKPA (SEQ ID NO: 44) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 66. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-11 (e.g., comprises an insertion of LNISPQTKPA (SEQ ID NO: 44) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 67. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-12 (e.g., comprises all of A591I and an insertion of RQAGETARPA (SEQ ID NO: 45) between position 587 and position 588, with all numbering according to SEQ ID NO: 1). 68. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more (e.g., all) of the mutation differences associated with VAR-12 (e.g., comprises all of A591I and an insertion of RQAGETARPA (SEQ ID NO: 45) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 69. The variant capsid polypeptide of any one of the preceding embodiments, wherein one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-12 (e.g., comprises all of A591I and an insertion of RQAGETARPA (SEQ ID NO: 45) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other 18 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 70. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-13 (e.g., comprises all of N587A and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). 71. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more (e.g., all) of the mutation differences associated with VAR-13 (e.g., comprises all of N587A and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 72. The variant capsid polypeptide of any one of the preceding embodiments, wherein the capsid polypeptide comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-13 (e.g., comprises all of N587A and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 73. A nucleic acid molecule comprising a sequence encoding a variant capsid polypeptide of any one of embodiments 1-72. 74. The nucleic acid molecule of embodiment 73, comprising one or more regulatory elements operably linked to the sequence encoding the variant capsid polypeptide. 75. The nucleic acid molecule of any one of embodiments 73-74, comprising SEQ ID NO: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 47, or a fragment thereof, or a variant thereof having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity thereto. 19 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 76. The nucleic acid molecule of any one of embodiments 73-75, wherein the nucleic acid molecule comprises a sequence encoding the VP1, VP2 or VP3 polypeptide of any one of SEQ ID NOs: 12-23 and 46. 77. A virus particle (e.g., adeno-associated virus (“AAV”) particle) comprising the variant capsid polypeptide of any one of embodiments 1-72 or comprising a variant capsid polypeptide encoded by the nucleic acid molecule of any one of embodiments 73-76. 78. The virus particle of embodiment 77, comprising a nucleic acid comprising a heterologous transgene and one or more regulatory elements. 79. A virus particle of any of embodiments 77-78 comprising the variant capsid polypeptide of any one of embodiments 1-72, wherein said virus particle, or a virus particle comprising said variant capsid polypeptide or a virus particle comprising a variant capsid polypeptide encoded by a nucleic acid molecule of any one of embodiments 73-76 exhibits increased ocular transduction, e.g., as measured in a mouse or in NHP, e.g., as described herein, relative to wild-type AAV2 (e.g., a virus particle comprising capsid polypeptides of SEQ ID NO: 1 or encoded by SEQ ID NO: 2). 80. The nucleic acid molecule of any one of embodiments 73-76 or virus particle of any one of embodiments 77-79 wherein the nucleic acid molecule is double-stranded or single- stranded, optionally wherein the nucleic acid molecule is linear or circular, e.g., wherein the nucleic acid molecule is a plasmid. 81. A method of producing a virus particle comprising a variant AAV2 capsid polypeptide, said method comprising introducing a nucleic acid molecule of any one of embodiments 73-76 or 80 into a cell (e.g., a HEK293 cell), and harvesting said virus particle therefrom. 82. A method of delivering a payload (e.g., a nucleic acid) to a cell comprising contacting the cell with a dependoparvovirus particle comprising a variant capsid polypeptide of any one of embodiments 1-72 or the virus particle of any of embodiments 77-79 and a payload. 83. The method of embodiment 82, wherein the cell is an ocular cell. 84. The method of embodiment 83, wherein the ocular cell is in the retina, the macula, or the trabecular meshwork. 85. A method of delivering a payload (e.g., a nucleic acid) to a subject comprising administering to the subject a dependoparvovirus particle comprising a variant capsid polypeptide of any one of embodiments 1-72 and the payload, or administering to the subject the virus particle of any one of embodiments 77-79. 20 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 86. The method of embodiment 85, wherein the particle delivers the payload to the eye. 87. The method of embodiment 86, wherein the particle delivers the payload to the retina, the macular, or the trabecular meshwork. 88. The method of any one of embodiments 85-87, wherein the particle delivers the payload to the eye with increased transduction in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1. 89. The method of embodiment 88, wherein the one or more regions of the eye is selected from the retina, the macula, the trabecular meshwork, or any combination thereof. 90. The method of embodiment 89, wherein the retina comprises non-macular retina. 91. The variant capsid polypeptide of any of embodiments 1-72, the virus particle of any of embodiments 77-79 or the method of any one of embodiments 81-90, wherein the particle (e.g., particle comprising the variant capsid polypeptide) delivers the payload to the eye with increased transduction in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is at least 1.5-times, 2-times, 4-times, 6-times, 8-times, 10-times, 15-times, 16-times, 19-times, 30-times, 60-times, 80-times, 100-times, 200-times, 300-times, or 400-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1. 92. The variant capsid polypeptide of any of embodiments 1-72, the virus particle of any of embodiments 77-79 or the method of any one of embodiments 81-90, wherein the particle (e.g., particle comprising the variant capsid polypeptide) delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in transduction is at least 1.5-times, 2-times, 4-times, 8-times, 16-times, or 19-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is specific to macular tissue relative to non-macular retina tissue. 93. The variant capsid polypeptide of any of embodiments 1-72, the virus particle of any of embodiments 77-79 or the method of any one of embodiments 81-90, wherein the particle (e.g., particle comprising the variant capsid polypeptide) delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in transduction is at least 1.5-times, 2-times, 4-times, 8-times, 16-times, or 19-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein 21 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT the increase in transduction is specific to macular tissue relative to trabecular meshwork tissue. 94. The variant capsid polypeptide of any of embodiments 1-72, the virus particle of any of embodiments 77-79 or the method of any one of embodiments 81-90, wherein the particle (e.g., particle comprising the variant capsid polypeptide) delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in transduction is at least 1.5-times, 2-times, 4-times, 8-times, or 15-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is specific to non-macular retina tissue relative to trabecular meshwork tissue. 95. The variant capsid polypeptide of any of embodiments 1-72, the virus particle of any of embodiments 77-79 or the method of any one of embodiments 81-90, wherein the particle (e.g., particle comprising the variant capsid polypeptide) delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in transduction is at least 1.5-times, 2-times, 4-times, 8-times, 15-times, or 19-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is specific to macular tissue and non-macular retina tissue relative to trabecular meshwork tissue. 96. The variant capsid polypeptide of any of embodiments 1-72, the virus particle of any of embodiments 77-79 or the method of any one of embodiments 81-90, wherein the particle (e.g., particle comprising the variant capsid polypeptide) delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1 without increased biodistribution in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1. 97. The method of any one of embodiments 82-90, wherein the administration to the subject is via an intravitreal injection, or an intracameral injection. 98. A method of treating a disease or condition in a subject, comprising administering to the subject a dependoparvovirus particle in an amount effective to treat the disease or condition, wherein the dependoparvovirus particle is a particle comprising a capsid polypeptide of any one of embodiments 1-72 and 91-96, or encoded by the nucleic acid of any one of embodiments 73-76 or 80, or is a virus particle of any one of embodiments 77-79. 22 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 99. A cell, cell-free system, or other translation system, comprising the capsid polypeptide, nucleic acid molecule, or virus particle of any one of embodiments 1-80 or 91-96. 100. A method of making a dependoparvovirus (e.g., an adeno-associated dependoparvovirus (AAV) particle, comprising: providing a cell, cell-free system, or other translation system, comprising a nucleic acid of any of embodiments 73-76 or 80; and cultivating the cell, cell-free system, or other translation system, under conditions suitable for the production of the dependoparvovirus particle, thereby making the dependoparvovirus particle. 101. The method of embodiment 100, wherein the cell, cell-free system, or other translation system comprises a second nucleic acid molecule and said second nucleic acid molecule is packaged in the dependoparvovirus particle. 102. The method of embodiment 101, wherein the second nucleic acid comprises a payload, e.g., a heterologous nucleic acid sequence encoding a therapeutic product. 103. The method of any one of embodiments 100-102, wherein the nucleic acid of any of embodiments 73-76 or 80 mediates the production of a dependoparvovirus particle which does not include said nucleic acid of any of embodiments 73-76 or 80. 104. The method of any one of embodiments 100-102, wherein the nucleic acid of any of embodiments 73-76 or 80 mediates the production of a dependoparvovirus particle at a level at least 10%, at least 20%, at least 50%, at least 100%, at least 200% or greater than the production level mediated by the nucleic acid of SEQ ID NO: 2. 105. A composition, e.g., a pharmaceutical composition, comprising a virus particle of any one of embodiments 77-79 or a virus particle produced by the method of any one of embodiments 81 or 100-104, and a pharmaceutically acceptable carrier. 106. The variant capsid polypeptide of any of embodiments 1-72 and 91-96, the nucleic acid molecule of any of embodiments 73-76 or 80, or the virus particle of any of embodiments 77- 79 for use in treating a disease or condition in a subject. 107. The variant capsid polypeptide of any of embodiments 1-72 and 91-96, the nucleic acid molecule of any of embodiments 73-76 or 80, or the virus particle of any of embodiments 77- 79 for use in the manufacture of a medicament for use in treating a disease or condition in a subject. DETAILED DESCRIPTION 23 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT The present disclosure is directed, in part, to the capsid polypeptides and dependoparvovirus particles comprising the same. In some embodiments, the dependoparvovirus particles have increased ocular transduction and can be used to deliver a transgene or molecule of interest to an eye with higher transduction efficiency in the eye as compared to a dependoparvovirus particle without the variant capsid polypeptides. Accordingly, provided herein are capsid polypeptides, nucleic acid molecules encoding the same, viral particles comprising the variant capsid polypeptides, and methods of making and using the same. Definitions A, An, The: As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. About, Approximately: As used herein, the terms “about” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 15 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values. Dependoparvovirus capsid: As used herein, the term “dependoparvovirus capsid” refers to an assembled viral capsid comprising dependoparvovirus polypeptides. In some embodiments, a dependoparvovirus capsid is a functional dependoparvovirus capsid, e.g., is fully folded and/or assembled, is competent to infect a target cell, or remains stable (e.g., folded/assembled and/or competent to infect a target cell) for at least a threshold time. Dependoparvovirus particle: As used herein, the term “dependoparvovirus particle” refers to an assembled viral capsid comprising dependoparvovirus polypeptides and a packaged nucleic acid, e.g., comprising a payload, one or more components of a dependoparvovirus genome (e.g., a whole dependoparvovirus genome), or both. In some embodiments, a dependoparvovirus particle is a functional dependoparvovirus particle, e.g., comprises a desired payload, is fully folded and/or assembled, is competent to infect a target cell, or remains stable (e.g., folded/assembled and/or competent to infect a target cell) for at least a threshold time. Dependoparvovirus X particle/capsid: As used herein, the term “dependoparvovirus X particle/capsid” refers to a dependoparvovirus particle/capsid comprising at least one polypeptide or polypeptide encoding nucleic acid sequence derived from a naturally occurring dependoparvovirus X species. For example, a dependoparvovirus B particle refers 24 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT to a dependoparvovirus particle comprising at least one polypeptide or polypeptide encoding nucleic acid sequence derived from a naturally occurring dependoparvovirus B sequence. Derived from, as used in this context, means having at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the sequence in question. Correspondingly, an AAVX particle/capsid, as used herein, refers to an AAV particle/capsid comprising at least one polypeptide or polypeptide encoding nucleic acid sequence derived from a naturally occurring AAV X serotype. For example, an AAV2 particle refers to an AAV particle comprising at least one polypeptide or polypeptide encoding nucleic acid sequence derived from a naturally occurring AAV2 sequence. Exogenous: As used herein, the term “exogenous” refers to a feature, sequence, or component present in a circumstance (e.g., in a nucleic acid, polypeptide, or cell) that does not naturally occur in said circumstance. For example, a nucleic acid sequence comprising a mutant capsid polypeptide or a nucleic acid molecule encoding the same may comprise a capsid polypeptide. Use of the term exogenous in this fashion means that the polypeptide or the nucleic acid molecule encoding a polypeptide comprising the mutation in question at this position does not occur naturally, e.g., is not present in AAV2, e.g., is not present in SEQ ID NO: 1. Functional: As used herein in reference to a polypeptide component of a dependoparvovirus capsid (e.g., Cap (e.g., VP1, VP2, and/or VP3) or Rep), the term “functional” refers to a polypeptide which provides at least 50, 60, 70, 80, 90, or 100% of the activity of a naturally occurring version of that polypeptide component (e.g., when present in a host cell). For example, a functional VP1 polypeptide may stably fold and assemble into a dependoparvovirus capsid (e.g., that is competent for packaging and/or secretion). As used herein in reference to a dependoparvovirus capsid or particle, “functional” refers to a capsid or particle comprising one or more of the following production characteristics: comprises a desired payload, is fully folded and/or assembled, is competent to infect a target cell, or remains stable (e.g., folded/assembled and/or competent to infect a target cell) for at least a threshold time. Nucleic acid: As used herein, in its broadest sense, the term “nucleic acid” refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, in some embodiments, "nucleic acid" refers to an individual nucleic acid 25 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT monomer (e.g., a nucleotide and/or nucleoside); in some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising individual nucleic acid monomers or a longer polynucleotide chain comprising many individual nucleic acid monomers. In some embodiments, a "nucleic acid" is or comprises RNA; in some embodiments, a "nucleic acid" is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid is, comprises, or consists of one or more modified, synthetic, or non-naturally occurring nucleotides. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a nucleic acid is, comprises, or consists of one or more "peptide nucleic acids", which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention. Alternatively or additionally, in some embodiments, a nucleic acid has one or more phosphorothioate and/or 5'-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a nucleic acid is partly or wholly single stranded; in some embodiments, a nucleic acid is partly or wholly double stranded. Variant: As used herein, a "variant capsid polypeptide" refers to a polypeptide that differs from a reference sequence (e.g. SEQ ID NO: 1). The variant can, for example, comprise a mutation (e.g. substitution, deletion, or insertion). In some embodiments, the variant is about, or at least, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%., 97%, 98%, or 99% identical to the reference sequence. In some embodiments, the reference sequence is a polypeptide comprising SEQ ID NO: 1. Capsid Polypeptides and Nucleic Acids Encoding the Same The disclosure is directed, in part, to capsid polypeptides comprising a mutation (insertion, deletion, or substitution) as compared to the wild-type sequence, viral particles comprising variant capsid polypeptides, such as those described here, nucleic acid molecules, and nucleic acid molecules encoding capsid polypeptides such as those described herein. In some embodiments, the wild-type sequence is SEQ ID NO: 1. The disclosure is directed, in part, to variant capsid polypeptides comprising SEQ ID NO: 1 with one or more mutations as compared to SEQ ID NO: 1. The mutation can be, for example, an insertion, deletion, or 26 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT substitution as compared to the wild-type sequence. In some embodiments, the wild-type sequence is SEQ ID NO: 1. The disclosure is directed, in part, to a variant capsid polypeptide comprising any one of SEQ ID NO: 12 to SEQ ID NO: 23 or SEQ ID NO: 46. The disclosure is directed, in part, to a variant capsid polypeptide comprising a VP1 sequence of any one of SEQ ID NO: 12 to SEQ ID NO: 23. The disclosure is directed, in part, to a variant capsid polypeptide comprising a VP2 sequence of any one of SEQ ID NO: 12 to SEQ ID NO: 23. The disclosure is directed, in part, to a variant capsid polypeptide comprising a VP3 sequence of any one of SEQ ID NO: 12 to SEQ ID NO: 23. In some embodiments, the capsid polypeptide comprises a mutation selected from the mutation differences disclosed in any of Tables 1A-1F, e.g., selected from the mutation differences associated with any variant disclosed in any of Tables 1A-1F. In some embodiments, the mutation differences disclosed in any of Tables 1A-1F, e.g., selected from the mutation differences associated with any variant disclosed in any of Tables 1A-1F comprises mutations at positions corresponding to residues 551-597 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation within the 551- 597 amino acid region of SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation selected from the mutation differences disclosed in any of Tables 1A- 1F, e.g., selected from the mutation differences associated with any variant disclosed in any of Tables 1A-1F. In some embodiments, the mutation selected from the mutation differences disclosed in any of Tables 1A-1F, e.g., selected from the mutation differences associated with any variant disclosed in any of Tables 1A-1F is a substitution, e.g., a substitution of at least 2 or more residues, e.g., at least 2-17 residues, e.g., at least 5-17 residues, e.g., at least 6-17 residues, e.g., at least 7-17 residues, e.g., at least 8-17 residues, e.g., at least 10-17 residues, e.g., at least 11-17 residues, e.g., at least 13-17 residues, e.g., at least 14-17 residues, e.g., at least 15-17 residues, e.g., at least 17 residues that correspond to a substitution at positions between 551 and 597 as compared to SEQ ID NO: 1. In some embodiments, the mutation selected from the mutation differences disclosed in any of Tables 1A-1F, e.g., selected from the mutation differences associated with any variant disclosed in any of Tables 1A-1F is a substitution and further comprises at least one other mutation between positions 551 and 597, wherein the mutations are substitutions, insertions, or deletions. In some embodiments, the mutation selected from the mutation differences disclosed in any of Tables 1A-1F, e.g., selected from the mutation differences associated with any variant disclosed in any of Tables 1A-1F is an insertion, e.g., an insertion of 1 or more amino acids, e.g., 1 amino acid, e.g., 1-2 27 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT amino acids, that correspond to an insertion between positions 584 and 585, 586 and 587, or 587 and 588 as compared to SEQ ID NO.1. In some embodiments, the mutation selected from the mutation differences disclosed in any of Tables 1A-1F, e.g., selected from the mutation differences associated with any variant disclosed in any of Tables 1A-1F is an insertion, e.g., an insertion of 1 or more amino acids, e.g., 1 amino acid, e.g., 1-2 amino acids, that correspond to an insertion between positions 584 and 585, 586 and 587, or 587 and 588 as compared to SEQ ID NO.1; and a substitution, e.g., a substitution of at least 2 or more residues, e.g., at least 2-17 residues, e.g., at least 5-17 residues, e.g., at least 6-17 residues, e.g., at least 7-17 residues, e.g., at least 8-17 residues, e.g., at least 10-17 residues, e.g., at least 11-17 residues, e.g., at least 13-17 residues, e.g., at least 14-17 residues, e.g., at least 15- 17 residues, e.g., at least 17 residues that correspond to a substitution at positions between 551 and 597 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 551, 575, 584, 586, 587, 589, 591, 597, or any combination thereof, according to SEQ ID NO: 1, optionally wherein the mutation comprises an insertion, a deletion or a substitution. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 551, 575, 584, 586, 587, 589, 591, or 597, or any combination thereof, according to SEQ ID NO: 1, optionally wherein the mutation comprises a substation, or comprises a deletion, or comprises a combination of substitutions and deletions. In some embodiments, the capsid polypeptide comprises an insertion between positions 584 and 585, 586 and 587, or 587 and 588, or any combination thereof, according to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 551 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 575 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 584 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 586 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 589 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at 28 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT position 591 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 597 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between 587 and 588 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 551, 575, 584, 586, 587, 589, 591, 597 or any combination thereof, an insertion between positions 584 and 585, 586 and 587, 587 and 588, or any combination thereof according to SEQ ID NO: 1, and wherein the mutation comprises an insertion, a deletion or a substitution. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 551, 586 (e.g., an insertion of one or more amino acids after position 586), 587, 589, and 597 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 584 (e.g., an insertion of one or more amino acids after position 584), 586, and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 586 (e.g., an insertion of one or more amino acids after position 586) and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 586 (e.g., an insertion of one or more amino acids after position 586), 587, and 597 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 575, 586 (e.g., an insertion of one or more amino acids after position 586), and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 584 (e.g., an insertion of one or more amino acids after position 584) and 587 as compared to SEQ ID NO: 1. 29 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587 (e.g., an insertion of one or more amino acids after position 587) as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587 (e.g., an insertion of one or more amino acids after position 587) and 591 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that comprises an insertion, e.g., an insertion of 1 or more amino acids, e.g., 1 amino acid, e.g., 1-2 amino acids, that correspond to an insertion between positions 584 and 585, 586 and 587, or 587 and 588, as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that comprises an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587, and an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 586 and 587, and an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that comprises an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 587 and 597, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 575 and 587, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 551, 587, 589, and 597, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that comprises an insertion between positions 587 and 588 as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a mutation at position 591, and an insertion between positions 587 and 588 as compared to SEQ ID NO: 1. 30 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the mutation that corresponds to position 551 is a substitution as compared to SEQ ID NO: 1. In some embodiments, the substitution is to a naturally occurring amino acid. In some embodiments, the substitution is histidine (H). In some embodiments, the substitution at position 551 is N551H according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to N551 of SEQ ID NO: 1 is a substitution to histidine (H) at the position corresponding to N551 of SEQ ID NO: 1 in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a N551H mutation as compared to SEQ ID NO: 1. In some embodiments, the mutation that corresponds to position 575 is a substitution as compared to SEQ ID NO: 1. In some embodiments, the substitution is to a naturally occurring amino acid. In some embodiments, the substitution is serine (S). In some embodiments, the substitution at position 575 is Q575S according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to Q575 of SEQ ID NO: 1 is a substitution to serine (S) at the position corresponding to Q575 of SEQ ID NO: 1 in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a Q575S mutation as compared to SEQ ID NO: 1. In some embodiments, the mutation that corresponds to position 586 is a substitution as compared to SEQ ID NO: 1. In some embodiments, the substitution is to a naturally occurring amino acid. In some embodiments, the substitution is proline (P). In some embodiments, the substitution at position 586 is G586P according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to G586 of SEQ ID NO: 1 is a substitution to proline (P) at the position corresponding to G586 of SEQ ID NO: 1 in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a G586P mutation as compared to SEQ ID NO: 1. In some embodiments, the mutation that corresponds to position 587 is a substitution as compared to SEQ ID NO: 1. In some embodiments, the substitution is to a naturally occurring amino acid. In some embodiments, the substitution is alanine (A). In some embodiments, the substitution at position 587 is N587A according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to N587 of SEQ ID NO: 1 is a substitution to alanine (A) at the position corresponding to N587 of SEQ ID NO: 1 in a 31 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a N587A mutation as compared to SEQ ID NO: 1. In some embodiments, the mutation that corresponds to position 589 is a substitution as compared to SEQ ID NO: 1. In some embodiments, the substitution is to a naturally occurring amino acid. In some embodiments, the substitution is alanine (A). In some embodiments, the substitution at position 589 is Q589A according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to Q589 of SEQ ID NO: 1 is a substitution to alanine (A) at the position corresponding to Q589 of SEQ ID NO: 1 in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a Q589A mutation as compared to SEQ ID NO: 1. In some embodiments, the mutation that corresponds to position 591 is a substitution as compared to SEQ ID NO: 1. In some embodiments, the substitution is to a naturally occurring amino acid. In some embodiments, the substitution is isoleucine (I). In some embodiments, the substitution at position 591 is A591I according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to A591 of SEQ ID NO: 1 is a substitution to isoleucine (I) at the position corresponding to A591 of SEQ ID NO: 1 in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a A591I mutation as compared to SEQ ID NO: 1. In some embodiments, the mutation that corresponds to position 597 is a substitution as compared to SEQ ID NO: 1. In some embodiments, the substitution is to a naturally occurring amino acid. In some embodiments, the substitution is asparagine (N). In some embodiments, the substitution at position 597 is T597N according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to T597 of SEQ ID NO: 1 is a substitution to asparagine (N) at the position corresponding to T597 of SEQ ID NO: 1 in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a T597N mutation as compared to SEQ ID NO: 1. In some embodiments, the substitution is leucine (L). In some embodiments, the substitution at position 597 is T597L according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to T597 of SEQ ID NO: 1 is a substitution to leucine (L) at the position corresponding to T597 of SEQ ID NO: 1 32 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a T597L mutation as compared to SEQ ID NO: 1. In some embodiments, the substitution is tryptophan (W). In some embodiments, the substitution at position 597 is T597W according to SEQ ID NO: 1. In some embodiments, the substitution at a position corresponding to T597 of SEQ ID NO: 1 is a substitution to tryptophan (W) at the position corresponding to T597 of SEQ ID NO: 1 in a reference capsid sequence other than SEQ ID NO: 1, e.g., as described herein. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to a T597W mutation as compared to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide that has at least 44.4%, 55.5%, 66.6%, 77.7%, 88.8%, or 100% identity to LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 4 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the mutation further corresponds to a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-1 and VAR-3). In some embodiments, the mutation further corresponds to a N551H, N587A, Q589A, and T597N mutation (e.g., as in VAR-1). In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between residues 584 and 585 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide that has at least 50%, 62.5%, 75%, 87.5%, or 100% identity to RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, or 4 mutations as compared to 33 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 4 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the mutation further corresponds to a G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-2). In some embodiments, the mutation further corresponds to any one or more mutations of VAR-14 through VAR-22 in Example 5. In some embodiments, the mutation further corresponds to a E555M, R566A, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-14 in Example 5). In some embodiments, the mutation further corresponds to a T550M, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-15 in Example 5). In some embodiments, the mutation further corresponds to a Q575C, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-16 in Example 5). In some embodiments, the mutation further corresponds to a A593T, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-17 in Example 5). In some embodiments, the mutation further corresponds to a R566S, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-18 in Example 5). In some embodiments, the mutation further corresponds to a T550F, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-19 in Example 5). In some embodiments, the mutation further corresponds to a D553N, K556Q, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-20 in Example 5). In some embodiments, the mutation further corresponds to a I559L, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-21 in Example 5). In some embodiments, the mutation further corresponds to a T550N, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-22 in Example 5). In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide that has at least 44.4%, 55.5%, 66.6%, 77.7%, 88.8%, or 100% identity to GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations 34 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT as compared to GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 4 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the mutation further corresponds to a N587A mutation and a substitution at position 597 as compared to SEQ ID NO: 1 (e.g., as in VAR-4 and VAR-5). In some embodiments, the substitution at position 597 is T597W according to SEQ ID NO: 1. In some embodiments, the substitution at position 597 is T597N according to SEQ ID NO: 1. In some embodiments, the capsid polypeptide comprises a mutation that corresponds an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide that has at least 50%, 60%, 70%, 80%, 90%, or 100% identity to ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the mutation further corresponds to a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-6). In some embodiments, the mutation further corresponds to any one or more mutations of VAR-23 through VAR-25 in Example 5. In some embodiments, the mutation further corresponds to a Q575A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-23 in Example 5). In some embodiments, the mutation further corresponds to a Q575I mutation as 35 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT compared to SEQ ID NO: 1 (e.g., as in VAR-24 in Example 5). In some embodiments, the mutation further corresponds to a Q598S mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-25 in Example 5). In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide that has at least 45%, 54%, 63%, 72%, 81%, 90%, or 100% identity to PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, 5, or 6 mutations as compared to PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 10 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the mutation further corresponds to a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-7). In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide that has at least 45%, 54%, 63%, 72%, 81%, 90%, or 100% identity to QNLALGNTTRQP (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, 5, or 6 mutations as compared to QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment 36 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT of at least 7 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 10 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the mutation further corresponds to a Q575S and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-8). In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between residues 584 and 585 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide that has at least 50%, 66.6%, 83.3%, or 100% identity to RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, or 3 mutations as compared to RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 3 amino acids of RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 4 amino acids of RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of RASNDT (SEQ ID NO: 42). In some embodiments, the mutation further corresponds to a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-9). In some embodiments, the capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide that has at least 45%, 54%, 63%, 72%, 81%, 90%, or 100% identity to INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, 5, or 6 mutations as compared to INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the 37 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 10 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the mutation further corresponds to a N587Aand T597L mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-10). In some embodiments, the capsid polypeptide comprises a mutation that corresponds an insertion between residues 587 and 588 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide that has at least 50%, 60%, 70%, 80%, 90%, or 100% identity to LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the capsid polypeptide comprises a mutation that corresponds an insertion between residues 587 and 588 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide that has at least 50%, 60%, 70%, 80%, 90%, or 100% identity to RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of 38 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the mutation further corresponds to a A591I mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-12). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-1 (e.g., comprises all of N551H, N587A, Q589A, T597N, and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-1 (e.g., comprises all of N551H, N587A, Q589A, T597N, and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-1 (e.g., comprises all of N551H, N587A, Q589A, T597N, and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ 39 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-14 (e.g., comprises all of E555M, R566A, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-15 (e.g., comprises all of T550M, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, 40 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-16 (e.g., comprises all of Q575C, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-17 (e.g., comprises all of A593T, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-18 (e.g., comprises all of R566S, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-19 (e.g., comprises all of T550F, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all 41 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-20 (e.g., comprises all of D553N, K556Q, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-21 (e.g., comprises all of I559L, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-22 (e.g., comprises all of T550N, G586P, N587A and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-14 (e.g., comprises all of E555M, R566A, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 42 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-15 (e.g., comprises all of T550M, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-16 (e.g., comprises all of Q575C, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-17 (e.g., comprises all of A593T, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-18 (e.g., comprises all of 43 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT R566S, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-19 (e.g., comprises all of T550F, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-20 (e.g., comprises all of D553N, K556Q, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-21 (e.g., comprises all of I559L, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, 44 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), further comprising one or more (e.g., all) of the mutation differences associated with VAR-22 (e.g., comprises all of T550N, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-14 (e.g., comprises all of E555M, R566A, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-15 (e.g., comprises all of T550M, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ 45 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-16 (e.g., comprises all of Q575C, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-17 (e.g., comprises all of A593T, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-18 (e.g., comprises all of R566S, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated 46 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-19 (e.g., comprises all of T550F, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-20 (e.g., comprises all of D553N, K556Q, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-21 (e.g., comprises all of I559L, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises 47 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-2 (e.g., comprises all of G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-22 (e.g., comprises all of T550N, G586P, N587A, and an insertion of RARLDETA (SEQ ID NO: 37) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-3 (e.g., comprises all of N587A and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-3 (e.g., comprises all of N587A and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-3 (e.g., comprises all of N587A and an insertion of LAKGETMRP (SEQ ID NO: 36) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated 48 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT with VAR-4 (e.g., comprises all of N587A, T597W, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-4 (e.g., comprises all of N587A, T597W, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-4 (e.g., comprises all of N587A, T597W, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-5 (e.g., comprises all of N587A, T597N, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-5 (e.g., comprises all of N587A, T597N, and an insertion of GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-5 (e.g., comprises all of N587A, T597N, and an insertion of 49 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GVRAETTRP (SEQ ID NO: 38) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-23 (e.g., comprises all of Q575A, N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID 50 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-24 (e.g., comprises all of Q575I, N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-25 (e.g., comprises all of N587A, Q598S and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-23 (e.g., comprises all of Q575A, N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-24 (e.g., comprises all of Q575I, N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 51 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more (e.g., all) of the mutation differences associated with VAR-25 (e.g., comprises all of N587A, Q598S and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-23 (e.g., comprises all of Q575A, N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-24 (e.g., comprises all of Q575I, N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, 52 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-6 (e.g., comprises all of N587A and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and further comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-25 (e.g., comprises all of N587A, Q598S and an insertion of ANLAIEQTRP (SEQ ID NO: 39) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-7 (e.g., comprises all of N587A and an insertion of PNLALGATARPP (SEQ ID NO: 40) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-7 (e.g., comprises all of N587A and an insertion of PNLALGATARPP (SEQ ID NO: 40) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-7 (e.g., comprises all of N587A and an insertion of PNLALGATARPP (SEQ ID NO: 40) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). 53 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-8 (e.g., comprises all of Q575S, N587A, and an insertion of QNLALGNTTRQ (SEQ ID NO: 41) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-8 (e.g., comprises all of Q575S, N587A, and an insertion of QNLALGNTTRQ (SEQ ID NO: 41) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-8 (e.g., comprises all of Q575S, N587A, and an insertion of QNLALGNTTRQ (SEQ ID NO: 41) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-9 (e.g., comprises all of N587A and an insertion of RASNDT (SEQ ID NO: 42) between position 584 and position 585, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-9 (e.g., comprises all of N587A and an insertion of RASNDT (SEQ ID NO: 42) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. 54 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-9 (e.g., comprises all of N587A and an insertion of RASNDT (SEQ ID NO: 42) between position 584 and position 585, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-10 (e.g., comprises all of N587A, T597L, and an insertion of INMAKGETARP (SEQ ID NO: 43) between position 586 and position 587, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-10 (e.g., comprises all of N587A, T597L, and an insertion of INMAKGETARP (SEQ ID NO: 43) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-10 (e.g., comprises all of N587A, T597L, and an insertion of INMAKGETARP (SEQ ID NO: 43) between position 586 and position 587, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated 55 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT with VAR-11 (e.g., comprises an insertion of LNISPQTKPA (SEQ ID NO: 44) between position 587 and position 588, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-11 (e.g., comprises an insertion of LNISPQTKPA (SEQ ID NO: 44) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-11 (e.g., comprises an insertion of LNISPQTKPA (SEQ ID NO: 44) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In an aspect, described herein is a variant capsid polypeptide that has at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to VP1, VP2, or VP3 sequence of SEQ ID NO: 1, and comprises one or more (e.g., all) of the mutation differences associated with VAR-12 (e.g., comprises all of A591I and an insertion of RQAGETARPA (SEQ ID NO: 45) between position 587 and position 588, with all numbering according to SEQ ID NO: 1). In an aspect, described herein is a variant capsid polypeptide that comprises one or more (e.g., all) of the mutation differences associated with VAR-12 (e.g., comprises all of A591I and an insertion of RQAGETARPA (SEQ ID NO: 45) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), and comprises a sequence having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, but fewer than 40, 39, 38, 37, 36, 35, 34, 33, 32, 32, 31, 29, 28, 27, 26, or 25 additional mutations as compared to SEQ ID NO: 1. In an aspect, described herein is a variant capsid polypeptide that comprises one or more mutations that correspond to one or more (e.g., all) of the mutation differences associated with VAR-12 (e.g., comprises all of A591I and an insertion of RQAGETARPA (SEQ ID NO: 45) between position 587 and position 588, with all numbering according to SEQ ID NO: 1), wherein the variant capsid polypeptide comprises a sequence that has at least 56 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 95, 96, 97, 98, 99% identity to VP1, VP2, or VP3 sequence of a reference sequence other than SEQ ID NO: 1 (e.g., a reference sequence corresponding to wild-type AAV5, AAV8, AAV9, or AAVrh74, e.g., a reference sequence of SEQ ID NO: 3, 5, 7, 9 or 10). In some embodiments, a nucleic acid molecule is provided. In some embodiments, the nucleic acid molecule has the sequence selected from Table 2 and Table 9. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 24-35 and 60-71. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 24. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 25. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 26. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 27. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 28. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 29. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 30. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 31. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 32. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 33. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 34. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 35. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 60. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 61. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 62. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 63. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 64. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 65. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 66. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 67. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 68. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 69. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 70. In some embodiments, the nucleic acid molecule has the sequence of SEQ ID NO: 71. In some embodiments, the nucleic acid molecule comprises a sequence encoding the VP1, VP2 or VP3 polypeptide of any one of SEQ ID NO: 12-23 and 48-59. 57 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 551, 575, 584, 586, 587, 589, 591, 597, or any combination thereof, an insertion between positions 584 and 585, 586 and 587, or 587 and 588, or any combination thereof according to SEQ ID NO: 1, and optionally wherein the mutation comprises an insertion, a deletion or a substitution. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 551 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 575 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 584 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 586 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 589 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 591 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 597 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to an insertion between positions 587 and 588 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 551, 575, 584, 586, 587, 589, 591, 597 or any combination thereof, an insertion between positions 584 and 585, 586 and 58 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 587, 587 and 588, or any combination thereof according to SEQ ID NO: 1, and wherein the mutation comprises an insertion, a deletion or a substitution. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 449, 456, 457, 458, 459, and 461 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 551, 586 (e.g., an insertion of one or more amino acids after position 586), 587, 589, and 597 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 584 (e.g., an insertion of one or more amino acids after position 584), 586, and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 586 (e.g., an insertion of one or more amino acids after position 586) and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 575, 586 (e.g., an insertion of one or more amino acids after position 586), and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 584 (e.g., an insertion of one or more amino acids after position 584) and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at 587 (e.g., an insertion of one or more amino acids after position 587) as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at 587 (e.g., an insertion of one or more amino acids after position 587) and 591 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that comprises an insertion, e.g., an insertion of 1 or more amino acids, e.g., 1 amino acid, e.g., 1-2 amino acids, that correspond to an insertion between positions 584 and 585, 586 and 587, or 587 and 588 as compared to SEQ ID NO: 1. 59 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that comprises an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 587, and an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 586 and 587, and an insertion between positions 584 and 585 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that comprises an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 587, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 587 and 597, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 575 and 587, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 551, 587, 587, and 597, and an insertion between positions 586 and 587 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that comprises an insertion between positions 587 and 588 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation at position 591, and an insertion between positions 587 and 588 as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation N551H mutation as compared to SEQ ID NO: 1. 60 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation Q575S mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation G586P mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation N587A mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation Q589A mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation T597N mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation T597W mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation T597L mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to a mutation A591I mutation as compared to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that comprises a mutation that corresponds to an insertion between insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 24. In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 26. In some embodiments, the insertion comprises a polypeptide that has at least 44.4%, 55.5%, 66.6%, 77.7%, 88.8%, or 100% identity to LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to LAKGETMRP (SEQ ID NO: 36). In some embodiments, the 61 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of LAKGETMRP (SEQ ID NO: 36). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-1 and VAR-3). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N551H, N587A, Q589A, and T597N mutation (e.g., as in VAR-1). In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds to an insertion between residues 584 and 585 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of RARLDETA (SEQ ID NO: 37). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 25. In some embodiments, the insertion comprises a polypeptide that has at least 50%, 62.5%, 75%, 87.5%, or 100% identity to RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, or 4 mutations as compared to RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 4 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of RARLDETA (SEQ ID NO: 37). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-2). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises any one or more mutations of VAR-14 through VAR-22 in Example 5. In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a E555M, R566A, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-14 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a T550M, G586P and N587A mutation as compared to SEQ ID NO: 1 62 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT (e.g., as in VAR-15 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a Q575C, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-16 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a A593T, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-17 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a R566S, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-18 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a T550F, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-19 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a D553N, K556Q, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-20 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a I559L, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-21 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a T550N, G586P and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-22 in Example 5). In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 27. In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 28. In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 47. In some embodiments, the insertion comprises a polypeptide that has at least 44.4%, 55.5%, 66.6%, 77.7%, 88.8%, or 100% identity to GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of GVRAETTRP (SEQ ID NO: 38). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of GVRAETTRP (SEQ ID NO: 38). In some 63 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N587A mutation as compared to SEQ ID NO: 1 (e.g, as in VAR-13). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N587A mutation and a substitution at position 597 as compared to SEQ ID NO: 1 (e.g., as in VAR-4 and VAR-5). In some embodiments, the substitution at position 597 is T597W according to SEQ ID NO: 1. In some embodiments, the substitution at position 597 is T597N according to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 29. In some embodiments, the insertion comprises a polypeptide that has at least 50%, 60%, 70%, 80%, 90%, or 100% identity to ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-6). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises any one or more mutations of VAR-23 through VAR-25 in Example 5. In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a Q575A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-23 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a Q575I mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-24 in Example 5). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a Q598S mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-25 in Example 5). 64 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 30. In some embodiments, the insertion comprises a polypeptide that has at least 45%, 54%, 63%, 72%, 81%, 90%, or 100% identity to PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, 5, or 6 mutations as compared to PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 10 amino acids of PNLALGATARP (SEQ ID NO: 40). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-7). In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 21. In some embodiments, the insertion comprises a polypeptide that has at least 45%, 54%, 63%, 72%, 81%, 90%, or 100% identity to QNLALGNTTRQP (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, 5, or 6 mutations as compared to QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of QNLALGNTTRQ (SEQ ID 65 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 10 amino acids of QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a Q575S and N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-8). In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds to an insertion between residues 584 and 585 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of RASNDT (SEQ ID NO: 42). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 32. In some embodiments, the insertion comprises a polypeptide that has at least 50.1%, 66.8%, 83.5%, or 100% identity to RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, or 3 mutations as compared to RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 3 amino acids of RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 4 amino acids of RASNDT (SEQ ID NO: 42). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of RASNDT (SEQ ID NO: 42). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N587A mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-9). In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds to an insertion between residues 586 and 587 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 33. In some embodiments, the insertion comprises a polypeptide that has at least 45%, 54%, 63%, 72%, 81%, 90%, or 100% identity to INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, 5, or 6 mutations as compared to INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion 66 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT comprises a polypeptide comprising a fragment of at least 6 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 10 amino acids of INMAKGETARP (SEQ ID NO: 43). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a N587Aand T597L mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-10). In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds an insertion between residues 587 and 588 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 34. In some embodiments, the insertion comprises a polypeptide that has at least 50%, 60%, 70%, 80%, 90%, or 100% identity to LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 mutations as compared to LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the nucleic acid molecule encodes a capsid polypeptide comprises a mutation that corresponds an insertion between residues 587 and 588 as compared to SEQ ID NO: 1, wherein the insertion comprises, e.g., consists of, a polypeptide of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the nucleic acid has a sequence of SEQ ID NO: 35. In some embodiments, the insertion comprises a polypeptide that has at least 50%, 60%, 70%, 80%, 90%, or 100% identity to RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide that has at least 1, 2, 3, 4, or 5 67 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT mutations as compared to RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 5 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 6 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 7 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 8 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the insertion comprises a polypeptide comprising a fragment of at least 9 amino acids of RQAGETARPA (SEQ ID NO: 45). In some embodiments, the capsid polypeptide encoded by the nucleic acid molecule further comprises a A591I mutation as compared to SEQ ID NO: 1 (e.g., as in VAR-12). In some embodiments, including in the embodiments described above, a capsid polypeptide is provided that comprises a sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence of a capsid polypeptide provided herein. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide as provided herein. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a capsid polypeptide as provided herein. In some embodiments, including in the embodiments described above, a capsid polypeptide is provided that comprises a sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99 identical to SEQ ID NO: 1. In some embodiments, including in the embodiments described above, a capsid polypeptide is provided that comprises a sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99 identical to any one of SEQ ID NO: 3, 5, 7, 9 or 10. In some embodiments, the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NOs: 1, 3, 5, 7, 9, or 10. In some embodiments, the reference nucleic acid for purposes of % identity, comprises a sequence of SEQ ID NOs: 2, 4, 6, 8, or 11. 68 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 46. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NOs: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 47. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 24. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 25. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 26. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 27. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 28. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 29. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 30. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 31. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 32. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 33. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 34. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 35. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 47. 69 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NOs: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 47 that encodes a sequence of SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 46, respectively. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 24 that encodes a sequence of SEQ ID NO: 12. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 25 that encodes a sequence of SEQ ID NO: 13. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 26 that encodes a sequence of SEQ ID NO: 14. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 27 that encodes a sequence of SEQ ID NO: 15. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 28 that encodes a sequence of SEQ ID NO: 16. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 29 that encodes a sequence of SEQ ID NO: 17. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 30 that encodes a sequence of SEQ ID NO: 18. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 31 that encodes a sequence of SEQ ID NO: 19. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 32 that encodes a sequence of SEQ ID NO: 20. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 33 that encodes a sequence of SEQ ID NO: 21. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 34 that encodes a sequence of SEQ ID NO: 22. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of 70 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SEQ ID NO: 35 that encodes a sequence of SEQ ID NO: 23. In some embodiments, the nucleic acid molecules encoding the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 47 that encodes a sequence of SEQ ID NO: 46. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 46 that is encoded by a nucleotide sequence of SEQ ID NOs: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 47, respectively. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 12 that is encoded by a nucleotide sequence of SEQ ID NO: 24. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 13 that is encoded by a nucleotide sequence of SEQ ID NO: 25. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 14 that is encoded by a nucleotide sequence of SEQ ID NO: 26. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 15 that is encoded by a nucleotide sequence of SEQ ID NO: 27. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 16 that is encoded by a nucleotide sequence of SEQ ID NO: 28. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 17 that is encoded by a nucleotide sequence of SEQ ID NO: 29. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 18 that is encoded by a nucleotide sequence of SEQ ID NO: 30. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 19 that is encoded by a nucleotide sequence of SEQ ID NO: 31. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 20 that is encoded by a nucleotide sequence of SEQ ID NO: 32. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 21 that is encoded by a nucleotide sequence of SEQ ID NO: 33. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 22 that is encoded by a nucleotide sequence of SEQ ID NO: 34. In some embodiments, the capsid polypeptide, or 71 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 23 that is encoded by a nucleotide sequence of SEQ ID NO: 35. In some embodiments, the capsid polypeptide, or the reference polypeptide for purposes of % identity, comprises a sequence of SEQ ID NO: 46 that is encoded by a nucleotide sequence of SEQ ID NO: 47. In some embodiments, the capsid polypeptide comprises a sequence that includes all of the mutation differences associated with any one of VAR-1 through VAR-13 (e.g., as indicated in Tables 1A, 1B, 1C, 1D, 1E, and 1F), and further includes no more than 30, no more than 20, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3, no more than 2 or no more than 1 additional mutations relative to SEQ ID NO: 1. In some embodiments, the capsid polypeptide is a VP1 capsid polypeptide. In some embodiments, the capsid polypeptide is a VP2 capsid polypeptide. In some embodiments, the capsid polypeptide is a VP3 capsid polypeptide. With respect to reference sequence SEQ ID NO: 1, a VP1 capsid polypeptide comprises amino acids 1-724 of SEQ ID NO: 1. With respect to reference sequence SEQ ID NO: 1, a VP2 capsid polypeptide comprises amino acids 138-724 of SEQ ID NO: 1. With respect to reference sequence SEQ ID NO: 1, a VP3 capsid polypeptide comprises amino acids 203-724 of SEQ ID NO: 1. Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, and Table 1F list information regarding exemplary variant dependoparvovirus particles comprising the variant capsids, and describing the ocular transduction properties and production characteristics of said non- limiting exemplary variants. Exemplary sequences of capsid polypeptides and nucleic acid molecules encoding the same are provided in Table 2. Table 2 illustrates the VP1, VP2 and VP3 polypeptide starting amino acid sequences of each of SEQ ID NO: 12 to SEQ ID NO: 23 and SEQ ID NO: 46. The exemplary nucleic acid sequences provided in Table 2 include a stop codon at the 3’-end of the sequence (e.g., the TAA stop codon). It will be understood by a skilled artisan that in some embodiments, the TAA stop codon is removed or replaced with a different stop codon (e.g., TGA or TAG). Table 1A, Table 1B, and Table 1C represent data produced in a first (Table 1A) high throughput experiment (Library Experiment 1) and second (Table 1B-1C) high throughput experiment (Library Experiment 2). Tables 1D, 1E, and 1F represent data produced in a medium throughput experiment (Library Experiment 3). Transduction and virus production of exemplary variant dependoparvovirus (e.g., AAV) particles comprising variant capsid polypeptides. Injection route is as indicated in the column headings. Substitutions are notated 72 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT as n###N where “N” is the final amino acid, “n” is the reference amino acid and “###” is the reference amino acid position of SEQ ID NO: 1; deletions are notated as n###- where “-“ indicates the deletion of “n” at position “###” of the reference sequence SEQ ID NO: 1; insertions are notated as ###_Naa_###_(n)y, where “###” are the amino acid positions in the reference sequence SEQ ID NO: 1 between which the insertion occurs, “Naa” refers to the length of the insertion (having “N” amino acids) and “(n)y” providing the sequence of the insertion). Each individual Mutation Difference (e.g., within a row, each mutation in quotations (‘’) in column 8 of Table 1A, column 6 of Table 1B, column 7 of Table 1C, column 6 of Table 1D, column 6 of Table 1E, and column 7 of Table 1F) and combinations of such individual mutation differences is sometimes referred to herein as a “mutation associated with VAR-X”, where VAR-X is the variant identifier listed in the “Name column.” Macular Retina Transduction refers to transduction of the neural retina layer of tissues in the macula. In Tables 1A and 1C, Non-Macular Retina Transduction refers to transduction of the neural retina layer of the retina excluding the macula. Retinal Transduction refers to the aggregated measurements from Macular Retina Transduction and Non-Macular Retina Transduction. For purposes of Table 1A, Average Retinal Transduction is calculated as the average of Macular Transduction and Non-Macular Retina Transduction. Trabecular Transduction refers to transduction of tissue samples collected from the trabecular meshwork and/or Schlemm’s canal. For purposes of Tables 1D and 1E, Neural Retina Transduction refers to transduction of tissue samples collected from the neural retina layer, including the macular region. “Not Measured” indicates the variant was not detected in the indicated sample. Unless otherwise indicated, measurements are made relative to wild-type AAV2 (SEQ ID NO: 1). Trabecular transduction measurements shown in Table 1F is shown relative to an AAV2 variant identified from the ocular literature having a capsid with polypeptide of SEQ ID NO: 72, encoded by exemplary nucleic acid SEQ ID NO: 73. Data shown in Tables 1A-1C is on a log2 scale. Table 1A Name SEQ Macular Average Trabecular Non-Macular Virus Mutation ID as IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ID NO: 1 ID NO: 1 ID NO: 1 SEQ ID NO: (Log2) (Log2) (Log2) 1 (Log2) VAR-3 14 429 413 152 397 161 [‘5869aa587_ Table 1B Name SEQ ID Trabecular Trabecular Virus Mutation Differences as NO: of Transduction Transduction Production compared to SEQ ID NO: 1 VP1 (intr mrl (intrvitr l m rd , , Table 1C Name SEQ ID Choroidal Non-Macular Macular Retinal Mutation NO: of Transducti Retina Retina Transduction Differences as VP1 on Transduction Transduction (intravitrea compared to SEQ ID IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT to wild- wild-type SEQwild-type SEQ ID NO: 1 type SEQ ID NO: 1 SEQ ID NO: 1 (Log2) ID NO: 1 (Log2) (Log2) ET LD AE AE LA LA ] AL ND MA , IS AG Table 1D Name SEQ ID NO: Virus Neural Retina Mutation of VP1 Production Transduction Differences as D ET LD GE IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT VAR-5 16 1.51 7.04 1.11 ['586_9aa_587_GVRAE TTRP', 'N587A', 'T597N'] LA LA ] AL MA , IS AG AE Name SEQ ID NO: Virus Neural Retina Mutation of VP1 Production Transduction Differences as TM DE ET ET AI AL LG AK IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 'T597L'] VAR-1122 ['587_10aa_588_LNISP ' GE ET Name SEQ ID Macular Trabecular Transduction Mutation NO: of Transduction (intravitreal Differences as G ] R K ] R , N N L N ] N Q R 77 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT AETTRP', 'N587A'] Variant capsid polypeptide (SEQ ID Sequence(SEQ ID NO) NO; starting amino acid of A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T G C A G C IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GGACTTAAACACCCTCCTCCACAGATTCTCATCAAGAA CACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTG CGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACG A A T T A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A 79 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT CTTAAACACCCTCCTCCACAGATTCTCATCAAGAACAC CCCGGTACCTGCGAATCCTTCGACCACCTTCAGTGCGG CAAAGTTTGCTTCCTTCATCACACAGTACTCCACGGGA A T G G A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T G C A G C 80 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GGACTTAAACACCCTCCTCCACAGATTCTCATCAAGAA CACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTG CGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACG A A T T A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T G C A G C 81 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GGACTTAAACACCCTCCTCCACAGATTCTCATCAAGAA CACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTG CGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACG A A T T A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T G C A G C 82 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GGACTTAAACACCCTCCTCCACAGATTCTCATCAAGAA CACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTG CGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACG A A T T D A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C A T A A 83 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT TTCGGACTTAAACACCCTCCTCCACAGATTCTCATCAA GAACACCCCGGTACCTGCGAATCCTTCGACCACCTTCA GTGCGGCAAAGTTTGCTTCCTTCATCACACAGTACTCC A T T C A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A A A C T 84 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GGATTCGGACTTAAACACCCTCCTCCACAGATTCTCAT CAAGAACACCCCGGTACCTGCGAATCCTTCGACCACCT TCAGTGCGGCAAAGTTTGCTTCCTTCATCACACAGTAC T C C G A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C A A C T 85 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GGATTCGGACTTAAACACCCTCCTCCACAGATTCTCAT CAAGAACACCCCGGTACCTGCGAATCCTTCGACCACCT TCAGTGCGGCAAAGTTTGCTTCCTTCATCACACAGTAC T C C G A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T G A G T A 86 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT CACCCTCCTCCACAGATTCTCATCAAGAACACCCCGGT ACCTGCGAATCCTTCGACCACCTTCAGTGCGGCAAAGT TTGCTTCCTTCATCACACAGTACTCCACGGGACAGGTC G T T G ) A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C G A C T T 87 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT CAAGAACACCCCGGTACCTGCGAATCCTTCGACCACCT TCAGTGCGGCAAAGTTTGCTTCCTTCATCACACAGTAC TCCACGGGACAGGTCAGCGTGGAGATCGAGTGGGAGCT C C G A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C A T A A A 88 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GAACACCCCGGTACCTGCGAATCCTTCGACCACCTTCA GTGCGGCAAAGTTTGCTTCCTTCATCACACAGTACTCC ACGGGACAGGTCAGCGTGGAGATCGAGTGGGAGCTGCA T T C A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C A T A A A 89 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GAACACCCCGGTACCTGCGAATCCTTCGACCACCTTCA GTGCGGCAAAGTTTGCTTCCTTCATCACACAGTACTCC ACGGGACAGGTCAGCGTGGAGATCGAGTGGGAGCTGCA T T C A A T A C C C G C A C G A G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T G C A G C A 90 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT CACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGTG CGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACG GGACAGGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAA A T T In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence as provided in Table 2. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 12. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 13. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 14. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 15. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 16. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 17. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 18. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 19. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 20. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 21. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 22. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 23. In some embodiments, the capsid polypeptide has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 46. 91 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 12-23 or SEQ ID NO: 46. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 12. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 13. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 14. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 15. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 16. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 17. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 18. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 19. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 20. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 21. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 22. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 23. In some embodiments, the capsid polypeptide has a sequence of SEQ ID NO: 46. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence as provided in Table 2. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 12. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 13. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 14. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 15. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 16. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 17. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 18. In some embodiments, the nucleic acid molecule 92 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 19. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 20. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 21. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 22. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 23. In some embodiments, the nucleic acid molecule encodes a capsid polypeptide that has at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 46. In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, 80%, 85%, 90%, or 95%, or 100% of the mutations (insertions, deletions, or substitutions) as shown in the Mutation Differences column of Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, and Table 1F of VAR-1, VAR-2, VAR-3, VAR-4, VAR-5, VAR-6, VAR-7, VAR-8, VAR-9, VAR-10, VAR-11, VAR-12, or VAR-13. In some embodiments, the reference capsid sequence comprises at least, about, or exactly, 80% of the mutations (insertions, deletions, or substitutions). In some embodiments, the reference capsid sequence comprises at least, about, or exactly, 85% of the mutations (insertions, deletions, or substitutions). In some embodiments, the reference capsid sequence comprises at least, about, or exactly, 90% of the mutations (insertions, deletions, or substitutions). In some embodiments, the reference capsid sequence comprises at least, about, or exactly, 95% of the mutations (insertions, deletions, or substitutions). In some embodiments, the reference capsid sequence comprises 100% of the mutations (insertions, deletions, or substitutions). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of one of the following groups of mutations (the terminology for these groups of mutations is provided for in the legend of Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, and Table 1F above): 93 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT [‘N551H’, ‘586_9aa_587_LAKGETMRP’, ‘N587A’, ‘Q589A’, ‘T597N’]; [‘584_8aa_585_RARLDETA’, ‘G586P’, ‘N587A’]; [‘586_9aa_587_LAKGETMRP’, ‘N587A’]; [‘586_9aa_587_GVRAETTRP’, ‘N587A’, ‘T597W’]; [‘586_9aa_587_GVRAETTRP’, ‘N587A’, ‘T597N’]; [‘586_10aa_587_ANLAIEQTRP’, ‘N587A’]; [‘586_11aa_587_PNLALGATARP’, ‘N587A’]; [‘Q575S’, ‘586_11aa_587_QNLALGNTTRQ’, ‘N587A’]; [‘584_6aa_585_RASNDT’, ‘N587A’]; [‘586_11aa_587_INMAKGETARP’, ‘N587A’, ‘T597L’]; [‘587_10aa_588_LNISPQTKPA’]; [‘587_10aa_588_RQAGETARPA’, ‘A591I’]; [‘586_9aa_587_GVRAETTRP’, ‘N587A’]. In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘N551H’, ‘586_9aa_587_LAKGETMRP’, ‘N587A’, ‘Q589A’, ‘T597N’]. In some embodiments, the capsid polypeptide comprises at least 7, 8, or all of the amino acid residues of the 9 amino acid insertion LAKGETMRP (SEQ ID NO: 36). In some embodiments, the capsid polypeptide comprises at least 10, 11, 12, or all of the mutations of N551H, N587A, Q589A, T597N, and the amino acid residues of the 9 amino acid insertion LAKGETMRP (SEQ ID NO: 36). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘584_8aa_585_RARLDETA’, ‘G586P’, ‘N587A’]. In some embodiments, the capsid polypeptide comprises at least 6, 7, or all of the amino acid residues of the 8 amino acid insertion RARLDETA (SEQ ID NO: 37). In some embodiments, the capsid polypeptide comprises at least 8, 9, or all of the mutations of G586P, N587A, and the amino acid residues of the 8 amino acid insertion RARLDETA (SEQ ID NO: 37). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘586_9aa_587_LAKGETMRP’, ‘N587A’]. In some embodiments, the capsid polypeptide comprises 7, 8, or all of the amino acid residues of the 9 amino acid insertion LAKGETMRP (SEQ ID NO: 36). In some embodiments, the capsid polypeptide comprises at least 8, 9, or 94 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT all of the mutations of N587A and the amino acid residues of the 9 amino acid insertion LAKGETMRP (SEQ ID NO: 36). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘586_9aa_587_GVRAETTRP’, ‘N587A’, ‘T597W’]. In some embodiments, the capsid polypeptide comprises at least 7, 8, or all of the amino acid residues of the 9 amino acid insertion GVRAETTRP (SEQ ID NO: 38). In some embodiments, the capsid polypeptide comprises at least 9, 10, or all of the mutations of N587A, T597W, and the amino acid residues of the 9 amino acid insertion GVRAETTRP (SEQ ID NO: 38). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘586_9aa_587_GVRAETTRP’, ‘N587A’, ‘T597N’]. In some embodiments, the capsid polypeptide comprises at least 7, 8, or all of the amino acid residues of the 9 amino acid insertion GVRAETTRP (SEQ ID NO: 38). In some embodiments, the capsid polypeptide comprises at least 9, 10, or all of the mutations of N587A, T597N, and the amino acid residues of the 9 amino acid insertion GVRAETTRP (SEQ ID NO: 38). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘586_10aa_587_ANLAIEQTRP’, ‘N587A’]. In some embodiments, the capsid polypeptide comprises at least 8, 9, or all of the amino acid residues of the 10 amino acid insertion ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the capsid polypeptide comprises at least 9, 10, or all of the mutations of N587A and the amino acid residues of the 10 amino acid insertion ANLAIEQTRP (SEQ ID NO: 39). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘586_11aa_587_PNLALGATARP’, ‘N587A’]. In some embodiments, the capsid polypeptide comprises at least 10, 11, or all of the amino acid residues of the 11 amino acid insertion PNLALGATARP (SEQ ID NO: 40). In some embodiments, the capsid polypeptide comprises at least 10, 11, or all of the mutations of N587A and the amino acid residues of the 11 amino acid insertion PNLALGATARP (SEQ ID NO: 40). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘Q575S’, ‘586_11aa_587_QNLALGNTTRQ’, ‘N587A’]. In some embodiments, the 95 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT capsid polypeptide comprises at least 9, 10, or all of the amino acid residues of the 11 amino acid insertion QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the capsid polypeptide comprises at least 10, 11, 12, or all of the mutations of Q575S, N587A, and the amino acid residues of the 11 amino acid insertion QNLALGNTTRQ (SEQ ID NO: 41). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘584_6aa_585_RASNDT’, ‘N587A’]. In some embodiments, the capsid polypeptide comprises 5 or all of the amino acid residues of the 6 amino acid insertion RASNDT (SEQ ID NO: 42). In some embodiments, the capsid polypeptide comprises at least 6 or all of the mutations of N587A and the amino acid residues of the 6 amino acid insertion RASNDT (SEQ ID NO: 42). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘586_11aa_587_INMAKGETARP’, ‘N587A’, ‘T597L’]. In some embodiments, the capsid polypeptide comprises at least 9, 10, or all of the amino acid residues of the 11 amino acid insertion INMAKGETARP (SEQ ID NO: 43). In some embodiments, the capsid polypeptide comprises at least 10, 11, 12, or all of the mutations of N587A, T597L, and the amino acid residues of the 11 amino acid insertion INMAKGETARP (SEQ ID NO: 43). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘587_10aa_588_LNISPQTKPA’]. In some embodiments, the capsid polypeptide comprises at least 8, 9, or all of the amino acid residues of the 10 amino acid insertion LNISPQTKPA (SEQ ID NO: 44). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘587_10aa_588_RQAGETARPA’, ‘A591I’]. In some embodiments, the capsid polypeptide comprises at least 8, 9, or all of the amino acid residues of the 10 amino acid insertion RQAGETARPA (SEQ ID NO: 45). In some embodiments, the capsid polypeptide comprises at least 9, 10, or all of the mutations of A591I and the amino acid residues of the 10 amino acid insertion RQAGETARPA (SEQ ID NO: 45). In some embodiments, the capsid polypeptide comprises a reference capsid sequence, such as SEQ ID NO: 1, and at least, or about, or exactly, 80%, 85%, 90%, or 95%, or 100% of [‘586_9aa_587_GVRAETTRP’, ‘N587A’]. In some embodiments, the capsid polypeptide 96 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT comprises at least 7, 8, or all of the amino acid residues of the 9 amino acid insertion GVRAETTRP (SEQ ID NO: 38). In some embodiments, the capsid polypeptide comprises at least 8, 9, or all of the mutations of N587A and the amino acid residues of the 9 amino acid insertion GVRAETTRP (SEQ ID NO: 38). In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 12; and has at least 80% of the mutations in SEQ ID NO: 12 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 12; and has at least 80% of the mutations in SEQ ID NO: 12 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 12; and has less than 80% of the mutations in SEQ ID NO: 12 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, at least 30-fold, or at least 80-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 13; and has at least 80% of the mutations in SEQ ID NO: 13 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity 97 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT to an amino acid sequence of SEQ ID NO: 13; and has at least 80% of the mutations in SEQ ID NO: 13 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 13; and has less than 80% of the mutations in SEQ ID NO: 13 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, at least 30-fold, at least 100-fold, at least 200- fold, or at least 240-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 14; and has at least 80% of the mutations in SEQ ID NO: 14 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 14; and has at least 80% of the mutations in SEQ ID NO: 14 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 14; and has less than 80% of the mutations in SEQ ID NO: 14 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, 98 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, the increase is at least 2-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, or at least 20-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 15; and has at least 80% of the mutations in SEQ ID NO: 15 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 15; and has at least 80% of the mutations in SEQ ID NO: 15 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 15; and has less than 80% of the mutations in SEQ ID NO: 15 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, or at least 16-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some 99 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 16; and has at least 80% of the mutations in SEQ ID NO: 16 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 16; and has at least 80% of the mutations in SEQ ID NO: 16 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 16; and has less than 80% of the mutations in SEQ ID NO: 16 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, at least 40-fold, or at least 80-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 17; and has at least 80% of the mutations in SEQ ID NO: 17 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity 100 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT to an amino acid sequence of SEQ ID NO: 17; and has at least 80% of the mutations in SEQ ID NO: 17 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 17; and has less than 80% of the mutations in SEQ ID NO: 17 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, the increase is at least 1.5-fold, at least 1-fold, at least 2.5-fold, at least 2.7-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 72. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, at least 40-fold, at least 100-fold, at least 200-fold, at least 300-fold, at least 400-fold, or at least 440-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 18; and has at least 80% of the mutations in SEQ ID NO: 18 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 18; and has at least 80% of the mutations in SEQ ID NO: 18 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 18; and has less than 80% of the mutations in SEQ ID NO: 18 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising 101 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, or at least 50-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 19; and has at least 80% of the mutations in SEQ ID NO: 19 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 19; and has at least 80% of the mutations in SEQ ID NO: 19 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 19; and has less than 80% of the mutations in SEQ ID NO: 19 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold or at least 16-fold over the transduction of a virus particle 102 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 20; and has at least 80% of the mutations in SEQ ID NO: 20 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 20; and has at least 80% of the mutations in SEQ ID NO: 20 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 20; and has less than 80% of the mutations in SEQ ID NO: 20 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold or at least 16-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 21; and has at least 80% of the mutations in SEQ ID NO: 21 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided 103 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 21; and has at least 80% of the mutations in SEQ ID NO: 21 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 21; and has less than 80% of the mutations in SEQ ID NO: 21 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, at least 40-fold, or at least 80-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 22; and has at least 80% of the mutations in SEQ ID NO: 22 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 22; and has at least 80% of the mutations in SEQ ID NO: 22 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 22; and has less than 80% of the mutations in SEQ ID NO: 22 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, 104 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold or at least 16-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 23; and has at least 80% of the mutations in SEQ ID NO: 23 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 23; and has at least 80% of the mutations in SEQ ID NO: 23 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 23; and has less than 80% of the mutations in SEQ ID NO: 23 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold or at least 16-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the 105 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with an amino acid sequence of SEQ ID NO: 46; and has at least 80% of the mutations in SEQ ID NO: 46 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has less than 95% amino acid sequence identity to an amino acid sequence of SEQ ID NO: 46; and has at least 80% of the mutations in SEQ ID NO: 46 as compared to SEQ ID NO: 1. In some embodiments, a variant capsid polypeptide is provided that comprises an amino acid sequence that has 95% or more amino acid sequence identity with SEQ ID NO: 46; and has less than 80% of the mutations in SEQ ID NO: 46 as compared to SEQ ID NO: 1. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor, such as the structures described herein, including, but not limited to the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a virus particle comprising the variant capsid polypeptide has increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the increase is at least 2-fold, at least 4-fold, at least 8-fold, at least 16-fold, or at least 40-fold over the transduction of a virus particle comprising capsid polypeptides of a reference sequence, e.g., SEQ ID NO: 1. In some embodiments, the increased transduction is measured as described in the Examples, e.g., by NGS sequencing of viral RNA in cells of the target tissue. In some embodiments, the transduction is as measured after intravitreal administration. In some embodiments, the transduction is as measured after intracameral injection. As used herein, the phrase “80% of the mutations” in reference to a variant capsid sequence means that the variant has at least 80% of the mutations present in the variant capsid sequence, wherein the total number of mutations are based on a comparison to a reference sequence, such as a wild-type sequence. If a variant capsid polypeptide is a mixture of an insertion and substitution or deletion, then each amino acid residue of the insert is counted in the total number of mutations. For example, if the variant capsid polypeptide has a mutation that is a mixture of substitutions of ‘N551H, ‘N587A’, ‘Q589A’, and 106 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ‘T597N’, and an insertion of a polypeptide comprising the sequence of LAKGETMRP (SEQ ID NO: 36) then the total number of mutations is 13, which is the 9 amino acid insertion and the 4 amino acid substitutions, and the variant capsid having “80% of the mutations” will comprise at least 10, 11, 12, or all of the mutations. Variant Capsids (Corresponding Positions) The mutations to capsid polypeptide sequences described herein are described in relation to a position and/or amino acid at a position within a reference sequence, e.g., SEQ ID NO: 1. Thus, in some embodiments, the capsid polypeptides described herein are variant capsid polypeptides of the reference sequence, e.g., SEQ ID NO: 1, e.g., include capsid polypeptides comprising at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the reference capsid polypeptide sequence (e.g., reference capsid polypeptide VP1, VP2 and/or VP3 sequence), e.g., SEQ ID NO: 1 (or VP2 or VP3 sequence comprised therein) and further including one or more mutations described herein. It will be understood by the skilled artisan, and without being bound by theory, that each amino acid position within a reference sequence corresponds to a position within the sequence of other capsid polypeptides such as capsid polypeptides derived from dependoparvoviruses with different serotypes. Such corresponding positions are identified using sequence alignment tools known in the art. A particularly preferred sequence alignment tool is Clustal Omega (Sievers F., et al., Mol. Syst. Biol.7:359, 2011, DOI: 10.1038/msb.2011.75, incorporated herein by reference in its entirety). An alignment of exemplary reference capsid polypeptides is shown in FIG.2A-2C. Thus, in some embodiments, the variant capsid polypeptides of the invention include variants of reference capsid polypeptides that include one or more mutations described herein in such reference capsid polypeptides at positions corresponding to the position of the mutation described herein in relation to a different reference capsid polypeptide. Thus, for example, a mutation described as XnnnY relative to SEQ ID NO: 1 (where X is the amino acid present at position nnn in SEQ ID NO: 1 and Y is the amino acid mutation at that position, e.g., described herein), the disclosure provides variant capsid polypeptides comprising at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99 identity to the reference capsid polypeptide sequence (e.g., reference capsid polypeptide VP1, VP2 and/or VP3 sequence) other than SEQ 107 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ID NO: 1 (or VP2 or VP3 sequence comprised therein) and further comprising the disclosed mutation at a position corresponding to position nnn of SEQ ID NO: 1 (e.g., comprising Y at the position in the new variant capsid polypeptide sequence that corresponds to position nnn of SEQ ID NO: 1). As described above, such corresponding position is determined using a sequence alignment tool, such as, for example, the clustal omega tool described above. Examples of corresponding amino acid positions of exemplary known AAV serotypes is provided in FIG.2A-2C. In some embodiments, the variant is a variant of the AAV2 capsid polypeptide, which can be referred to as a “variant AAV2 capsid polypeptide.” Thus, in some embodiments, the disclosure provides capsid polypeptide sequences that are variants of a reference sequence other than SEQ ID NO: 1, e.g., a reference sequence other than SEQ ID NO: 1 as described herein, which include one or more mutations corresponding to the mutations described herein. In some embodiments, such variants include mutations corresponding to all of the mutations associated with any one of VAR-1 through VAR-13 according to Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, and Table 1F. As used herein, the term “corresponds to” as used in reference to a position in a sequence, such as an amino acid or nucleic acid sequence, can be used in reference to an entire capsid polypeptide or polynucleotide sequence, such as the full length sequence of the capsid polypeptide that comprises a VP1, VP2, and VP3 polypeptide, or a nucleic acid molecule encoding the same. In some embodiments, the term “corresponds to” can be used in reference to a region or domain of the capsid polypeptide. For example, a position that corresponds to a position in the VP1 section of the reference capsid polypeptide can correspond to the VP1 portion of the polypeptide of the variant capsid polypeptide. Thus, when aligning the two sequences to determine whether a position corresponds to another position the full length polypeptide can be used or domains (regions) can be used to determine whether a position corresponds to a specific position. In some embodiments, the region is the VP1 polypeptide. In some embodiments, the region is the VP2 polypeptide. In some embodiments, the region is the VP3 polypeptide. In some embodiments, when the reference polypeptide is the wild-type sequence (e.g., full length or region) of a certain serotype of AAV, the variant polypeptide can be of the same serotype with a mutation made at such corresponding position as compared to the reference sequence (e.g., full length or region). In some embodiments, the variant capsid polypeptide is a different serotype as compared to the reference sequence. 108 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT The variant capsid polypeptides described herein are optionally variants of reference capsids serotypes known in the art. Non-limiting examples of such reference AAV serotypes include AAV1, AAVrh10, AAV-DJ, AAV-DJ8, AAV5, AAVPHP.B (PHP.B), AAVPHP.A (PHP.A), AAVG2B-26, AAVG2B-13, AAVTH1.1-32, AAVTH1.1- 35, AAVPHP.B2 (PHP.B2), AAVPHP.B3 (PHP.B3), AAVPHP.N/PHP.B-DGT, AAVPHP.B-EST, AAVPHP.B-GGT, AAVPHP.B-ATP, AAVPHP.B-ATT-T, AAVPHP.B- DGT-T, AAVPHP.B-GGT-T, AAVPHP.B-SGS, AAVPHP.B-AQP, AAVPHP.B-QQP, AAVPHP.B- SNP(3), AAVPHP.B-SNP, AAVPHP.B-QGT, AAVPHP.B-NQT, AAVPHP.B- EGS, AAVPHP.B-SGN, AAVPHP.B-EGT, AAVPHP.B-DST, AAVPHP.B-DST, AAVPHP.B- STP, AAVPHP.B-PQP, AAVPHP.B-SQP, AAVPHP.B-QLP, AAVPHP.B-TMP, AAVPHP.B-TTP, AAVPHP.S/G2A12, AAVG2A15/G2A3 (G2A3), AAVG2B4 (G2B4), AAVG2B5 (G2B5), PHP.S, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8, AAV9.11, AAV9.13, AAV9, AAV9 K449R (or K449R AAV9), AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV12, AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42- 1b, AAV42-2, AAV42-3a, AAV42-3b, AAV42- 4, AAV42-5a, AAV42-5b, AAV42-6b, AAV42-8, AAV42-10, AAV42-11, AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12, AAV43-20, AAV43-21, AAV43-23, AAV43-25, AAV43-5, AAV44.1, AAV44.2, AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7, AAV1-7/rh.48, AAV1-8/rh.49, AAV2- 15/rh.62, AAV2-3/rh.61, AAV2-4/rh.50, AAV2-5/rh.51, AAV3.1/hu.6, AAV3.1/hu.9, AAV3-9/rh.52, AAV3-11/rh.53, AAV4- 8/r11.64, AAV4-9/rh.54, AAV4-19/rh.55, AAV5- 3/rh.57, AAV5-22/rh.58, AAV7.3/hu.7, AAV16.8/hu.10, AAV16.12/hu.11, AAV29.3/bb.1, AAV29.5/bb.2, AAV106.1/hu.37, AAV114.3/hu.40, AAV127.2/hu.41, AAV127.5/hu.42, AAV128.3/hu.44, AAV130.4/hu.48, AAV145.1/hu.53, AAV145.5/hu.54, AAV145.6/hu.55, AAV161.10/hu.60, AAV161.6/hu.61, AAV33.12/hu.17, AAV33.4/hu.15, AAV33.8/hu.16, AAV52/hu.19, AAV52.1/hu.20, AAV58.2/hu.25, AAVA3.3, AAVA3.4, AAVA3.5, AAVA3.7, AAVC1, AAVC2, AAVC5, AAVF3, AAVF5, AAVH2, AAVrh.72, AAVhu.8, AAVrh.68, AAVrh.70, AAVpi.1, AAVpi.3, AAVpi.2, AAVrh.60, AAVrh.44, AAVrh.65, AAVrh.55, AAVrh.47, AAVrh.69, AAVrh.45, AAVrh.59, AAVhu.12, AAVH6, AAVH- 1/hu.1, AAVH-5/hu.3, AAVLG- 10/rh.40, AAVLG-4/rh.38, AAVLG-9/hu.39, AAVN721- 8/rh.43, AAVCh.5, AAVCh.5R1, AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVCy.5R1, AAVCy.5R2, AAVCy.5R3, AAVCy.5R4, AAVcy.6, AAVhu.1, AAVhu.2, AAVhu.3, 109 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT AAVhu.4, AAVhu.5, AAVhu.6, AAVhu.7, AAVhu.9, AAVhu.10, AAVhu.11, AAVhu.13, AAVhu.15, AAVhu.16, AAVhu.17, AAVhu.18, AAVhu.20, AAVhu.21, AAVhu.22, AAVhu.23.2, AAVhu.24, AAVhu.25, AAVhu.27, AAVhu.28, AAVhu.29, AAVhu.29R, AAVhu.31, AAVhu.32, AAVhu.34, AAVhu.35, AAVhu.37, AAVhu.39, AAVhu.40, AAVhu.41, AAVhu.42, AAVhu.43, AAVhu.44, AAVhu.44R1, AAVhu.44R2, AAVhu.44R3, AAVhu.45, AAVhu.46, AAVhu.47, AAVhu.48, AAVhu.48R1, AAVhu.48R2, AAVhu.48R3, AAVhu.49, AAVhu.51, AAVhu.52, AAVhu.54, AAVhu.55, AAVhu.56, AAVhu.57, AAVhu.58, AAVhu.60, AAVhu.61, AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14/9, AAVhu.t 19, AAVrh.2, AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.12, AAVrh.13, AAVrh.13R, AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.20, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54, AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74 (also referred to as AAVrh74), AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, caprine AAV, bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhER1.23, AAVhEr3.1, AAV2.5T , AAV- PAEC, AAV-LK01, AAV-LK02, AAV- LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV- LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV- LK17, AAV-LK18, AAV-LK19, AAV- PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV- PAEC12, AAV-2-pre-miRNA-101 , AAV-8h, AAV- 8b, AAV-h, AAV-b, AAV SM 10-2 , AAV Shuffle 100-1 , AAV Shuffle 100-3, AAV Shuffle 100-7, AAV Shuffle 10-2, AAV Shuffle 10-6, AAV Shuffle 10-8, AAV Shuffle 100- 2, AAV SM 10-1, AAV SM 10-8 , AAV SM 100-3, AAV SM 100-10, BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.11, AAVhu.53, AAV4-8/rh.64, AAVLG-9/hu.39, AAV54.5/hu.23, AAV54.2/hu.22, AAV54.7/hu.24, AAV54.1/hu.21, AAV54.4R/hu.27, AAV46.2/hu.28, AAV46.6/hu.29, AAV128.1/hu.43, true type AAV (ttAAV), UPENN AAV 10, Japanese AAV 10 serotypes, AAV CBr-7.1, AAV CBr-7.10, AAV CBr-7.2, AAV CBr-7.3, AAV CBr-7.4, AAV CBr-7.5, AAV CBr-7.7, AAV CBr-7.8, 110 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT AAV CBr-B7.3, AAV CBr-B7.4, AAV CBr-E1, AAV CBr- E2, AAV CBr-E3, AAV CBr- E4, AAV CBr-E5, AAV CBr-e5, AAV CBr-E6, AAV CBr-E7, AAV CBr-E8, AAV CHt-1, AAV CHt-2, AAV CHt-3, AAV CHt-6.1, AAV CHt-6.10, AAV CHt-6.5, AAV CHt-6.6, AAV CHt-6.7, AAV CHt-6.8, AAV CHt-P1, AAV CHt-P2, AAV CHt-P5, AAV CHt-P6, AAV CHt-P8, AAV CHt-P9, AAV CKd-1, AAV CKd-10, AAV CKd-2, AAV CKd-3, AAV CKd-4, AAV CKd-6, AAV CKd-7, AAV CKd-8, AAV CKd-B1, AAV CKd-B2, AAV CKd- B3, AAV CKd-B4, AAV CKd-B5, AAV CKd-B6, AAV CKd-B7, AAV CKd-B8, AAV CKd-H1, AAV CKd-H2, AAV CKd-H3, AAV CKd-H4, AAV CKd- H5, AAV CKd-H6, AAV CKd-N3, AAV CKd-N4, AAV CKd-N9, AAV CLg-F1, AAV CLg-F2, AAV CLg-F3, AAV CLg-F4, AAV CLg-F5, AAV CLg-F6, AAV CLg-F7, AAV CLg-F8, AAV CLv-1, AAV CLv1-1, AAV Clv1-10, AAV CLv1-2, AAV CLv-12, AAV CLv1-3, AAV CLv-13, AAV CLv1-4, AAV Clv1-7, AAV Clv1-8, AAV Clv1-9, AAV CLv- 2, AAV CLv-3, AAV CLv-4, AAV CLv-6, AAV CLv-8, AAV CLv-D1, AAV CLv-D2, AAV CLv-D3, AAV CLv- D4, AAV CLv-D5, AAV CLv-D6, AAV CLv-D7, AAV CLv-D8, AAV CLv-E1, AAV CLv- K1, AAV CLv-K3, AAV CLv-K6, AAV CLv-L4, AAV CLv-L5, AAV CLv-L6, AAV CLv- M1, AAV CLv-M11, AAV CLv-M2, AAV CLv-M5, AAV CLv- M6, AAV CLv-M7, AAV CLv-M8, AAV CLv-M9, AAV CLv-R1, AAV CLv-R2, AAV CLv-R3, AAV CLv-R4, AAV CLv-R5, AAV CLv-R6, AAV CLv-R7, AAV CLv-R8, AAV CLv-R9, AAV CSp-1, AAV CSp-10, AAV CSp-11, AAV CSp-2, AAV CSp-3, AAV CSp-4, AAV CSp-6, AAV CSp-7, AAV CSp-8, AAV CSp-8.10, AAV CSp-8.2, AAV CSp-8.4, AAV CSp-8.5, AAV CSp-8.6, AAV CSp-8.7, AAV CSp-8.8, AAV CSp-8.9, AAV CSp-9, AAV.hu.48R3, AAV.VR-355, AAV3B, AAV4, AAV5, AAVF1/HSC1, AAVF11/HSC11, AAVF12/HSC12, AAVF13/HSC13, AAVF14/HSC14, AAVF15/HSC15, AAVF16/HSC16, AAVF17/HSC17, AAVF2/HSC2, AAVF3/HSC3, AAVF4/HSC4, AAVF5/HSC5, AAVF6/HSC6, AAVF7/HSC7, AAVF8/HSC8, and/or AAVF9/HSC9, 7m8, Spark100, AAVMYO and variants thereof. In some embodiments, the reference AAV capsid sequence comprises an AAV2 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAV5 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAV8 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAV9 sequence. In some embodiments, the reference AAV capsid sequence comprises an AAVrh74 sequence. While not wishing to be bound by theory, it is understood that a reference AAV capsid sequence comprises a VP1 region. In certain embodiments, a reference AAV capsid 111 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT sequence comprises a VP1, VP2 and/or VP3 region, or any combination thereof. A reference VP1 sequence may be considered synonymous with a reference AAV capsid sequence. An exemplary reference sequence of SEQ ID NO: 1 (wild-type AAV2) is as follows: MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPKPAERHKDDSRGLVLPGYKYLGPFNGLD KGEPVNEADAAALEH DKAYDRQLDSGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRVLEPLGLVEEP VKTAPGKKRPVEHSP VEPDSSSGTGKAGQQPARKRLNFGQTGDADSVPDPQPLGQPPAAPSGLGTNTMATGSGAP MADNNEGADGVGNSS GNWHCDSTWMGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPWGYFDFN RFHCHFSPRDWQRLI NNNWGFRPKRLNFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQG CLPPFPADVFMVPQY GYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMN PLIDQYLYYLSRTNT PSGTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHL NGRDSLVNPGPAMAS HKDDEEKFFPQSGVLIFGKQGSEKTNVDIEKVMITDEEEIRTTNPVATEQYGSVSTNLQR GNRQAATADVNTQGV LPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTT FSAAKFASFITQYST GQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVNVDFTVDTNGVYSEPRPIGTRYLTRNL .(SEQ ID NO: 1) Unless otherwise noted, SEQ ID NO: 1 is the reference sequence. In the sequence above, the sequence found in VP1, VP2 and VP3 is underlined (e.g., a VP3 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 203-735 of SEQ ID NO: 1), the sequence found in both VP1 and VP2 is in bold (e.g., a VP2 capsid polypeptide includes, e.g., consists of, the sequence corresponding to amino acids 138-735 of SEQ ID NO: 1) and the sequence that is not underlined or bold is found only in VP1 (e.g., a VP1 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 1-735 of SEQ ID NO: 1). An example nucleic acid sequence encoding SEQ ID NO: 1 is SEQ ID NO: 2: ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACACTCTCTCTGAAGGAATAAGA CAGT GGTGGAAGCTCAAACCTGGCCCACCACCACCAAAGCCCGCAGAGCGGCATAAGGACGACA GCA GGGGTCTTGTGCTTCCTGGGTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGAG AGC CGGTCAACGAGGCAGACGCCGCGGCCCTCGAGCACGACAAAGCCTACGACCGGCAGCTCG AC AGCGGAGACAACCCGTACCTCAAGTACAACCACGCCGACGCGGAGTTTCAGGAGCGCCTT AAA GAAGATACGTCTTTTGGGGGCAACCTCGGACGAGCAGTCTTCCAGGCGAAAAAGAGGGTT CTTG AACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTCCGGGAAAAAAGAGGCCGGTAG AGC ACTCTCCTGTGGAGCCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCAGCCTGCAA GAA AAAGATTGAATTTTGGTCAGACTGGAGACGCAGACTCAGTACCTGACCCCCAGCCTCTCG GACA GCCACCAGCAGCCCCCTCTGGTCTGGGAACTAATACGATGGCTACAGGCAGTGGCGCACC AAT GGCAGACAATAACGAGGGCGCCGACGGAGTGGGTAATTCCTCGGGAAATTGGCATTGCGA TTC CACATGGATGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTA CAA CAACCACCTCTACAAACAAATTTCCAGCCAATCAGGAGCCTCGAACGACAATCACTACTT TGGCT ACAGCACCCCTTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTTTCACCACGTG ACTGG CAAAGACTCATCAACAACAACTGGGGATTCCGACCCAAGAGACTCAACTTCAAGCTCTTT AACAT TCAAGTCAAAGAGGTCACGCAGAATGACGGTACGACGACGATTGCCAATAACCTTACCAG CACG GTTCAGGTGTTTACTGACTCGGAGTACCAGCTCCCGTACGTCCTCGGCTCGGCGCATCAA GGAT GCCTCCCGCCGTTCCCAGCAGACGTCTTCATGGTGCCACAGTATGGATACCTCACCCTGA ACAA CGGGAGTCAGGCAGTAGGACGCTCTTCATTTTACTGCCTGGAGTACTTTCCTTCTCAGAT GCTGC GTACCGGAAACAACTTTACCTTCAGCTACACTTTTGAGGACGTTCCTTTCCACAGCAGCT ACGCT CACAGCCAGAGTCTGGACCGTCTCATGAATCCTCTCATCGACCAGTACCTGTATTACTTG AGCAG AACAAACACTCCAAGTGGAACCACCACGCAGTCAAGGCTTCAGTTTTCTCAGGCCGGAGC GAGT GACATTCGGGACCAGTCTAGGAACTGGCTTCCTGGACCCTGTTACCGCCAGCAGCGAGTA TCAA AGACATCTGCGGATAACAACAACAGTGAATACTCGTGGACTGGAGCTACCAAGTACCACC TCAAT GGCAGAGACTCTCTGGTGAATCCGGGCCCGGCCATGGCAAGCCACAAGGACGATGAAGAA AAG 112 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT TTTTTTCCTCAGAGCGGGGTTCTCATCTTTGGGAAGCAAGGCTCAGAGAAAACAAATGTG GACAT TGAAAAGGTCATGATTACAGACGAAGAGGAAATCAGGACAACCAATCCCGTGGCTACGGA GCAG TATGGTTCTGTATCTACCAACCTCCAGAGAGGCAACAGACAAGCAGCTACCGCAGATGTC AACA CACAAGGCGTTCTTCCAGGCATGGTCTGGCAGGACAGAGATGTGTACCTTCAGGGGCCCA TCTG ^{GGCAAAGATTCCACACACGGACGGACATTTTCACCCCTCTCCCCTCATGGGTGGA TTCGGACTT} AAACACCCTCCTCCACAGATTCTCATCAAGAACACCCCGGTACCTGCGAATCCTTCGACC ACCTT CAGTGCGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACGGGACAGGTCAGCGTGGA GATC GAGTGGGAGCTGCAGAAGGAAAACAGCAAACGCTGGAATCCCGAAATTCAGTACACTTCC AACT ACAACAAGTCTGTTAATGTGGACTTTACTGTGGACACTAATGGCGTGTATTCAGAGCCTC GCCCC ^{ATTGGCACCAGATACCTGACTCGTAATCTGTAA (SEQ ID NO: 2)} An exemplary reference sequence of wild type AAV5, SEQ ID NO: 3 (wild-type AAV5), is as follows: MSFVDHPPDWLEEVGEGLREFLGLEAGPPKPKPNQQHQDQARGLVLPGYNYLGPGNGLDR GEPVNRADEVAREHD ISYNEQLEAGDNPYLKYNHADAEFQEKLADDTSFGGNLGKAVFQAKKRVLEPFGLVEEGA KTAPTGKRIDDHFPK RKKARTEEDSKPSTSSDAEAGPSGSQQLQIPAQPASSLGADTMSAGGGGPLGDNNQGADG VGNASGDWHCDSTWM GDRVVTKSTRTWVLPSYNNHQYREIKSGSVDGSNANAYFGYSTPWGYFDFNRFHSHWSPR DWQRLINNYWGFRPR SLRVKIFNIQVKEVTVQDSTTTIANNLTSTVQVFTDDDYQLPYVVGNGTEGCLPAFPPQV FTLPQYGYATLNRDN TENPTERSSFFCLEYFPSKMLRTGNNFEFTYNFEEVPFHSSFAPSQNLFKLANPLVDQYL YRFVSTNNTGGVQFN KNLAGRYANTYKNWFPGPMGRTQGWNLGSGVNRASVSAFATTNRMELEGASYQVPPQPNG MTNNLQGSNTYALEN TMIFNSQPANPGTTATYLEGNMLITSESETQPVNRVAYNVGGQMATNNQSSTTAPATGTY NLQEIVPGSVWMERD VYLQGPIWAKIPETGAHFHPSPAMGGFGLKHPPPMMLIKNTPVPGNITSFSDVPVSSFIT QYSTGQVTVEMEWEL KKENSKRWNPEIQYTNNYNDPQFVDFAPDSTGEYRTTRPIGTRYLTRPL (SEQ ID NO: 3) In the sequence above, the sequence found in VP1, VP2 and VP3 is underlined (e.g., a VP3 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 193-725 of SEQ ID NO: 3), the sequence found in both VP1 and VP2 is in bold (e.g., a VP2 capsid polypeptide includes, e.g., consists of, the sequence corresponding to amino acids 137- 725 of SEQ ID NO: 3) and the sequence that is not underlined or bold is found only in VP1 (e.g., a VP1 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 1-725 of SEQ ID NO: 3). An example nucleic acid sequence encoding SEQ ID NO: 3 is SEQ ID NO: 4: ATGTCTTTTGTTGATCACCCTCCAGATTGGTTGGAAGAAGTTGGTGAAGGTCTTCGCGAG TTTTT GGGCCTTGAAGCGGGCCCACCGAAACCAAAACCCAATCAGCAGCATCAAGATCAAGCCCG TGG TCTTGTGCTGCCTGGTTATAACTATCTCGGACCCGGAAACGGGCTCGATCGAGGAGAGCC TGTC AACAGGGCAGACGAGGTCGCGCGAGAGCACGACATCTCGTACAACGAGCAGCTTGAGGCG GGA GACAACCCCTACCTCAAGTACAACCACGCGGACGCCGAGTTTCAGGAGAAGCTCGCCGAC GAC ACATCCTTCGGGGGAAACCTCGGAAAGGCAGTCTTTCAGGCCAAGAAAAGGGTTCTCGAA CCTT TTGGCCTGGTTGAAGAGGGTGCTAAGACGGCCCCTACCGGAAAGCGGATAGACGACCACT TTC CAAAAAGAAAGAAGGCTCGGACCGAAGAGGACTCCAAGCCTTCCACCTCGTCAGACGCCG AAG CTGGACCCAGCGGATCCCAGCAGCTGCAAATCCCAGCCCAACCAGCCTCAAGTTTGGGAG CTG ATACAATGTCTGCGGGAGGTGGCGGCCCATTGGGCGACAATAACCAAGGTGCCGATGGAG TGG GCAATGCCTCGGGAGATTGGCATTGCGATTCCACGTGGATGGGGGACAGAGTCGTCACCA AGT CCACCCGAACCTGGGTGCTGCCCAGCTACAACAACCACCAGTACCGAGAGATCAAAAGCG GCT CCGTCGACGGAAGCAACGCCAACGCCTACTTTGGATACAGCACCCCCTGGGGGTACTTTG ACTT TAACCGCTTCCACAGCCACTGGAGCCCCCGAGACTGGCAAAGACTCATCAACAACTACTG GGGC TTCAGACCCCGGTCCCTCAGAGTCAAAATCTTCAACATTCAAGTCAAAGAGGTCACGGTG CAGG ACTCCACCACCACCATCGCCAACAACCTCACCTCCACCGTCCAAGTGTTTACGGACGACG ACTA CCAGCTGCCCTACGTCGTCGGCAACGGGACCGAGGGATGCCTGCCGGCCTTCCCTCCGCA GGT 113 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT CTTTACGCTGCCGCAGTACGGTTACGCGACGCTGAACCGCGACAACACAGAAAATCCCAC CGAG AGGAGCAGCTTCTTCTGCCTAGAGTACTTTCCCAGCAAGATGCTGAGAACGGGCAACAAC TTTG AGTTTACCTACAACTTTGAGGAGGTGCCCTTCCACTCCAGCTTCGCTCCCAGTCAGAACC TGTTC AAGCTGGCCAACCCGCTGGTGGACCAGTACTTGTACCGCTTCGTGAGCACAAATAACACT GGCG ^{GAGTCCAGTTCAACAAGAACCTGGCCGGGAGATACGCCAACACCTACAAAAACTG GTTCCCGGG} GCCCATGGGCCGAACCCAGGGCTGGAACCTGGGCTCCGGGGTCAACCGCGCCAGTGTCAG CG CCTTCGCCACGACCAATAGGATGGAGCTCGAGGGCGCGAGTTACCAGGTGCCCCCGCAGC CGA ACGGCATGACCAACAACCTCCAGGGCAGCAACACCTATGCCCTGGAGAACACTATGATCT TCAA CAGCCAGCCGGCGAACCCGGGCACCACCGCCACGTACCTCGAGGGCAACATGCTCATCAC CAG ^{CGAGAGCGAGACGCAGCCGGTGAACCGCGTGGCGTACAACGTCGGCGGGCAGATG GCCACCA} ACAACCAGAGCTCCACCACTGCCCCCGCGACCGGCACGTACAACCTCCAGGAAATCGTGC CCG GCAGCGTGTGGATGGAGAGGGACGTGTACCTCCAAGGACCCATCTGGGCCAAGATCCCAG AGA CGGGGGCGCACTTTCACCCCTCTCCGGCCATGGGCGGATTCGGACTCAAACACCCACCGC CCA TGATGCTCATCAAGAACACGCCTGTGCCCGGAAATATCACCAGCTTCTCGGACGTGCCCG TCAG ^{CAGCTTCATCACCCAGTACAGCACCGGGCAGGTCACCGTGGAGATGGAGTGGGAG CTCAAGAA} GGAAAACTCCAAGAGGTGGAACCCAGAGATCCAGTACACAAACAACTACAACGACCCCCA GTTT GTGGACTTTGCCCCGGACAGCACCGGGGAATACAGAACCACCAGACCTATCGGAACCCGA TAC CTTACCCGACCCCTTTAA (SEQ ID NO: 4) An exemplary reference sequence of wild-type AAV8, SEQ ID NO: 5 (wild-type AAV8), is as follows: MAADGYLPDWLEDNLSEGIREWWALKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLD KGEPVNAADAAALEH DKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEG AKTAPGKKRPVEPSP QRSPDSSTGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGPNTMAAGGGA PMADNNEGADGVGSS SGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGATNDNTYFGYSTPWGYF DFNRFHCHFSPRDWQ RLINNNWGFRPKRLSFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSA HQGCLPPFPADVFMI PQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFQFTYTFEDVPFHSSYAHSQSLDR LMNPLIDQYLYYLSR TQTTGGTANTQTLGFSQGGPNTMANQAKNWLPGPCYRQQRVSTTTGQNNNSNFAWTAGTK YHLNGRNSLANPGIA MATHKDDEERFFPSNGILIFGKQNAARDNADYSDVMLTSEEEIKTTNPVATEEYGIVADN LQQQNTAPQIGTVNS ^{QGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTP VPADPPTTFNQSKLNSFITQ} YSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTSVDFAVNTEGVYSEPRPIGTRYLT RNL (SEQ ID NO: 5) In the sequence above, the sequence found in VP1, VP2 and VP3 is underlined (e.g., a VP3 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 204-739 of SEQ ID NO: 5), the sequence found in both VP1 and VP2 is in bold (e.g., a VP2 capsid polypeptide includes, e.g., consists of, the sequence corresponding to amino acids 138- 735 of SEQ ID NO: 5) and the sequence that is not underlined or bold is found only in VP1 (e.g., a VP1 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 1-739 of SEQ ID NO: 5). An example nucleic acid sequence encoding SEQ ID NO: 5 is SEQ ID NO: 6: ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGC GAGT GGTGGGCGCTGAAACCTGGAGCCCCGAAGCCCAAAGCCAACCAGCAAAAGCAGGACGACG GC ^{CGGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACA AGGGGGAG} CCCGTCAACGCGGCGGACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTG CA GGCGGGTGACAATCCGTACCTGCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCT GCA AGAAGATACGTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGT TCT CGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACGGCTCCTGGAAAGAAGAGACCGGT AGA 114 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GCCATCACCCCAGCGTTCTCCAGACTCCTCTACGGGCATCGGCAAGAAAGGCCAACAGCC CGC CAGAAAAAGACTCAATTTTGGTCAGACTGGCGACTCAGAGTCAGTTCCAGACCCTCAACC TCTCG GAGAACCTCCAGCAGCGCCCTCTGGTGTGGGACCTAATACAATGGCTGCAGGCGGTGGCG CAC CAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCGGGAAATTGGCATT GCG ^{ATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCT GCCCACCT} ACAACAACCACCTCTACAAGCAAATCTCCAACGGGACATCGGGAGGAGCCACCAACGACA ACAC CTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTT TTCAC CACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAGCT TCAA GCTCTTCAACATCCAGGTCAAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAA TAAC ^{CTCACCAGCACCATCCAGGTGTTTACGGACTCGGAGTACCAGCTGCCGTACGTTC TCGGCTCTG} CCCACCAGGGCTGCCTGCCTCCGTTCCCGGCGGACGTGTTCATGATTCCCCAGTACGGCT ACCT AACACTCAACAACGGTAGTCAGGCCGTGGGACGCTCCTCCTTCTACTGCCTGGAATACTT TCCTT CGCAGATGCTGAGAACCGGCAACAACTTCCAGTTTACTTACACCTTCGAGGACGTGCCTT TCCAC AGCAGCTACGCCCACAGCCAGAGCTTGGACCGGCTGATGAATCCTCTGATTGACCAGTAC CTGT ^{ACTACTTGTCTCGGACTCAAACAACAGGAGGCACGGCAAATACGCAGACTCTGGG CTTCAGCCA} AGGTGGGCCTAATACAATGGCCAATCAGGCAAAGAACTGGCTGCCAGGACCCTGTTACCG CCAA CAACGCGTCTCAACGACAACCGGGCAAAACAACAATAGCAACTTTGCCTGGACTGCTGGG ACCA AATACCATCTGAATGGAAGAAATTCATTGGCTAATCCTGGCATCGCTATGGCAACACACA AAGAC GACGAGGAGCGTTTTTTTCCCAGTAACGGGATCCTGATTTTTGGCAAACAAAATGCTGCC AGAGA CAATGCGGATTACAGCGATGTCATGCTCACCAGCGAGGAAGAAATCAAAACCACTAACCC TGTG GCTACAGAGGAATACGGTATCGTGGCAGATAACTTGCAGCAGCAAAACACGGCTCCTCAA ATTG GAACTGTCAACAGCCAGGGGGCCTTACCCGGTATGGTCTGGCAGAACCGGGACGTGTACC TGC AGGGTCCCATCTGGGCCAAGATTCCTCACACGGACGGCAACTTCCACCCGTCTCCGCTGA TGG GCGGCTTTGGCCTGAAACATCCTCCGCCTCAGATCCTGATCAAGAACACGCCTGTACCTG CGGA TCCTCCGACCACCTTCAACCAGTCAAAGCTGAACTCTTTCATCACGCAATACAGCACCGG ACAGG TCAGCGTGGAAATTGAATGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGAACCCCGAGA TCC AGTACACCTCCAACTACTACAAATCTACAAGTGTGGACTTTGCTGTTAATACAGAAGGCG TGTAC TCTGAACCCCGCCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAA (SEQ ID NO: 6) An exemplary reference sequence of wild-type AAV9, SEQ ID NO: 7 (wild-type AAV9), is as follows: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLD KGEPVNAADAAALEH DKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEA AKTAPGKKRPVEQSP QEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAP VADNNEGADGVGSSS ^{GNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTP WGYFDFNRFHCHFSPRDWQR} LINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAH EGCLPPFPADVFMIP QYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRL MNPLIDQYLYYLSKT INGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWA LNGRNSLMNPGPAMA SHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQ SAQAQAQTGWVQNQG ^{ILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVP ADPPTAFNKDKLNSFITQYS} TGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRN L (SEQ ID NO: 7) In the sequence above, the sequence found in VP1, VP2 and VP3 is underlined (e.g., a VP3 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 203-737 of SEQ ID NO: 7), the sequence found in both VP1 and VP2 is in bold (e.g., a VP2 capsid polypeptide includes, e.g., consists of, the sequence corresponding to amino acids 138- 737 of SEQ ID NO: 7) and the sequence that is not underlined or bold is found only in VP1 (e.g., a VP1 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 1-737 of SEQ ID NO: 7). 115 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT An example nucleic acid sequence encoding SEQ ID NO: 7 is SEQ ID NO: 8: ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGTATTCGC GAGT GGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAACAACATCAAGACAACG CTCG AGGTCTTGTGCTTCCGGGTTACAAATACCTTGGACCCGGCAACGGACTCGACAAGGGGGA GCC GGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAA GG CCGGAGACAACCCGTACCTCAAGTACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCA AAG AAGATACGTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTC TTGA ACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACGGCTCCTGGAAAGAAGAGGCCTGTAGA GCA GTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCCCGCTAA AAA GAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGACCCTCAACCAATCGG AGAA CCTCCCGCAGCCCCCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCA GTG GCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGCGAT TCCC AATGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACA ACA ATCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCT ACTTC GGCTACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCA CGTGA CTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCT CTTC AACATTCAGGTCAAAGAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTT ACCAG CACGGTCCAGGTCTTCACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCA CGA GGGCTGCCTCCCGCCGTTCCCAGCGGACGTTTTCATGATTCCTCAGTACGGGTATCTGAC GCTT AATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCG CAAAT GCTAAGAACGGGTAACAACTTCCAGTTCAGCTACGAGTTTGAGAACGTACCTTTCCATAG CAGCT ACGCTCACAGCCAAAGCCTGGACCGACTAATGAATCCACTCATCGACCAATACTTGTACT ATCTC TCAAAGACTATTAACGGTTCTGGACAGAATCAACAAACGCTAAAATTCAGTGTGGCCGGA CCCAG CAACATGGCTGTCCAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGT CTCA ACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTTCTTCTTGGGCT CTCAA TGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAAAGAAGGAGAGGA CCGT TTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAAGAGACAACGTG GATGC GGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGTAGCAACGGA GTCCT ATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGACCGGCTGGGTTC AAA ACCAAGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCA TTTG GGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGG AATG AAGCACCCGCCTCCTCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACG GCCT TCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGG AGATC GAGTGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCC AAC ^{TATTACAAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTG AACCCCGCCCC} ATTGGCACCAGATACCTGACTCGTAATCTGTAA (SEQ ID NO: 8) An exemplary reference sequence of wild-type AAVrh74, SEQ ID NO: 9 (wild-type AAVrh74), is as follows: ^{MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGRGLVLPGYKYLGP FNGLDKGEPVNAADAAALEH} DKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVESP VKTAPGKKRPVEPSP QRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGTMAAGGGA PMADNNEGADGVGSS SGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYF DFNRFHCHFSPRDWQ RLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSA HQGCLPPFPADVFMI PQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDR LMNPLIDQYLYYLSR TQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATK YHLNGRDSLVNPGVA MATHKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADN LQQQNAAPIVGAVNS QGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADP PTTFNQAKLASFITQ YSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLT RNL (SEQ ID NO: 9) An alternative exemplary reference sequence of SEQ ID NO: 10 (alternate wild-type AAVrh74) is as follows: 116 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGRGLVLPGYKYLGPFNGLD KGEPVNAADAAALEH DKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVESP VKTAPGKKRPVEPSP QRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGTMAAGGGA PMADNNEGADGVGSS SGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYF DFNRFHCHFSPRDWQ RLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSA HQGCLPPFPADVFMI PQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDR LMNPLIDQYLYYLSR TQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATK YHLNGRDSLVNPGVA MATHKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADN LQQQNAAPIVGAVNS QGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADP PTTFTKAKLASFITQ YSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLT RNL (SEQ ID NO: 10) In the sequences above (SEQ ID NO: 9 or SEQ ID NO: 10), the sequence found in VP1, VP2 and VP3 is underlined (e.g., a VP3 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 204-739 of SEQ ID NO: 9), the sequence found in both VP1 and VP2 is in bold (e.g., a VP2 capsid polypeptide includes, e.g., consists of, the sequence corresponding to amino acids 137-739 of SEQ ID NO: 9) and the sequence that is not underlined or bold is found only in VP1 (e.g., a VP1 capsid polypeptide includes, e.g., consists of, amino acids corresponding to amino acids 1-739 of SEQ ID NO: 9). An example nucleic acid sequence encoding SEQ ID NO: 9 is SEQ ID NO: 11. ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGC GAGT GGTGGGACCTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACAACG GCC GGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGG AGC ^{CCGTCAACGCGGCGGACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCA GCTCCAA} GCGGGTGACAATCCGTACCTGCGGTATAATCACGCCGACGCCGAGTTTCAGGAGCGTCTG CAA GAAGATACGTCTTTTGGGGGCAACCTCGGGCGCGCAGTCTTCCAGGCCAAAAAGCGGGTT CTC GAACCTCTGGGCCTGGTTGAATCGCCGGTTAAGACGGCTCCTGGAAAGAAGAGGCCGGTA GAG CCATCACCCCAGCGCTCTCCAGACTCCTCTACGGGCATCGGCAAGAAAGGCCAGCAGCCC GCA ^{AAAAAGAGACTCAATTTTGGGCAGACTGGCGACTCAGAGTCAGTCCCCGACCCTC AACCAATCG} GAGAACCACCAGCAGGCCCCTCTGGTCTGGGATCTGGTACAATGGCTGCAGGCGGTGGCG CTC CAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCAGGAAATTGGCATT GCGA TTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGCACCTGGGCCCTGCCCAC CTA CAACAACCACCTCTACAAGCAAATCTCCAACGGGACCTCGGGAGGAAGCACCAACGACAA CACC ^{TACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCC ACTTTTCACC} ACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGGCTCAACTT CAAG CTCTTCAACATCCAAGTCAAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAAT AACC TTACCAGCACGATTCAGGTCTTTACGGACTCGGAATACCAGCTCCCGTACGTGCTCGGCT CGGC GCACCAGGGCTGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGGTA CCTG ^{ACTCTGAACAATGGCAGTCAGGCTGTGGGCCGGTCGTCCTTCTACTGCCTGGAGT ACTTTCCTT} CTCAAATGCTGAGAACGGGCAACAACTTTGAATTCAGCTACAACTTCGAGGACGTGCCCT TCCAC AGCAGCTACGCGCACAGCCAGAGCCTGGACCGGCTGATGAACCCTCTCATCGACCAGTAC TTGT ACTACCTGTCCCGGACTCAAAGCACGGGCGGTACTGCAGGAACTCAGCAGTTGCTATTTT CTCA GGCCGGGCCTAACAACATGTCGGCTCAGGCCAAGAACTGGCTACCCGGTCCCTGCTACCG GCA ^{GCAACGTGTCTCCACGACACTGTCGCAGAACAACAACAGCAACTTTGCCTGGACG GGTGCCACC} AAGTATCATCTGAATGGCAGAGACTCTCTGGTGAATCCTGGCGTTGCCATGGCTACCCAC AAGG ACGACGAAGAGCGATTTTTTCCATCCAGCGGAGTCTTAATGTTTGGGAAACAGGGAGCTG GAAA AGACAACGTGGACTATAGCAGCGTGATGCTAACCAGCGAGGAAGAAATAAAGACCACCAA CCCA GTGGCCACAGAACAGTACGGCGTGGTGGCCGATAACCTGCAACAGCAAAACGCCGCTCCT ATT GTAGGGGCCGTCAATAGTCAAGGAGCCTTACCTGGCATGGTGTGGCAGAACCGGGACGTG TAC CTGCAGGGTCCCATCTGGGCCAAGATTCCTCATACGGACGGCAACTTTCATCCCTCGCCG CTGA TGGGAGGCTTTGGACTGAAGCATCCGCCTCCTCAGATCCTGATTAAAAACACACCTGTTC CCGC 117 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GGATCCTCCGACCACCTTCAATCAGGCCAAGCTGGCTTCTTTCATCACGCAGTACAGTAC CGGC CAGGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAGAACAGCAAACGCTGGAACCCA GAG ATTCAGTACACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTCAATACTGAG GGTACT TATTCCGAGCCTCGCCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAA (SEQ ID NO: 11) An exemplary reference sequence of an AAV2 variant identified from the ocular literature, SEQ ID NO: 72, is as follows: MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPKPAERHKDDSRGLVLPGYKYLGPFNGLD KGEPVNEADAAALEH DKAYDRQLDSGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRVLEPLGLVEEP VKTAPGKKRPVEHSP VEPDSSSGTGKAGQQPARKRLNFGQTGDADSVPDPQPLGQPPAAPSGLGTNTMATGSGAP MADNNEGADGVGNSS GNWHCDSTWMGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPWGYFDFN RFHCHFSPRDWQRLI NNNWGFRPKRLNFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQG CLPPFPADVFMVPQY GYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMN PLIDQYLYYLSRTNT PSGTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHL NGRDSLVNPGPAMAS HKDDEEKFFPQSGVLIFGKQGSEKTNVDIEKVMITDEEEIRTTNPVATEQYGSVSTNLQR GNLALGETTRPARQA ATADVNTQGVLPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKN TPVPANPSTTFSAAK FASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVNVDFTVDTNGVYSEPRP IGTRYLTRNL (SEQ ID NO: 72). An example nucleic acid sequence encoding SEQ ID NO: 72 is SEQ ID NO: 73. ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACACTCTCTCTGAAGGAATAAGA CAGTGGTGGAA GCTCAAACCTGGCCCACCACCACCAAAGCCCGCAGAGCGGCATAAGGACGACAGCAGGGG TCTTGTGCTT CCTGGGTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGAGAGCCGGTCAACGAG GCAGACGCCG CGGCCCTCGAGCACGACAAAGCCTACGACCGGCAGCTCGACAGCGGAGACAACCCGTACC TCAAGTACAA CCACGCCGACGCGGAGTTTCAGGAGCGCCTTAAAGAAGATACGTCTTTTGGGGGCAACCT CGGACGAGCA GTCTTCCAGGCGAAAAAGAGGGTTCTTGAACCTCTGGGCCTGGTTGAGGAACCTGTTAAG ACGGCTCCGGG AAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAGCCAGACTCCTCCTCGGGAACCGGAAA GGCGGGCCAG CAGCCTGCAAGAAAAAGATTGAATTTTGGTCAGACTGGAGACGCAGACTCAGTACCTGAC CCCCAGCCTCT ^{CGGACAGCCACCAGCAGCCCCCTCTGGTCTGGGAACTAATACGATGGCTACAGGC AGTGGCGCACCAATG} GCAGACAATAACGAGGGCGCCGACGGAGTGGGTAATTCCTCGGGAAATTGGCATTGCGAT TCCACATGGAT GGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAACCA CCTCTACAAAC AAATTTCCAGCCAATCAGGAGCCTCGAACGACAATCACTACTTTGGCTACAGCACCCCTT GGGGGTATTTTG ACTTCAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAAAGACTCATCAACAACA ACTGGGGATTCC ^{GACCCAAGAGACTCAACTTCAAGCTCTTTAACATTCAAGTCAAAGAGGTCACGCA GAATGACGGTACGACGA} CGATTGCCAATAACCTTACCAGCACGGTTCAGGTGTTTACTGACTCGGAGTACCAGCTCC CGTACGTCCTCG GCTCGGCGCATCAAGGATGCCTCCCGCCGTTCCCAGCAGACGTCTTCATGGTGCCACAGT ATGGATACCTC ACCCTGAACAACGGGAGTCAGGCAGTAGGACGCTCTTCATTTTACTGCCTGGAGTACTTT CCTTCTCAGATG CTGCGTACCGGAAACAACTTTACCTTCAGCTACACTTTTGAGGACGTTCCTTTCCACAGC AGCTACGCTCAC ^{AGCCAGAGTCTGGACCGTCTCATGAATCCTCTCATCGACCAGTACCTGTATTACT TGAGCAGAACAAACACT} CCAAGTGGAACCACCACGCAGTCAAGGCTTCAGTTTTCTCAGGCCGGAGCGAGTGACATT CGGGACCAGTC TAGGAACTGGCTTCCTGGACCCTGTTACCGCCAGCAGCGAGTATCAAAGACATCTGCGGA TAACAACAACA 118 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT GTGAATACTCGTGGACTGGAGCTACCAAGTACCACCTCAATGGCAGAGACTCTCTGGTGA ATCCGGGCCCG GCCATGGCAAGCCACAAGGACGATGAAGAAAAGTTTTTTCCTCAGAGCGGGGTTCTCATC TTTGGGAAGCA AGGCTCAGAGAAAACAAATGTGGACATTGAAAAGGTCATGATTACAGACGAAGAGGAAAT CAGGACAACCAA TCCCGTGGCTACGGAGCAGTATGGTTCTGTATCTACCAACCTCCAGAGAGGCAACTTGGC TCTTGGGGAAA ^{CTACGCGTCCTGCAAGACAAGCAGCTACCGCAGATGTCAACACACAAGGCGTTCT ACCAGGCATGGTCTGG} CAGGACAGAGATGTGTACCTTCAGGGGCCCATCTGGGCAAAGATTCCACACACGGACGGA CATTTTCACCC CTCTCCCCTCATGGGTGGATTCGGACTTAAACACCCTCCTCCACAGATTCTCATCAAGAA CACCCCGGTACC TGCGAATCCTTCGACCACCTTCAGTGCGGCAAAGTTTGCTTCCTTCATCACACAGTACTC CACGGGACAGGT CAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAACAGCAAACGCTGGAATCCCGAAAT TCAGTACACTT ^{CCAACTACAACAAGTCTGTTAATGTGGACTTTACTGTGGACACTAATGGCGTGTA TTCAGAGCCTCGCCCCA} TTGGCACCAGATACCTGACTCGTAATCTGTAA (SEQ ID NO: 73). In some embodiments, described herein are capsid polypeptides, e.g., as described in Table 2, that when included in a virus particle comprising a payload, provide increased delivery of such payload to one or more tissues or cell types of the eye (such as, for example, the neural retina, the macula, and/or the choroid/RPE), e.g., after intravitreal administration, relative to an otherwise identical virus particle comprising the capsid polypeptides of SEQ ID NO: 72. In some embodiments, described herein are capsid polypeptides, e.g., as described in Table 2, that when included in a virus particle comprising a payload, provide increased delivery of such payload to one or more tissues or cell types of the eye (such as, for example, tissues or cells of the trabecular meshwork and Schlemm’s canal), e.g., after intravitreal or intracameral administration, relative to an otherwise identical virus particle comprising the capsid polypeptides of SEQ ID NO: 72. The present disclosure refers to structural capsid proteins (including VP1, VP2 and VP3) which are encoded by capsid (Cap) genes. These capsid proteins form an outer protein structural shell (i.e., capsid) of a viral vector such as AAV. VP capsid proteins synthesized from Cap polynucleotides generally include a methionine as the first amino acid in the polypeptide sequence (Met1), which is associated with the start codon (AUG or ATG) in the corresponding Cap nucleotide sequence. However, it is common for a first-methionine (Met1) residue or generally any first amino acid (AA1) to be cleaved off after or during polypeptide synthesis by protein processing enzymes such as Met-aminopeptidases. This “Met/AA-clipping” process often correlates with a corresponding acetylation of the second amino acid in the polypeptide sequence (e.g., alanine, valine, serine, threonine, etc.). Met- clipping commonly occurs with VP1 and VP3 capsid proteins but can also occur with VP2 capsid proteins. Where the Met/AA-clipping is incomplete, a mixture of one or more (one, two or three) VP capsid proteins comprising the viral capsid can be produced, some of which include a Met1/AA1 amino acid (Met+/AA+) and some of which lack a Met1/AA1 amino 119 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT acid as a result of Met/AA-clipping (Met-/AA-). For further discussion regarding Met/AA- clipping in capsid proteins, see Jin, et al. Direct Liquid Chromatography/Mass Spectrometry Analysis for Complete Characterization of Recombinant Adeno-Associated Virus Capsid Proteins. Hum Gene Ther Methods.2017 Oct.28(5):255-267; Hwang, et al. N- Terminal Acetylation of Cellular Proteins Creates Specific Degradation Signals. Science.2010 February 19.327(5968): 973–977; the contents of which are each incorporated herein by reference in its entirety. According to the present disclosure, references to capsid polypeptides is not limited to either clipped (Met-/AA-) or unclipped (Met+/AA+) and, in context, also refer to independent capsid polypeptides, viral capsids comprised of a mixture of capsid proteins, and/or polynucleotide sequences (or fragments thereof) which encode, describe, produce or result in capsid polypeptides of the present disclosure. A direct reference to a “capsid polypeptide” (such as VP1, VP2 or VP3) also comprise VP capsid proteins which include a Met1/AA1 amino acid (Met+/AA+) as well as corresponding VP capsid polypeptide which lack the Met1/AA1 amino acid e.g. as a result of Met/AA-clipping (Met- /AA-). Further according to the present disclosure, a reference to a specific SEQ ID NO: (whether a protein or nucleic acid) which comprises or encodes, respectively, one or more capsid polypeptides which include a Met1/AA1 amino acid (Met+/AA+) should be understood to teach the VP capsid polypeptides which lack the Met1/AA1 amino acid as upon review of the sequence, it is readily apparent that the first listed amino acid (whether or not Met1/AA1) may be absent. As a non-limiting example, reference to a VP1 polypeptide sequence which is 736 amino acids in length and which includes a “Met1” amino acid (Met+) encoded by the AUG/ATG start codon is also understood to teach a VP1 polypeptide sequence which is 735 amino acids in length and which does not include the “Met1” amino acid (Met-) of the 736 amino acid Met+ sequence. As a second non-limiting example, reference to a VP1 polypeptide sequence which is 736 amino acids in length and which includes an “AA1” amino acid (AA1+) encoded by any NNN initiator codon can also be understood to teach a VP1 polypeptide sequence which is 735 amino acids in length and which does not include the “AA1” amino acid (AA1-) of the 736 amino acid AA1+ sequence. References to viral capsids formed from VP capsid proteins (such as reference to specific AAV capsid serotypes), can incorporate VP capsid proteins which include a Met1/AA1 amino acid (Met+/AA1+), corresponding VP capsid proteins which lack the Met1/AA1 amino acid e.g. as a result of Met/AA1-clipping (Met-/AA1-), and combinations thereof (Met+/AA1+ and Met-/AA1-). As a non-limiting example, an AAV capsid serotype can 120 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT include VP1 (Met+/AA1+), VP1 (Met-/AA1-), or a combination of VP1 (Met+/AA1+) and VP1 (Met- /AA1-). An AAV capsid serotype can also include VP3 (Met+/AA1+), VP3 (Met- /AA1-), or a combination of VP3 (Met+/AA1+) and VP3 (Met-/AA1-); and can also include similar optional combinations of VP2 (Met+/AA1) and VP2 (Met-/AA1-). In some embodiments, the reference AAV capsid sequence comprises an amino acid sequence with 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any of the those described above. In some embodiments, the reference AAV capsid sequence is encoded by a nucleotide sequence with 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any of those described above. In certain embodiments, the reference sequence is not an AAV capsid sequence and is instead a different vector (e.g., lentivirus, plasmid, etc.). In some embodiments, a nucleic acid of the disclosure (e.g., encoding an AAV2 variant capsid protein) comprises conventional control elements or sequences which are operably linked to the nucleic acid molecule in a manner which permits transcription, translation and/or expression in a cell transfected with the nucleic acid (e.g., a plasmid vector comprising said nucleic acid) or infected with a virus comprising said nucleic acid. As used herein, “operably linked” sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. Expression control sequences include efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; appropriate transcription initiation, termination, promoter and enhancer sequences; sequences that stabilize cytoplasmic mRNA; sequences that enhance protein stability; sequences that enhance translation efficiency (e.g., Kozak consensus sequence); and in some embodiments, sequences that enhance secretion of the encoded transgene product. Expression control sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized with the compositions and methods disclosed herein. 121 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the native promoter for the transgene may be used. Without wishing to be bound by theory, the native promoter may mimic native expression of the transgene, or provide temporal, developmental, or tissue-specific expression, or expression in response to specific transcriptional stimuli. In some embodiment, the transgene may be operably linked to other native expression control elements, such as enhancer elements, polyadenylation sites or Kozak consensus sequences, e.g., to mimic the native expression. In some embodiments, the transgene is operably linked to a tissue-specific promoter. In some embodiments, a vector, e.g., a plasmid, carrying a transgene may also include a selectable marker or a reporter gene. Such selectable reporters or marker genes can be used to signal the presence of the vector, e.g., plasmid, in bacterial cells. Other components of the vector, e.g., plasmid, may include an origin of replication. Selection of these and other promoters and vector elements are conventional, and many such sequences are available (see, e.g., Sambrook et al, and references cited therein). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the eye as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the retina as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the non-macular retina as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the macula as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the trabecular meshwork as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the macula relative to retina as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the macula relative to non- macular retina as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the 122 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT capsid polypeptide present in a viral particle increases transduction in the macula relative to trabecular meshwork as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the macula relative to non-macular retina and trabecular meshwork as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the macula relative to retina and trabecular meshwork as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the retina relative to macula and trabecular meshwork as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 1-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 1.5-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 2-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 4-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 6-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 8-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 10-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid 123 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT polypeptide present in a viral particle increases ocular transduction 15-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 16-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 19-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 32-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 50-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 60-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 80-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 100-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 100-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild- type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 200-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 300-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction 400-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, with the wild-type capsid polypeptide (SEQ ID NO: 1). In some 124 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT embodiments, increased ocular transduction is measured by comparing the level of mRNA in the target tissue (e.g., in a cell or population of cells of the target tissue) produced from a nucleic acid packaged in the variant viral particle with the level of mRNA in the target tissue (e.g., in a cell or population of cells of the target tissue) produced from a nucleic acid packaged in a reference viral particle (e.g., packaged in a capsid comprising capsid polypeptides of SEQ ID NO: 1). In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the eye as compared to a viral particle with a reference capsid polypeptide, for example, with a reference capsid polypeptide of SEQ ID NO: 72. In some embodiments, the capsid polypeptide present in a viral particle increases transduction in the trabecular meshwork as compared to a viral particle with a reference capsid polypeptide, for example, a reference capsid polypeptide of SEQ ID NO: 72. In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 1-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, a reference capsid polypeptide of SEQ ID NO: 72. In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 1.5-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, a reference capsid polypeptide of SEQ ID NO: 72. In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 2-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, a reference capsid polypeptide of SEQ ID NO: 72. In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 2.5-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, a reference capsid polypeptide of SEQ ID NO: 72. In some embodiments, the capsid polypeptide present in a viral particle increases ocular transduction at least 2.7-fold, e.g., as compared to a viral particle with a reference capsid polypeptide, for example, a reference capsid polypeptide of SEQ ID NO: 72. In some embodiments, the increased ocular transduction is measured in the trabecular meshwork, e.g., as described in Example 3. In some embodiments, the capsid polypeptide is an isolated or purified polypeptide (e.g., isolated or purified from a cell, other biological component, or contaminant). In some embodiments, the variant polypeptide is present in a dependoparvovirus particle, e.g., described herein. In some embodiments, the variant capsid polypeptide is present in a cell, cell-free system, or translation system, e.g., described herein. 125 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, the cell is a non-human cell. In other embodiments, the cell is not a human pluripotent stem cell, e.g. it is not a human embryonic stem cell. In some embodiments, the capsid polypeptide is present in a dependoparvovirus B (e.g., AAV2) particle. In some embodiments, the capsid particle has increased ocular transduction. In some embodiments, a dependoparvovirus particle comprises an amino acid sequence that has at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the amino acid sequences provided for herein (e.g., SEQ ID NO: 12-23, SEQ ID NO: 46). In some embodiments, the variant capsid polypeptide comprises an amino acid sequence that differs by no more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acids from the amino acid sequence of a variant capsid polypeptide provided for herein. In some embodiments, the additional alteration improves a production characteristic of a viral particle, such as but not limited to, a dependoparvovirus particle or method of making the same. In some embodiments, the additional alteration improves or alters another characteristic of a viral particle, such as but not limited to, a dependoparvovirus particle, e.g., tropism. In some embodiments, the improved transduction is as measured by quantification of viral RNA from the target tissue. In some embodiments, the improved biodistribution is as measured by quantification of viral DNA from the target tissue. In some embodiments, the improved transduction is as measured following production from HEK293 cells, for example as described in the Examples. VP1 Nucleic Acids and Polypeptides The disclosure is further directed, in part, to a nucleic acid comprising a sequence encoding a capsid polypeptide, such as but not limited to, a dependoparvovirus (e.g., dependoparvovirus B, e.g., an AAV2) capsid polypeptide as provided for herein, as well as to a VP1 polypeptide encoded by the same. In some embodiments, the polypeptide comprises a sequence of SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 46. Viral Particles 126 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT The disclosure is also directed, in part, to a viral particle, such as but not limited to, a dependoparvovirus particle (e.g., a functional dependoparvovirus particle) comprising a nucleic acid or polypeptide described herein or produced by a method described herein. Dependoparvovirus is a single-stranded DNA parvovirus that grows only in cells in which certain functions are provided, e.g., by a co-infecting helper virus. Several species of dependoparvovirus are known, including dependoparvovirus A and dependoparvovirus B, which include serotypes known in the art as adeno-associated viruses (AAV). At least thirteen serotypes of AAV that have been characterized. General information and reviews of AAV can be found in, for example, Carter, Handbook of Parvoviruses, Vol.1, pp.169-228 (1989), and Berns, Virology, pp.1743-1764, Raven Press, (New York, 1990). AAV serotypes, and to a degree, dependoparvovirus species, are significantly interrelated structurally and functionally. (See, for example, Blacklowe, pp.165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed. (1988); and Rose, Comprehensive Virology 3:1-61 (1974)). For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes; and all bear three related capsid proteins. In addition, heteroduplex analysis reveals extensive cross-hybridization between serotypes along the length of the genome, further suggesting interrelatedness. Dependoparvoviruses genomes also comprise self-annealing segments at the termini that correspond to “inverted terminal repeat sequences” (ITRs). The genomic organization of naturally occurring dependoparvoviruses, e.g., AAV serotypes, is very similar. For example, the genome of AAV is a linear, single-stranded DNA molecule that is approximately 5,000 nucleotides (nt) in length or less. Inverted terminal repeats (ITRs) flank the unique coding nucleotide sequences for the non-structural replication (Rep) proteins and the structural capsid (Cap) proteins. Three different viral particle (VP) proteins form the capsid. The terminal 145 nt are self-complementary and are organized so that an energetically stable intramolecular duplex forming a T-shaped hairpin may be formed. These hairpin structures function as an origin for viral DNA replication, serving as primers for the cellular DNA polymerase complex. The Rep genes encode the Rep proteins: Rep78, Rep68, Rep52, and Rep40. Rep78 and Rep68 are transcribed from the p5 promoter, and Rep 52 and Rep40 are transcribed from the p19 promoter. The cap genes encode the VP proteins, VP1, VP2, and VP3. The cap genes are transcribed from the p40 promoter. 127 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, a dependoparvovirus particle of the disclosure comprises a nucleic acid comprising a capsid polypeptide provided for herein. In some embodiments, the particle comprises a polypeptide as provided for herein. In some embodiments, the dependoparvovirus particle of the disclosure may be an AAV2 particle or a variant thereof. In some embodiments, the AAV2 particle comprises a capsid polypeptide as provided for herein or a nucleic acid molecule encoding the same. In some embodiments the dependoparvovirus particle comprises a capsid comprising a variant capsid polypeptide described herein. In some embodiments, the dependoparvovirus particle comprises variant capsid polypeptide described herein and a nucleic acid molecule. In some embodiments, the dependoparvovirus particle comprises variant capsid polypeptide described herein and a nucleic acid molecule comprising one or more inverted terminal repeat sequences (ITRs), for example, ITRs derived from an AAV2 dependoparvovirus, one or more regulatory elements (for example, a promoter), and a payload (e.g., as described herein). In some embodiments, at least one of the ITRs is modified. In some embodiments, the nucleic acid molecule is single-stranded. In some embodiments, the nucleic acid molecule is self- complementary. In some embodiments, the viral particle comprises a variant capsid polypeptide such as those provided herein. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence as provided in Table 2. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 12. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 13. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 14. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 15. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 16. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ 128 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ID NO: 17. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 18. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 19. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 20. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 21. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 22. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 23. In some embodiments, the viral particle comprises a variant capsid polypeptide having at least 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%, or 100% identity to a VP1, VP2, or VP3 sequence of SEQ ID NO: 46. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 12. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 13. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 14. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 15. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 16. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 17. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 18. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 19. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 20. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 21. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 22. In some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 23. In 129 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT some embodiments, the viral particle comprises a variant capsid polypeptide having a sequence of SEQ ID NO: 46. Increased Ocular Transduction Characteristics The disclosure is directed, in part, to nucleic acids, polypeptides, cells, cell free systems, translation systems, viral particles, and methods associated with making the same to produce virus particles that have increased ocular transduction as compared to a virus particle having capsid polypeptides of a reference sequence, e.g., with a wild-type sequence of SEQ ID NO: 1. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the eye, and, therefore, expression of the transgene in the eye. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the retina, and, therefore, expression of the transgene in the retina. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the non-macular retina, and, therefore, expression of the transgene in the non-macular retina. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the macula, and, therefore, expression of the transgene in the macula. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the trabecular meshwork, and, therefore, expression of the transgene in the trabecular meshwork. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the front third of the eye, which includes the structures in front of the vitreous humor. Examples of structures in front of the vitreous humor, include the cornea, iris, ciliary body, lens, trabecular meshwork, and Schlemm’s canal. Accordingly, in some embodiments, use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. Accordingly, in some embodiments, use of a viral particle comprising the variant capsid polypeptide leads to 130 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT increased ocular transduction of a transgene in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, a use of a viral particle comprising the variant capsid polypeptide leads to increased ocular transduction of a transgene in the front third of the eye and posterior to the lens. In some embodiments, the increase in ocular transduction is, on a log2 scale, about 0.4-4 times better (e.g., about 1-4 times better, e.g., about 2-4 times better) than a virus particle having a reference sequence capsid polypeptide, e.g., having the wild-type capsid polypeptide SEQ ID NO: 1. In some embodiments, the capsid polypeptide present in a viral particle increases transduction without increasing the biodistribution of the variant capsid polypeptide in the eye relative to SEQ ID NO: 1. In some embodiments, the capsid polypeptide present in a viral particle increases transduction without increasing the biodistribution of the variant capsid polypeptide in the retina relative to SEQ ID NO: 1. In some embodiments, the capsid polypeptide present in a viral particle increases transduction without increasing the biodistribution of the variant capsid polypeptide in the trabecular meshwork relative to SEQ ID NO: 1. Tables 3, 4A, 4B, 4C, 4D, and 4E list information regarding biodistribution of variant dependoparvovirus particles comprising capsid polypeptides of the indicated variant capsid in the different layers, structures, and/or parts of the eye. In Table 3, biodistribution in retina is as measured following IVT injection and biodistribution in trabecular meshwork is as measured following IC injection, in both cases in the Library Experiment 1. In Table 4A, biodistribution in trabecular meshwork is as measured following IC injection or IVT injection (as indicated in the table) and biodistribution in the choroid is as measured following IC injection or IVT injection (as indicated in the table), in all cases in the Library Experiment 2. In Table 4B, biodistribution in the cornea is as measured following IC injection or IVT injection (as indicated in the table) and biodistribution in the iris and the ciliary body is as measured following IC injection or IVT injection (as indicated in the table), in all cases in the Library Experiment 2. In Table 4C, biodistribution in limbal tissue is as measured following IC injection or IVT injection (as indicated in the table) and biodistribution in neural retina is as measured following IC injection or IVT injection (as indicated in the table), in all cases in the Library Experiment 2. In Table 4D, biodistribution in neural retina tissue is as measured following IVT injection, in all cases in the Library Experiment 3. In Table 4C, biodistribution 131 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT in neural retina tissue, biodistribution in macula tissue, and biodistribution in trabecular meshwork is as measured following IVT injection, in all cases in the Library Experiment 3. Unless otherwise indicated, measurements are made relative to wild-type AAV2 (SEQ ID NO: 1). Trabecular biodistribution measurements shown in Table 4E are shown relative to an AAV2 variant identified from the ocular literature having a capsid polypeptide SEQ ID NO: 72 and encoded by nucleic acid SEQ ID NO: 73. Data shown in Tables 3, 4A, 4B, and 4C is on a log2 scale. Table 3 Name SEQ ID Biodistribution in Biodistribution in NO: of Nonmacular Retina Trabecular Meshwork VP1 as compared to as compared to wild- capsid wild-type SEQ ID type SEQ ID NO: 1 poly- NO: 1 (Log2) peptide (Log2) VAR-3 14 2.25 0.91 Table 4A Name SEQ ID Biodistribution Biodistribution Biodistribution Biodistribution NO: of in Trabecular in Trabecular in Choroid in Choroid n) o 2) Table 4B 132 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Name SEQ ID Biodistribution Biodistribution Biodistribution Biodistribution NO: of in Cornea in Cornea in Iris/Ciliary in Iris/Ciliary VP1 (intracameral (intravitreal Body Body n) o 2) ab e C Name SEQ ID Biodistribution Biodistribution Biodistribution Biodistribution NO: of in Limbal in Limbal in Neural in Neural n) o 2) 133 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Table 4D Name SEQ ID NO: of Biodistribution in Neural Retina VP1 capsid Biodistribution (intravitreal polypeptide administration) as compared to a e Name SEQ ID NO: Neural Retina Macular Trabecular of VP1 Biodistribution Biodistribution Biodistribution id Q 134 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT According to some embodiments, variant capsid polypeptides described herein comprise a N587 substitution mutation in combination with a N-terminally juxtaposed insertion peptide (e.g., an insertion peptide originating after glycine (G) at position 586 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1)). In some embodiments, the peptide insertion is 8 or fewer amino acids. In some embodiments, the peptide insertion consists of 8 amino acids. In some embodiments, the peptide insertion is 9 or fewer amino acids. In some embodiments, the peptide insertion consists of 9 amino acids. In some embodiments, the peptide insertion is 8 or more amino acids, e.g., 8, 9, 10, or 11 amino acids. In some embodiments, the peptide insertion is between 8 and 11 amino acids. In some embodiments, the peptide insertion consists of 10 amino acids. In some embodiments, the peptide insertion consists of 11 amino acids. In some embodiments, the insertion peptide comprises a threonine-arginine-proline (“TRP”) sequence at its C-terminal end (e.g., as in VAR-4, VAR-5, VAR-6, and VAR-13). In some embodiments, the insertion peptide comprises a methionine-arginine-proline (“MRP”) sequence at its C-terminal end (e.g., as in VAR-1 and VAR-3). In some embodiments, the insertion peptide comprises a threonine- arginine-glutamine (“TRQ”) sequence at its C-terminal end (e.g., as in VAR-8). In some embodiments, a viral particle comprising the variant capsid polypeptide comprising the N587 substitution mutation (e.g., a N587A mutation) in combination with the N-terminally juxtaposed insertion peptide exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. According to some embodiments, variant capsid polypeptides described herein comprise a threonine-arginine-proline-alanine (“TRPA”) sequence. In some embodiments, the variant capsid polypeptide comprises a peptide insertion (relative to SEQ ID NO: 1) comprising at least some of the TRPA sequence (e.g., 3 or 4 amino acids forming the TRPA sequence). For example, VAR-4, VAR-5, VAR-6, and VAR-13 each comprise a TRPA sequence. In some embodiments, the insertion site is after glycine (G) at position 586 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the peptide insertion is after glycine (G) at position 586 and the alanine substitution is at position 587 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the TRPA sequence is formed by a peptide insertion comprising a threonine-arginine-proline (“TRP”) sequence at its C-terminal end followed by an alanine (A) substitution (e.g., N587A 135 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT substitution). In such embodiments, the alanine (A) substitution mutation in combination with a N-terminally juxtaposed insertion peptide comprising a TRP sequence forms the “TRPA” sequence (e.g., as in VAR-4, VAR-5, VAR-6, and VAR-13). In some embodiments, the peptide insertion is 9 or fewer amino acids. In some embodiments, the peptide insertion consists of 9 amino acids. In some embodiments, the peptide insertion is 10 or fewer amino acids. In some embodiments, the peptide insertion consists of 10 amino acids. In some embodiments, a viral particle comprising the variant capsid polypeptide comprising the TRPA sequence exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. According to some embodiments, variant capsid polypeptides described herein comprise a threonine-alanine-arginine-proline-alanine (“TARPA”) sequence. In some embodiments, the variant capsid polypeptide comprises a peptide insertion comprising at least some of the TARPA sequence (e.g., 2, 3 or 4 amino acids forming the TARPA sequence). In some embodiments, the variant capsid polypeptide comprises a peptide insertion (e.g., relative to SEQ ID NO: 1) comprising all of the TARPA sequence. In some embodiments, the insertion site is after glycine (G) at position 586 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the insertion site is after glutamine (Q) at position 584 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the TARPA sequence is formed as a combination of the peptide insertion and a substitution mutation (e.g., a G586P mutation, a N587A mutation) following the peptide insertion, e.g., a peptide insertion comprising TAR at its C-terminal end (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the TARPA sequence is formed as a combination of the peptide insertion, a substitution mutation (e.g., a G586P mutation, a N587A mutation) following the peptide insertion (according to WT AAV2 VP1 numbering; SEQ ID NO: 1) and an amino acid occurring in WT AAV2 VP1 (SEQ ID NO: 1), e.g., arginine (R) at position 585. In some embodiments, the variant capsid polypeptide comprises a peptide insertion comprising a threonine-alanine-arginine-proline (“TARP”) sequence at its C-terminal end and inserted after glycine (G) at position 586 followed by an alanine substitution is at position 587 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1), e.g., as in VAR-7 and VAR-10. In some embodiments, the variant capsid polypeptide comprises a peptide insertion comprising a threonine-alanine (“TA”) sequence at its C- 136 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT terminal end and inserted after glutamine (Q) at position 584 followed by a proline (P) substitution at position 586 and an alanine (A) substitution at position 587 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1), e.g., as in VAR-2, where the arginine (R) at 585 forms the TARPA sequence. In some embodiments, the peptide insertion is 8 or fewer amino acids. In some embodiments, the peptide insertion is 8 or more amino acids, e.g., 9, 10, or 11 amino acids. In some embodiments, the peptide insertion is between 8 and 11 amino acids. In some embodiments, the peptide insertion consists of 8 amino acids. In some embodiments, the peptide insertion consists of 10 amino acids. In some embodiments, the peptide insertion consists of 11 amino acids. In some embodiments, a viral particle comprising the variant capsid polypeptide comprising the TARPA sequence exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. According to some embodiments, variant capsid polypeptides described herein comprise a methionine-arginine-proline-alanine (“MRPA”) sequence. In some embodiments, the variant capsid polypeptide comprises a peptide insertion (e.g., relative to SEQ ID NO: 1) comprising at least some of the MRPA sequence (e.g., 3 amino acids forming the MRPA sequence). In some embodiments, the insertion site is after glycine (G) at position 586 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the MRPA sequence is formed as a combination of the peptide insertion and a substitution mutation (e.g., a N587A mutation) following the peptide insertion, e.g., a peptide insertion comprising MRP at its C-terminal end (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the variant capsid polypeptide comprises a peptide insertion comprising a methionine-arginine-proline-alanine (“MRPA”) sequence at its C-terminal end and inserted after glycine (G) at position 586 followed by an alanine substitution is at position 587 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1), e.g., as in VAR-1 and VAR-3. In some embodiments, the peptide insertion is 9 or fewer amino acids. In some embodiments, the peptide insertion is 9 or more amino acids. In some embodiments, the peptide insertion consists of 9 amino acids. In some embodiments, a viral particle comprising the variant capsid polypeptide comprising the MRPA sequence exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. 137 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT According to some embodiments, variant capsid polypeptides described herein comprise a T597 substitution mutation (e.g., a T597N mutation, a T597W mutation). In some embodiments, the variant capsid polypeptide comprises a peptide insertion (e.g., according to WT AAV2 VP1 numbering; SEQ ID NO: 1) in combination with the T597 substitution mutation. In some embodiments, the insertion site is after glycine (G) at position 586 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the peptide insertion is 9 or fewer amino acids. In some embodiments, the peptide insertion is 9 or more amino acids. In some embodiments, the peptide insertion consists of 9 amino acids. In some embodiments, the insertion peptide comprises a LAKGETMRP (SEQ ID NO: 36) sequence (e.g., as in VAR-1). In some embodiments, the insertion peptide comprises a GVRAETTRP (SEQ ID NO: 38) sequence (e.g., as in VAR-4 and VAR-5). In some embodiments, a viral particle comprising the variant capsid polypeptide comprising a T597 substitution mutation exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. In some embodiments, the variant capsid polypeptide comprises a threonine-arginine- proline-alanine (“TRPA”) sequence in combination with the T597 substitution mutation. For example, VAR-4 and VAR-5 each comprise a TRPA sequence in combination with a T597 substitution mutation (e.g., a T597W mutation as in VAR-4, and a T597N mutation as in VAR-5). In some embodiments, the TRPA sequence is formed by a peptide insertion comprising a threonine-arginine-proline (“TRP”) sequence at its C-terminal end followed by an alanine (A) substitution (e.g., N587A substitution). In some embodiments, the peptide insertion is after glycine (G) at position 586 and the alanine substitution is at position 587 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the insertion peptide comprises a GVRAETTRP (SEQ ID NO: 38) sequence (e.g., as in VAR-4 and VAR-5). In some embodiments, a viral particle comprising the variant capsid polypeptide comprising a T597 substitution mutation in combination with a TRPA sequence exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. In some embodiments, the variant capsid polypeptide comprises a methionine- arginine-proline-alanine (“MRPA”) sequence in combination with the T597 substitution mutation. For example, VAR-1 comprises a MRPA sequence in combination with a T597 138 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT substitution mutation (e.g., a T597N mutation). In some embodiments, the MRPA sequence is formed by a peptide insertion comprising a methionine-arginine-proline (“MRP”) sequence at its C-terminal end followed by an alanine (A) substitution (e.g., N587A substitution). In some embodiments, the peptide insertion is after glycine (G) at position 586 and the alanine substitution is at position 587 (according to WT AAV2 VP1 numbering; SEQ ID NO: 1). In some embodiments, the insertion peptide comprises a LAKGETMRP (SEQ ID NO: 36) sequence (e.g., as in VAR-1). In some embodiments, the variant capsid polypeptide comprises a N551 substitution mutation (e.g., a N551H mutation). In some embodiments, the variant capsid polypeptide comprises a Q589 substitution mutation (e.g., a Q589A mutation). In some embodiments, a viral particle comprising the variant capsid polypeptide comprising a T597 substitution mutation in combination with a MRPA sequence exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. In some embodiments, a viral particle comprising the variant capsid polypeptide comprising a T597 substitution mutation in combination with a MRPA sequence, a N551 substitution mutation, and a Q589 substitution mutation exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO:1. According to some embodiments, variant capsid polypeptides described herein comprise a peptide insertion comprising a sequence of ANALAIEQTRP (SEQ ID NO: 39) sequence inserted between positions G586 and N587 (according to WT AAV2; SEQ ID NO: 1). In some embodiments, the variant capsid polypeptides comprise a mutation at position N587 (according to SEQ ID NO: 1) to alanine (e.g., N587A substitution). In some embodiments, a viral particle comprising the variant capsid polypeptide comprising a peptide insertion comprising a sequence of ANALAIEQTRP (SEQ ID NO: 39) sequence inserted between positions G586 and N587 exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. According to some embodiments, variant capsid polypeptides described herein comprise a peptide insertion comprising a sequence of RARLDETA (SEQ ID NO: 37) inserted between positions Q584 and R585 (according to WT AAV2; SEQ ID NO: 1). In 139 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT some embodiments, the variant capsid polypeptides comprise a mutation at position G586 (according to SEQ ID NO: 1) to proline (e.g., G586P substitution). In some embodiments, the variant capsid polypeptides comprise a mutation at position N587 (according to SEQ ID NO: 1) to alanine (e.g., N587A substitution). In some embodiments, a viral particle comprising the variant capsid polypeptide comprising a peptide insertion comprising a sequence of RARLDETA (SEQ ID NO: 37) inserted between positions Q584 and R585 exhibits increased ocular transduction and/or biodistribution relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having a wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Category A (Neural Retina Transduction): In some aspects of the disclosure, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased neural retina transduction as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased neural retina transduction is as defined as any one of embodiments A-1 through A-11. Embodiment A-1: In an embodiment of Category A, the transduction is about (or at least about) 2 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-2: In an embodiment of Category A, the transduction is about (or at least about) 3 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-3: In an embodiment of Category A, the transduction is about (or at least about) 5 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-4: In an embodiment of Category A, the transduction is about (or at least about) 6 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-5: In an embodiment of Category A, the transduction is about (or at least about) 7 times better relative to a virus particle comprising a variant capsid polypeptide 140 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-6: In an embodiment of Category A, the transduction is about (or at least about) 9 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-7: In an embodiment of Category A, the transduction is about (or at least about) 10 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-8: In an embodiment of Category A, the transduction is about (or at least about) 11 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-9: In an embodiment of Category A, the transduction is about (or at least about) 13 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-10: In an embodiment of Category A, the transduction is about (or at least about) 30 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-11: In an embodiment of Category A, the transduction is about (or at least about) 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. In some embodiments, the improved transduction is in a range bounded by any two values set forth in embodiments A-1 to A-11. Exemplary ranges are set forth in embodiments A-12 to A-21 below. Embodiment A-12: In an embodiment of Category A, the transduction ranges are between about 2 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. 141 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Embodiment A-13: In an embodiment of Category A, the transduction ranges are between about 3 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-14: In an embodiment of Category A, the transduction ranges are between about 5 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-15: In an embodiment of Category A, the transduction ranges are between about 6 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-16: In an embodiment of Category A, the transduction ranges are between about 7 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-17: In an embodiment of Category A, the transduction ranges are between about 9 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-18: In an embodiment of Category A, the transduction ranges are between about 10 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-19: In an embodiment of Category A, the transduction ranges are between about 11 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment A-20: In an embodiment of Category A, the transduction ranges are between about 13 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. 142 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Embodiment A-21: In an embodiment of Category A, the transduction ranges are between about 30 and about 60 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Category B (Macular Transduction): In some aspects of the disclosure, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased macular transduction as compared to a viral particle with the wild- type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased macular transduction is as defined as any one of embodiments B-1 through B-9. Embodiment B-1: In an embodiment of Category B, the transduction is about (or at least about) 3 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-2: In an embodiment of Category B, the transduction is about (or at least about) 6 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-3: In an embodiment of Category B, the transduction is about (or at least about) 8 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-4: In an embodiment of Category B, the transduction is about (or at least about) 20 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-5: In an embodiment of Category B, the transduction is about (or at least about) 40 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-6: In an embodiment of Category B, the transduction is about (or at least about) 50 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. 143 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Embodiment B-7: In an embodiment of Category B, the transduction is about (or at least about) 80 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-8: In an embodiment of Category B, the transduction is about (or at least about) 240 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-9: In an embodiment of Category B, the transduction is about (or at least about) 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. In some embodiments, the improved transduction is in a range bounded by any two values set forth in embodiments B-1 to B-9. Exemplary ranges are set forth in embodiments B-10 to B-17 below. Embodiment B-10: In an embodiment of Category B, the transduction ranges are between about 3 and about 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-11: In an embodiment of Category B, the transduction ranges are between about 6 and about 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-12: In an embodiment of Category B, the transduction ranges are between about 8 and about 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-13: In an embodiment of Category B, the transduction ranges are between about 20 and about 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-14: In an embodiment of Category B, the transduction ranges are between about 40 and about 440 times better relative to a virus particle comprising a variant 144 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-15: In an embodiment of Category B, the transduction ranges are between about 50 and about 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-16: In an embodiment of Category B, the transduction ranges are between about 80 and about 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment B-17: In an embodiment of Category B, the transduction ranges are between about 240 and about 440 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Category C (Trabecular Transduction): In some aspects of the disclosure, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased trabecular transduction as compared to a viral particle with the capsid polypeptide of SEQ ID NO: 72. In some embodiments, the increased trabecular transduction is as defined as any one of embodiment C-1. Embodiment C-1: In an embodiment of Category C, the transduction is about (or at least about) 2 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 72. Category D (Virus Production): In some aspects of the disclosure, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased virus production as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased virus production is as defined as any one of embodiments D-1 through D-4. Embodiment D-1: In an embodiment of Category D, the virus production is about (or at least about) 1.3 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. 145 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Embodiment D-2: In an embodiment of Category D, the virus production is about (or at least about) 1.5 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment D-3: In an embodiment of Category D, the virus production is about (or at least about) 1.6 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment D-4: In an embodiment of Category D, the virus production is about (or at least about) 3.8 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. In some embodiments, the improved virus production is in a range bounded by any two values set forth in embodiments D-1 to D-4. Exemplary ranges are set forth in embodiments D-5 to D-7 below. Embodiment D-5: In an embodiment of Category D, the virus production ranges are between about 1.3 and about 3.8 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment D-6: In an embodiment of Category D, the virus production ranges are between about 1.5 and about 3.8 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment D-7: In an embodiment of Category D, the virus production ranges are between about 1.6 and about 3.8 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Category E (Neural Retina Biodistribution): In some aspects of the disclosure, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased neural retina biodistribution as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased neural retina biodistribution is as defined as any one of embodiments E-1 through E-9. 146 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Embodiment E-1: In an embodiment of Category E, the biodistribution is about (or at least about) 2 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-2: In an embodiment of Category E, the biodistribution is about (or at least about) 5 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-3: In an embodiment of Category E, the biodistribution is about (or at least about) 6 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-4: In an embodiment of Category E, the biodistribution is about (or at least about) 7 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-5: In an embodiment of Category E, the biodistribution is about (or at least about) 8 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-6: In an embodiment of Category E, the biodistribution is about (or at least about) 9 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-7: In an embodiment of Category E, the biodistribution is about (or at least about) 10 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-8: In an embodiment of Category E, the biodistribution is about (or at least about) 11 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. 147 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Embodiment E-9: In an embodiment of Category E, the biodistribution is about (or at least about) 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. In some embodiments, the improved biodistribution is in a range bounded by any two values set forth in embodiments E-1 to E-9. Exemplary ranges are set forth in embodiments E-10 and E-17 below. Embodiment E-10: In an embodiment of Category E, the improved biodistribution is in a range between about 2 and about 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-11: In an embodiment of Category E, the improved biodistribution is in a range between about 5 and about 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-12: In an embodiment of Category E, the improved biodistribution is in a range between about 6 and about 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-13: In an embodiment of Category E, the improved biodistribution is in a range between about 7 and about 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-14: In an embodiment of Category E, the improved biodistribution is in a range between about 8 and about 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-15: In an embodiment of Category E, the improved biodistribution is in a range between about 9 and about 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-16: In an embodiment of Category E, the improved biodistribution is in a range between about 10 and about 12 times better relative to a virus particle comprising a 148 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment E-17: In an embodiment of Category E, the improved biodistribution is in a range between about 11 and about 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Category F (Macular Biodistribution): In some aspects of the disclosure, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased macular biodistribution as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the increased macular biodistribution is as defined as any one of embodiments F-1 through F-11. Embodiment F-1: In an embodiment of Category F, the biodistribution is about (or at least about) 4 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-2: In an embodiment of Category F, the biodistribution is about (or at least about) 5 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-3: In an embodiment of Category F, the biodistribution is about (or at least about) 12 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-4: In an embodiment of Category F, the biodistribution is about (or at least about) 16 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-5: In an embodiment of Category F, the biodistribution is about (or at least about) 50 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-6: In an embodiment of Category F, the biodistribution is about (or at least about) 60 times better relative to a virus particle comprising a variant capsid polypeptide 149 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-7: In an embodiment of Category F, the biodistribution is about (or at least about) 80 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-8: In an embodiment of Category F, the biodistribution is about (or at least about) 120 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-9: In an embodiment of Category F, the biodistribution is about (or at least about) 130 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-10: In an embodiment of Category F, the biodistribution is about (or at least about) 160 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-11: In an embodiment of Category F, the biodistribution is about (or at least about) 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. In some embodiments, the improved biodistribution is in a range bounded by any two values set forth in embodiments F-1 to F-11. Exemplary ranges are set forth in embodiments F-12 to F-21 below. Embodiment F-12: In an embodiment of Category F, the biodistribution ranges are between about 4 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-13: In an embodiment of Category F, the biodistribution ranges are between about 5 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. 150 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Embodiment F-14: In an embodiment of Category F, the biodistribution ranges are between about 12 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-15: In an embodiment of Category F, the biodistribution ranges are between about 16 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-16: In an embodiment of Category F, the biodistribution ranges are between about 50 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-17: In an embodiment of Category F, the biodistribution ranges are between about 60 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-18: In an embodiment of Category F, the biodistribution ranges are between about 80 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-19: In an embodiment of Category F, the biodistribution ranges are between about 120 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-20: In an embodiment of Category F, the biodistribution ranges are between about 130 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. Embodiment F-21: In an embodiment of Category F, the biodistribution ranges are between about 160 and about 180 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having the wild-type capsid protein, e.g., having capsid polypeptides of SEQ ID NO: 1. 151 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Category G (Trabecular Biodistribution): In some aspects of the disclosure, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased trabecular biodistribution as compared to a viral particle with AAV2 capsid polypeptides of SEQ ID NO: 72. In some embodiments, the increased trabecular biodistribution is as defined as any one of embodiments G-1 and G-2. Embodiment G-1: In an embodiment of Category G, the transduction is about (or at least about) 1.25 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having capsid polypeptides of SEQ ID NO: 72. Embodiment G-2: In an embodiment of Category G, the transduction is about (or at least about) 2.7 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having capsid polypeptides of SEQ ID NO: 72. In some embodiments, the improved transduction is in a range bounded by any two values set forth in embodiments G-1 and G-2. Exemplary ranges are set forth in embodiment G-3 below. Embodiment G-3: In an embodiment of Category G, the transduction ranges are between about 1.25 and about 2.7 times better relative to a virus particle comprising a variant capsid polypeptide having a reference sequence, e.g., having capsid polypeptides of SEQ ID NO: 72. According to some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of one or more cell types as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, the cell type(s) is an ocular cell type found in the retinal tissue. In some embodiments, the cell type(s) is an ocular cell type found in the trabecula meshwork tissue. Examples of cell types include amacrine cells, biopolar cells, cones, horizontal cells, microglia, Müller glia, retinal ganglion cells, rods, corneal epithelium, ciliary muscle, melanocytes, Schwann cells, beam cells, juxtacanalicular tissue (JCT), fibroblasts, and pericytes. In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of retinal ganglion cells as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of amacrine cells as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID 152 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of bipolar cells as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of cones as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of Müller glia as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of rods as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of beam cells as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of ciliary muscle as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of corneal epithelium as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of juxtacanalicular tissue (JCT) as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of melanocytes as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of Schwann cells as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits decreased transduction of ciliary muscle as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). 153 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of one cell type over another cell type as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of retinal ganglion cells over amacrine cells, biopolar cells, cones, Müller glia, or rods as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of amacrine cells over biopolar cells, cones, Müller glia, or rods as compared to a viral particle with the wild- type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of cones over biopolar cells, amacrine cells, Müller glia, or rods as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). In some embodiments, a viral particle comprising the variant capsid polypeptide, e.g., the variant capsid polypeptide described herein, exhibits increased transduction of juxtacanalicular tissue (JCT) over beam cells, ciliary muscle, corneal epithelium, melanocytes, or Schwann cells as compared to a viral particle with the wild-type capsid polypeptide (SEQ ID NO: 1). Methods of Making Compositions Described Herein The disclosure is directed, in part, to a method of making a capsid polypeptide described herein or a virus particle, such as but not limited to a dependoparvovirus particle, e.g., a dependoparvovirus particle described herein. In some embodiments, a method of making dependoparvovirus particle comprises providing a cell, cell-free system, or other translation system, comprising a nucleic acid described herein encoding a variant capsid polypeptide provided for herein, or a polypeptide provided for herein (e.g., a variant capsid polypeptide); and cultivating the cell, cell-free system, or other translation system under conditions suitable for the production of the dependoparvovirus particle, thereby making the dependoparvovirus particle. In some embodiments, providing a cell comprising a nucleic acid described herein comprises introducing the nucleic acid to the cell, e.g., transfecting or transforming the cell with the nucleic acid. The nucleic acids of the disclosure may be situated as a part of any genetic element (vector) which may be delivered to a host cell, e.g., naked DNA, a plasmid, 154 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT phage, transposon, cosmid, episome, a protein in a non-viral delivery vehicle (e.g., a lipid- based carrier), virus, etc. which transfer the sequences carried thereon. Such a vector may be delivered by any suitable method, including transfection, liposome delivery, electroporation, membrane fusion techniques, viral infection, high velocity DNA- coated pellets, and protoplast fusion. A person of skill in the art possesses the knowledge and skill in nucleic acid manipulation to construct any embodiment of this invention and said skills include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. In some embodiments, a vector of the disclosure comprises sequences encoding a viral particle, such as but not limited to, a dependoparvovirus variant capsid polypeptide as provided for herein or a fragment thereof. In some embodiments, vectors of the disclosure comprises sequences encoding a viral particle, such as but not limited to, a dependoparvovirus rep protein or a fragment thereof. In some embodiments, such vectors may contain sequence encoding both dependoparvovirus cap (e.g., a variant capsid polypeptide described herein) and rep proteins. In vectors in which both AAV rep and cap are provided, the dependoparvovirus rep and dependoparvovirus cap sequences may both be of the same dependoparvovirus species or serotype origin, such as AAV2. Alternatively, the present disclosure also provides vectors in which the rep sequences are from a dependoparvovirus species or serotype which differs from that from which the cap sequences are dervied. In some embodiments, the rep and cap sequences are expressed from separate sources (e.g., separate vectors, or a host cell genome and a vector). In some embodiments, the rep sequences are fused in frame to cap sequences of a different dependoparvovirus species or serotype to form a chimeric dependoparvovirus vector. In some embodiments, the vectors of the invention further contain a payload, e.g., a minigene comprising a selected transgene (e.g., a payload as described herein), e.g., flanked by dependoparvovirus 5' ITR and dependoparvovirus 3' ITR. The vectors described herein, e.g., a plasmid, are useful for a variety of purposes, but are particularly well suited for use in production of recombinant viral particles, such as but not limited to, dependoparvovirus particles comprising dependoparvovirus sequences or a fragment thereof, and in some embodiments, a payload. In some embodiments, the disclosure provides a method of making a viral particle, such as but not limited to, a dependoparvovirus particle (e.g., a dependoparvovirus B particle, 155 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT e.g., an AAV2 particle or particle comprising a variant capsid polypeptide as described herein), or a portion thereof. In some embodiments, the method comprises culturing a host cell which contains a nucleic acid sequence encoding a dependoparvovirus variant capsid polypeptide as provided for herein, or fragment thereof; a functional rep gene; a payload (e.g., as described herein), e.g., a minigene comprising dependoparvovirus inverted terminal repeats (ITRs) and a transgene, optionally under the control of a regulatory element such as a promoter; and sufficient helper functions to promote packaging of the payload, e.g., minigene, into the dependoparvovirus capsid. The components necessary to be cultured in the host cell to package a payload, e.g., minigene, in a dependoparvovirus capsid may be provided to the host cell in trans. In some embodiments, any one or more of the required components (e.g., payload (e.g., minigene), rep sequences, cap sequences, and/or helper functions) may be provided by a host cell which has been engineered to stably comprise one or more of the required components using methods known to those of skill in the art. In some embodiments, a host cell which has been engineered to stably comprise the required component(s) comprises it under the control of an inducible promoter. In some embodiments, the required component may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein and further examples are known to those of skill in the art. In some embodiments, a selected host cell which has been engineered to stably comprise one or more components may comprise a component under the control of a constitutive promoter and another component under the control of one or more inducible promoters. For example, a host cell which has been engineered to stably comprise the required components may be generated from 293 cells (e.g., which comprise helper functions under the control of a constitutive promoter), which comprises the rep and/or cap proteins under the control of one or more inducible promoters. The payload (e.g., minigene), rep sequences, cap sequences, and helper functions required for producing a viral particle, such as but not limited to, a dependoparvovirus particle of the disclosure may be delivered to the packaging host cell in the form of any genetic element which transfers the sequences carried thereon (e.g., in a vector or combination of vectors). The genetic element may be delivered by any suitable method, including those described herein. Methods used to construct genetic elements, vectors, and other nucleic acids of the disclosure are known to those with skill and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, 156 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT NY. Similarly, methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, J. Virol, 70:520-532 (1993) and US Patent 5,478,745. Unless otherwise specified, the dependoparvovirus ITRs, and other selected dependoparvovirus components described herein, may be readily selected from among any dependoparvovirus species and serotypes, e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV9. ITRs or other dependoparvovirus components may be readily isolated using techniques available to those of skill in the art from a dependoparvovirus species or serotype. Dependoparvovirus species and serotypes may be isolated or obtained from academic, commercial, or public sources (e.g., the American Type Culture Collection, Manassas, VA). In some embodiments, the dependoparvovirus sequences may be obtained through synthetic or other suitable means by reference to published sequences such as are available in the literature or in databases such as, e.g., GenBank or PubMed. The viral particles, such as but not limited to, dependoparvovirus particles (e.g., including a variant capsid polypeptide and, for example, a payload) of the disclosure may be produced using any invertebrate cell type which allows for production of dependoparvovirus or biologic products and which can be maintained in culture. In some embodiments, an insect cell may be used in production of the compositions described herein or in the methods of making a dependoparvovirus particle described herein. For example, an insect cell line used can be from Spodoptera frugiperda, such as Sf9, SF21, SF900+, drosophila cell lines, mosquito cell lines, e.g., Aedes albopictus derived cell lines, domestic silkworm cell lines, e.g. Bombyxmori cell lines, Trichoplusia ni cell lines such as High Five cells or Lepidoptera cell lines such as Ascalapha odorata cell lines. In some embodiments, the insect cells are susceptible to baculovirus infection, including High Five, Sf9, Se301, SeIZD2109, SeUCR1, SP900+, Sf21, BTI-TN-5B1-4, MG-1, Tn368, HzAml, BM-N, Ha2302, Hz2E5 and Ao38. In some embodiments, the methods of the disclosure can be carried out with any mammalian cell type which allows for replication of dependoparvovirus or production of biologic products, and which can be maintained in culture. In some embodiments, the mammalian cells used can be HEK293, HEK293T, HeLa, CHO, NS0, SP2/0, PER.C6, Vero, RD, BHK, HT 1080, A549, Cos-7, ARPE-19 or MRC-5 cells. In some embodiments the culture is an adherent cell culture. In some embodiments, the culture is a suspension cell culture. 157 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Methods of expressing proteins (e.g., recombinant or heterologous proteins, e.g., viral polypeptides, such as but not limited to, dependoparvovirus polypeptides) in insect cells are well documented, as are methods of introducing nucleic acids, such as vectors, e.g., insect- cell compatible vectors, into such cells and methods of maintaining such cells in culture. See, for example, METHODS IN MOLECULAR BIOLOGY, ed. Richard, Humana Press, N J (1995); O'Reilly et al., BACULOVIRUS EXPRESSION VECTORS, A LABORATORY MANUAL, Oxford Univ. Press (1994); Samulski et al., J. Vir.63:3822-8 (1989); Kajigaya et al., Proc. Nat'l. Acad. Sci. USA 88:4646-50 (1991); Ruffing et al., J. Vir.66:6922-30 (1992); Kirnbauer et al., Vir.219:37-44 (1996); Zhao et al., Vir.272:382-93 (2000); and Samulski et al., U.S. Pat. No.6,204,059. In some embodiments, a nucleic acid construct encoding dependoparvovirus polypeptides (e.g., a dependoparvovirus genome) in insect cells is an insect cell-compatible vector. An “insect cell-compatible vector” as used herein refers to a nucleic acid molecule capable of productive transformation or transfection of an insect or insect cell. Exemplary biological vectors include plasmids, linear nucleic acid molecules, and recombinant viruses. Any vector can be employed as long as it is insect cell-compatible. The vector may integrate into the insect cell's genome or remain present extra-chromosomally. The vector may be present permanently or transiently, e.g., as an episomal vector. Vectors may be introduced by any means known in the art. Such means include but are not limited to chemical treatment of the cells, electroporation, or infection. In some embodiments, the vector is a baculovirus, a viral vector, or a plasmid. In some embodiments, a nucleic acid sequence encoding a viral polypeptide, such as but not limited to, a dependoparvovirus polypeptide is operably linked to regulatory expression control sequences for expression in a specific cell type, such as Sf9 or HEK cells. Techniques known to one skilled in the art for expressing foreign genes in insect host cells or mammalian host cells can be used with the compositions and methods of the disclosure. Methods for molecular engineering and expression of polypeptides in insect cells is described, for example, in Summers and Smith. A Manual of Methods for Baculovirus Vectors and Insect Culture Procedures, Texas Agricultural Experimental Station Bull. No. 7555, College Station, Tex. (1986); Luckow.1991. In Prokop et al., Cloning and Expression of Heterologous Genes in Insect Cells with Baculovirus Vectors' Recombinant DNA Technology and Applications, 97-152 (1986); King, L. A. and R. D. Possee, The baculovirus expression system, Chapman and Hall, United Kingdom (1992); O'Reilly, D. R., L. K. Miller, V. A. Luckow, Baculovirus Expression Vectors: A Laboratory Manual, New York (1992); 158 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT W. H. Freeman and Richardson, C. D., Baculovirus Expression Protocols, Methods in Molecular Biology, volume 39 (1995); U.S. Pat. No.4,745,051; US2003148506; and WO 03/074714. Promoters suitable for transcription of a nucleotide sequence encoding a dependoparvovirus polypeptide include the polyhedron, p10, p35 or IE-1 promoters and further promoters described in the above references are also contemplated. In some embodiments, providing a cell comprising a nucleic acid described herein comprises acquiring a cell comprising the nucleic acid. Methods of cultivating cells, cell-free systems, and other translation systems are known to those of skill in the art. In some embodiments, cultivating a cell comprises providing the cell with suitable media and incubating the cell and media for a time suitable to achieve viral particle production. In some embodiments, a method of making a viral particle, such as but not limited to a dependoparvovirus particle, further comprises a purification step comprising isolating the dependoparvovirus particle from one or more other components (e.g., from a cell or media component). In some embodiments, production of the viral particle, such as but not limited to, the dependoparvovirus particle comprises one or more (e.g., all) of: expression of dependoparvovirus polypeptides, assembly of a dependoparvovirus capsid (e.g., a capsid comprising a variant capsid polypeptide provided for herein), expression (e.g., duplication) of a dependoparvovirus genome, and packaging of the dependoparvovirus genome into the dependoparvovirus capsid to produce a dependoparvovirus particle. In some embodiments, production of the dependoparvovirus particle further comprises secretion of the dependoparvovirus particle. In some embodiments, and as described elsewhere herein, the nucleic acid molecule encoding the variant capsid polypeptide is disposed in a dependoparvovirus genome. In some embodiments, and as described elsewhere herein, the nucleic acid molecule encoding the variant capsid polypeptide is packaged into a dependoparvovirus particle along with the dependoparvovirus genome as part of a method of making a dependoparvovirus particle described herein. In other embodiments, the nucleic acid molecule encoding the variant capsid polypeptide is not packaged into a dependoparvovirus particle made by a method described herein. In some embodiments, a method of making a viral particle, such as but not limited to, a dependoparvovirus particle described herein produces a dependoparvovirus particle 159 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT comprising a payload (e.g., a payload described herein) and the variant capsid polypeptide. In some embodiments, the payload comprises a second nucleic acid (e.g., in addition to the dependoparvovirus genome), and production of the dependoparvovirus particle comprises packaging the second nucleic acid into the dependoparvovirus particle. In some embodiments, a cell, cell-free system, or other translation system for use in a method of making a dependoparvovirus particle comprises the second nucleic acid. In some embodiments, the second nucleic acid comprises an exogenous sequence (e.g., exogenous to the dependoparvovirus, the cell, or to a target cell or subject who will be administered the dependoparvovirus particle). In some embodiments, the exogenous sequence encodes an exogenous polypeptide. In some embodiments, the exogenous sequence encodes a therapeutic product. In some embodiments, the composition of the invention is a pharmaceutical composition In some embodiments, a nucleic acid or polypeptide described herein is produced by a method known to one of skill in the art. The nucleic acids, polypeptides, and fragments thereof of the disclosure may be produced by any suitable means, including recombinant production, chemical synthesis, or other synthetic means. Such production methods are within the knowledge of those of skill in the art and are not a limitation of the present invention. In some embodiments, a method of making a virus particle described herein provides increased production of the virus particle relative to a similar production system, e.g., producing virus particles comprising wild-type AAV2 capsid polypeptides from the same producer cell type (e.g., from HEK293 cells). In some embodiments, a method of making a virus particle described herein produces the virus particle at least 1.3-fold better than a similar production system, e.g., producing virus particles comprising wild-type AAV2 capsid polypeptides from the same producer cell type (e.g., from HEK293 cells). Applications The disclosure is directed, in part, to compositions comprising a nucleic acid, polypeptide, or particles described herein. The disclosure is further directed, in part, to methods of utilizing a composition, nucleic acid, polypeptide, or particles described herein. As will be apparent based on the disclosure, nucleic acids, polypeptides, particles, and methods disclosed herein have a variety of utilities. 160 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT The disclosure is directed, in part, to a vector comprising a nucleic acid described herein, e.g., a nucleic acid encoding a variant capsid polypeptide. Many types of vectors are known to those of skill in the art. In some embodiments, a vector comprises a plasmid. In some embodiments, the vector is an isolated vector, e.g., removed from a cell or other biological components. The disclosure is directed, in part to a cell, cell-free system, or other translation system, comprising a nucleic acid or vector described herein, e.g., a nucleic acid or vector comprising a nucleic acid molecule encoding a variant capsid polypeptide. In some embodiments, the cell, cell-free system, or other translation system is capable of producing dependoparvovirus particles comprising the variant capsid polypeptides. In some embodiments, the cell, cell-free system, or other translation system comprises a nucleic acid comprising a dependoparvovirus genome or components of a dependoparvovirus genome sufficient to promote production of dependoparvovirus particles comprising the variant capsid polypeptides. In some embodiments, the cell, cell-free system, or other translation system further comprises one or more non-dependoparvovirus nucleic acid sequences that promote dependoparvovirus particle production and/or secretion. Said sequences are referred to herein as helper sequences. In some embodiments, a helper sequence comprises one or more genes from another virus, e.g., an adenovirus or herpes virus. In some embodiments, the presence of a helper sequence is necessary for production and/or secretion of a dependoparvovirus particle. In some embodiments, a cell, cell-free system, or other translation system comprises a vector, e.g., plasmid, comprising one or more helper sequences. In some embodiments, a cell, cell-free system, or other translation system comprises a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a sequence encoding one or more dependoparvovirus genes (e.g., a Cap gene, a Rep gene, or a complete dependoparvovirus genome) and a helper sequence, and wherein the second nucleic acid comprises a payload. In some embodiments, a cell, cell-free system, or other translation system comprises a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a sequence encoding one or more dependoparvovirus genes (e.g., a Cap gene, a Rep gene, or a complete dependoparvovirus genome) and a payload, and wherein the second nucleic acid comprises a helper sequence. In some embodiments, a cell, cell-free system, or other translation system comprises a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a helper sequence and a payload, and wherein the second nucleic 161 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT acid comprises a sequence encoding one or more dependoparvovirus genes (e.g., a Cap gene, a Rep gene, or a complete dependoparvovirus genome). In some embodiments, a cell, cell- free system, or other translation system comprises a first nucleic acid, a second nucleic acid, and a third nucleic acid, wherein the first nucleic acid comprises a sequence encoding one or more dependoparvovirus genes (e.g., a Cap gene, a Rep gene, or a complete dependoparvovirus genome), the second nucleic acid comprises a helper sequence, and the third nucleic acid comprises a payload. In some embodiments, the first nucleic acid, second nucleic acid, and optionally third nucleic acid are situated in separate molecules, e.g., separate vectors or a vector and genomic DNA. In some embodiments, one, two, or all of the first nucleic acid, second nucleic acid, and optionally third nucleic acid are integrated (e.g., stably integrated) into the genome of a cell. A cell of the disclosure may be generated by transfecting a suitable cell with a nucleic acid described herein. In some embodiments, a method of making a dependoparvovirus particle comprising a variant capsid polypeptide as provided for herein or improving a method of making a dependoparvovirus particle comprises providing a cell described herein. In some embodiments, providing a cell comprises transfecting a suitable cell with one or more nucleic acids described herein. In some embodiments, the virus particle comprising the variant capsid is produced at a level at least 10%, at least 20%, at least 50%, at least 100%, at least 200% or greater than the production level of wt AAV2 from the same producer cell type, e.g., from HEK293 cells, e.g., from adherent culture of HEK293 cells. In some embodiments, a nucleic acid of the variant capsid mediates the production of a dependoparvovirus particle at a level at least 10%, at least 20%, at least 50%, at least 100%, at least 200% or greater than the production level mediated by the nucleic acid of SEQ ID NO: 2. Many types and kinds of cells suitable for use with the nucleic acids and vectors described herein are known in the art. In some embodiments, the cell is a human cell. In some embodiments, the cell is an immortalized cell or a cell from a cell line known in the art. In some embodiments, the cell is an HEK293 cell. Methods of delivering a payload The disclosure is directed, in part, to a method of delivering a payload to a cell, e.g., a cell in a subject or in a sample. In some embodiments, a method of delivering a payload to a 162 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT cell comprises contacting the cell with a dependoparvovirus particle comprising a variant capsid polypeptide (e.g., described herein) comprising the payload. In some embodiments, the dependoparvovirus particle is a dependoparvovirus particle described herein and comprises a payload described herein. In some embodiments, the cell is an ocular cell. In some embodiments, the ocular cell is in the retina, macula, or trabecular meshwork. In some embodiments, the ocular cell is in the retina. In some embodiments, the ocular cell is in the macula. In some embodiments, the ocular cell is in the trabecular meshwork. In some embodiments, the ocular cell is in the front third of the eye, which includes the structures in front of the vitreous humor. Examples of structures in front of the vitreous humor, include the cornea, iris, ciliary body, lens, trabecular meshwork, and Schlemm’s canal. Accordingly, in some embodiments, the cell is in the cornea, iris, ciliary body, lens, trabecular meshwork, or Schlemm’s canal, or any combination thereof. In some embodiments, the ocular cell is posterior to the lens, such as in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. Accordingly, in some embodiments, the cell is in the anterior hyaloid membrane and all of the optical structures behind it, such as the vitreous humor, retina, choroid or optic nerve, or any combination thereof. In some embodiments, the cell type is an ocular cell such as, for example, a neural retinal cell, a photoreceptive retinal ganglion cell, a bipolar cell, a horizontal cell, an amacrine cell, a photoreceptor (e.g., a rod or a cone cell), an endothelial cell (e.g., a retinal pigmented epithelial cell), and endothelial-like cell, and the like. The disclosure is further directed in part to a virus particle comprising a capsid polypeptide described herein. In some embodiments, the virus particle comprises a capsid polypeptide described herein and a nucleic acid expression construct. In some embodiments the nucleic acid expression construct of the virus particle comprises a payload. In some embodiments, the payload comprises a transgene. In some embodiments, the transgene is a nucleic acid sequence heterologous to the vector sequences flanking the transgene which encodes a polypeptide, RNA (e.g., a miRNA or siRNA) or other product of interest. The nucleic acid of the transgene may be operatively linked to a regulatory component in a manner sufficient to promote transgene transcription, translation, and/or expression in a host cell. A transgene may be any polypeptide or RNA encoding sequence and the transgene 163 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT selected will depend upon the use envisioned. In some embodiments, a transgene comprises a reporter sequence, which upon expression produces a detectable signal. Such reporter sequences include, without limitation, DNA sequences encoding colorimetric reporters (e.g., β-lactamase, β-galactosidase (LacZ), alkaline phosphatase), cell division reporters (e.g., thymidine kinase), fluorescent or luminescence reporters (e.g., green fluorescent protein (GFP) or luciferase), resistance conveying sequences (e.g., chloramphenicol acetyltransferase (CAT)), or membrane bound proteins including to which high affinity antibodies directed thereto exist or can be produced by conventional means, e.g., comprising an antigen tag, e.g., hemagglutinin or Myc. In some embodiments, a reporter sequence operably linked with regulatory elements which drive their expression, provide signals detectable by conventional means, including enzymatic, radiographic, colorimetric, fluorescence or other spectrographic assays, fluorescent activating cell sorting assays and immunological assays, including enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and immunohistochemistry. In some embodiments, the transgene encodes a product which is useful in biology and medicine, such as RNA, proteins, peptides, enzymes, dominant negative mutants. In some embodiments, the RNA comprises a tRNA, ribosomal RNA, dsRNA, catalytic RNAs, small hairpin RNA, siRNA, trans-splicing RNA, and antisense RNAs. In some embodiments, the RNA inhibits or abolishes expression of a targeted nucleic acid sequence in a treated subject (e.g., a human or animal subject). In some embodiments, the transgene may be used to correct or ameliorate gene deficiencies. In some embodiments, gene deficiencies include deficiencies in which normal genes are expressed at less than normal levels or deficiencies in which the functional gene product is not expressed. In some embodiments, the transgene encodes a therapeutic protein or polypeptide which is expressed in a host cell. In some embodiments, a dependoparvovirus particle may comprise or deliver multiple transgenes, e.g., to correct or ameliorate a gene defect caused by a multi-subunit protein. In some embodiments, a different transgene (e.g., each situated/delivered in a different dependoparvovirus particle, or in a single dependoparvovirus particle) may be used to encode each subunit of a protein, or to encode different peptides or proteins, e.g., when the size of the DNA encoding the protein subunit is large, e.g., for immunoglobulin, platelet-derived growth factor, or dystrophin protein. In some embodiments, different subunits of a protein may be encoded by the same transgene, e.g., a single transgene encoding each of the subunits with the DNA for each subunit separated by 164 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT an internal ribozyme entry site (IRES). In some embodiments, the DNA may be separated by sequences encoding a 2A peptide, which self-cleaves in a post-translational event. See, e.g., Donnelly et al, J. Gen. Virol., 78(Pt 1):13-21 (January 1997); Furler, et al, Gene Ther., 8(11):864-873 (June 2001); Klump et al., Gene Ther 8(10):811-817 (May 2001). In some embodiments, virus particles comprising a genome are provided, wherein the genome includes a nucleic acid expression construct. The nucleic acid expression construct can include a heterologous transgene and one or more regulatory elements. In some embodiments, the particle delivers the payload to the eye with increased transduction in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is at least 1.5- times, 2-times, 4-times, 5-times, 6-times, 7-times, 8-times, 9-times, 10-times, 11-times, 13- times, 15-times, 16-times, 19-times, 20-times, 30-times, 40-times, 50-times, 60-times, 80- times, 240-times, or 440-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1. In some embodiments, the particle delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in transduction is at least 1.5-times, 2-times, 4-times, 8-times, 16-times, or 19-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is specific to macular tissue relative to non-macular retina tissue. In some embodiments, the particle delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in transduction is at least 1.5- times, 2-times, 4-times, 8-times, 16-times, or 19-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is specific to macular tissue relative to trabecular meshwork tissue. In some embodiments, the particle delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in transduction is at least 1.5-times, 2-times, 4-times, 8-times, or 15-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is specific to non-macular retina tissue relative to trabecular meshwork tissue. In some embodiments, the particle delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, wherein the increase in 165 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT transduction is at least 1.5-times, 2-times, 4-times, 8-times, 15-times, or 19-times as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1, and wherein the increase in transduction is specific to macular tissue and non-macular retina tissue relative to trabecular meshwork tissue. In some embodiments, the particle delivers the payload to the eye with increased transduction specificity in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1 without increased biodistribution in one or more regions of the eye as compared to a virus particle comprising capsid polypeptides of SEQ ID NO: 1. In some embodiments, the regulatory elements include a promotor. In some embodiments, the promoter is a ubiquitous or constitutive promoter active in a mammalian cell, for example a human cell, for example, in a human cell type of interest. Examples of ubiquitous promoters include, but are not limited, to a CAG promoter (hybrid from a cytomegalovirus early enhancer element, a chicken-beta actin promoter, e.g., the first exon and the first intron of the chicken beta actin gene, and optionally the splice acceptor of the rabbit beta globin gene), chicken-beta actin promoter, CBA promoter, CMV promoter, human PGK promoter, ubiquitin promoter, human EF1-alpha promoter and fragments thereof. In some embodiments, the promoter is a tissue-specific promoter, for example, a promoter specific in ocular tissue or cells of the eye. Examples of ocular tissue- specific promoters include but are not limited to TBG promoters, hAAT promoters, CK8 promoters and SPc5-12 promoters, rho promoters, which are active in rods, or opsin promoters, which are active in cones. In some embodiments, the regulatory element includes a photoreceptor cell-specific regulatory element (e.g., promoter) such as, e.g., a rhodopsin promoter; a rhodopsin kinase promoter; a beta phosphodiesterase gene promoter; a retinitis pigmentosa gene promoter; an interphotoreceptor retinoid-binding protein (IRBP) gene enhancer; an IRBP gene promoter, an opsin gene promoter, a retinoschisin gene promoter, a CRX homeodomain protein gene promoter, a guanine nucleotide binding protein alpha transducing activity polypeptide 1 (GNAT1) gene promoter, a neural retina-specific leucine zipper protein (NRL) gene promoter, human cone arrestin (hCAR) promoter, and the PR2.1, PR1.7, PR1.5, and PR1.1 promoters. In some embodiments, the regulatory element includes, a retinal pigment epithelia (RPE) cell-specific regulatory element (e.g., a RPE-specific promoter), e.g., a regulatory element that confers selective expression of the operably linked gene in a RPE cell, such as, e.g., an RPE65 gene promoter, a cellular retinaldehyde-binding protein (CRALBP) gene promoter, a pigment epithelium-derived factor (PEDF aka serpin F1) 166 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT gene promoter, and a vitelliform macular dystrophy (VMD2) promoter. In some embodiments, the regulatory element includes a promoter specific to a glial cell, e.g., a regulatory element that confers selective expression of the operably linked payload in a retinal glial cell, such as, e.g., a glial fibrillary acidic protein (GFAP) promoter. In some instances, the regulatory element includes a promoter that is specific to a bipolar cell (e.g., a bipolar-specific promoter), e.g., a regulatory element that confers selective expression of the operably linked payload in a bipolar cell, such as, e.g., a GRM6 promoter. In some embodiments, the promoter sequence is between 100 and 1000 nucleotides in length. In some embodiments, the promoter sequence is about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900 or about 1000 nucleotides in length. As used in the preceding sentence, “about” refers to a value within 50 nucleotides of the recited length. Suitable regulatory elements, e.g., promoters, may be readily selected by persons of skill in the art, such as those, but not limited to, those described herein. In some embodiments, the nucleic acid expression construct comprises an intron. The intron may be disposed between the promoter and the heterologous transgene. In some aspects, the intron is disposed 5’ to the heterologous transgene on the expression construct, for example immediately 5’ to the heterologous transgene or 100 nucleotides or less 5’ to the heterologous transgene. In some aspects, the intron is a chimeric intron derived from human b-globin and Ig heavy chain (also known as b- globin splice donor/immunoglobulin heavy chain splice acceptor intron, or b-globin/IgG chimeric intron; Reed, R., et al. Genes and Development, 1989, incorporated herein by reference in its entirety). In other aspects, the intron is a VH4 intron or a SV40 intron. As provided herein, in some embodiments, virus particles comprising a payload, wherein the payload includes a nucleic acid that includes a heterologous transgene are provided. In some embodiments, the heterologous transgene encodes an RNA interference agent, for example a siRNA, shRNA or other interfering nucleic acid. In some embodiments, the payload includes a heterologous transgene that encodes a therapeutic polypeptide. In some aspects, the heterologous transgene is a human gene or fragment thereof. In some aspects, the therapeutic polypeptide is a human protein. In some embodiments, the heterologous transgene of the virus particle encodes a molecule useful in treating a disease, and the virus particle is administered to a patient in need thereof to treat said disease. Examples of diseases (and heterologous transgenes or molecules encoded by said heterologous transgenes) according to the present disclosure include: MPSI (alpha-L- 167 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT iduronidase (IDUA)); MPS II – Hunter syndrome (iduronate-2-sulfatase (IDS)); Ceroid lipofuscinosis-Batten disease (CLN1, CLN2, CLN10, CLN13, CLN5, CLN11, CLN4, CNL14, CLN3, CLN6, CLN7, CLN8, CLN12); MPS Illa - Sanfilippo Type A syndrome (heparin sulfate sulfatase (also called N-sulfoglucosamine sulfohydrolase (SGSH)); MPS IIIB – Sanfilippo Type b syndrome (N-acetyl-alpha-D-glucosaminidase (NAGLU)); MPS VI - Maroteaux-Lamy syndrome (arylsulfatase B); MPS IV A - Morquio syndrome type A (GALNS); MPS IV B – Morquio syndrome type B (GLB1); Osteogenesis Imperfecgta Type I, II, III or IV (COL1Al and/or COL1A2); hereditary angioedema (SERPING1, C1NH); Osteogenesis Imperfecta Type V (IFITM5); Osteogenesis Imperfecta Type VI (SERPINF1); Osteogenesis Imperfecta Type VII (CRTAP); Osteogenesis Imperfecta Type VIII (LEPRE1 and/or P3H1); Osteogenesis Imperfecta Type IX (PPIB); Gaucher disease type I, II and III (Glucocerebrosidase; GBAl); Parkinson's Disease (Glucocerebrosidase; GBAl and/or dopamine decarboxylase); Pompe (acid maltase; GAA; hGAA); Metachromatic leukodystrophy (Aryl sulfatase A); MPS VII - Sly syndrome (beta-glucuronidase); MPS VIII (glucosamine-6-sulfate sulfatase); MPS IX (Hyaluronidase); maple syrup urine disease (BCKDHA, BCKDHB, and/or DBT); Niemann-Pick disease (Sphingomyelinase); Parkinson’s disease (anti-alpha synuclein RNAi); Alzheimer’s disease (anit-mutant APP RNAi); Niemann-Pick disease without sphingomyelinase deficiency (NPC1 or NPC gene encoding a cholesterol metabolizing enzyme); Tay-Sachs disease (alpha subunit of beta- hexosaminidase); Sandhoff disease (both alpha and beta subunit of beta-hexosaminidase); Fabry Disease (alpha-galactosidase); Fucosidosis (fucosidase (FUCAl)); Alpha-mannosidosis (alpha-mannosidase); Beta-mannosidosis (beta-mannosidase); Wolman disease (cholesterol ester hydrolase); Dravet syndrome (SCN1A, SCN1B, SCN2A, GABRG2); Parkinson's disease (Neurturin); Parkinson's disease (glial derived growth factor (GDGF)); Parkinson's disease (tyrosine hydroxylase); Parkinson's disease (glutamic acid decarboxylase; FGF-2; BDGF); Spinal Muscular Atrophy (SMN, including SMN1 or SMN2); Friedreich's ataxia (Frataxin); Amyotrophic lateral sclerosis (ALS) (SOD1 inhibitor, e.g., anti-SOD1 RNAi); Glycogen Storage Disease la (Glucose-6-phosphatase); XLMTM (MTMl); Crigler Najjar (UGTlAl); CPVT (CASQ2); spinocerebellar ataxia (ATXN2; ATXN3 or other ATXN gene; anti-mutant Machado-Joseph disease/SCA3 allele RNAi); Rett syndrome (MECP2 or fragment thereof); Achromatopsia (CNGB3, CNGA3, GNAT2, PDE6C); Choroidermia (CDM); Danon Disease (LAMP2); Cystic Fibrosis (CFTR or fragment thereof); Duchenne Muscular Dystrophy (Mini-/ Micro-Dystrophin Gene); SARS-Cov-2 infection (anti-SARS- 168 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Cov-2 RNAi, SARS-Cov-2 genome fragments or S protein (including variants)); Limb Girdle Muscular Dystrophy Type 2C - Gamma-sarcoglycanopathy (human-alpha-sarcoglycan); Advanced Heart Failure (SERCA2a); Rheumatoid Arthritis (TNFR:Fc Fusion; anti-TNF antibody or fragment thereof); Leber Congenital Amaurosis (GAA); X-linked adrenoleukodystrophy (ABCD1); Limb Girdle Muscular Dystrophy Type 2C - Gamma- sarcoglycanopathy (gamma-sarcoglycan); Angelman syndrome (UBE3A); Retinitis Pigmentosa (hMERTK); Age-Related Macular Degeneration (sFLT01); Phelan-McDermid syndrome (SHANK3; 22q13.3 replacement); Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis (huFollistatin344); Parkinson's Disease (GDNF); Metachromatic Leukodystrophy – MLD (cuARSA); Hepatitis C (anti-HCV RNAi); Limb Girdle Muscular Dystrophy Type 2D (hSGCA); Human Immunodeficiency Virus Infections; (PG9DP); Acute Intermittant Porphyria (PBGD); Leber's Hereditary Optical Neuropathy (PIND4v2); Alpha-1 Antitrypsin Deficiency (alphaIAT); X-linked Retinoschisis (RS1); Choroideremia (hCHM); Giant Axonal Neuropathy (GAN); Hemophilia B (Factor IX); Homozygous FH (hLDLR); Dysferlinopathies (DYSF); Achromatopsia (CNGA3 or CNGB3); Progressive supranuclear palsy (MAPT; anti-Tau; anti-MAPT RNAi); Omithine Transcarbamylase deficiency (OTC); Hemophilia A (Factor VIII); Age-related macular degeneration (AMD), including wetAMD (anti-VEGF antibody or RNAi); X-Linked Retinitis Pigmentosa (RPGR); Myotonic dystrophy Type 1 (DMPK; anti-DMPK RNAi, including anti-CTG trinucleotide repeat RNAi); Myotonic dystrophy Type 2 (CNBP); Facioscapulohumeral muscular dystrophy (D4Z4 DNA); oculopharynggeal muscular dystrophy (PABPN1; mutated PABPN1 inhibitor (e.g., RNAi)); Mucopolysaccharidosis Type VI (hARSB); Leber Hereditary Optic Neuropathy (ND4); X-Linked myotubular Myopathy (MTMl); Crigler-Najjar Syndrome (UGTlAl); Retinitis Pigmentosa (hPDE6B); Mucopolysaccharidosis Type 3B (hNAGLU); Duchenne Muscular Dystrophy (GALGT2); Alzheimer's Disease (NGF; ApoE4; ApoE2; ApoE3; Anti-ApoE RNAi); Familial Lipoprotein Lipase Deficiency (LPL); Alpha-1 Antitrypsin Deficiency (hAAT); Leber Congenital Amaurosis 2 (hRPE65v2); Batten Disease; Late Infantile Neuronal Lipofuscinosis (CLN2); Huntington’s disease (HTT; anti- HTT RNAi); Fragile X syndrome (FMR1); Leber's Hereditary Optical Neuropathy (PlND4v2); Aromatic Amino Acid Decarboxylase Deficiency (hAADC); Retinitis Pigmentosa (hMERKTK); and Retinitis Pigmentosa (RLBP1). In some aspects, the heterologous transgene encodes an antibody or fragment thereof (for example an antibody light chain, an antibody heavy chain, a Fab or an scFv). Examples 169 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT of antibodies or fragments thereof that are encoded by the heterologous transgene include but are not limited to: an anti-Ab antibody (e.g. solanezumab, GSK933776, and lecanemab), anti- sortilin ( e.g. AL-001), anti-Tau (e.g. ABBV-8E12, UCB-0107, and NI- 105), anti-SEMA4D (e.g. VX15/2503), anti-alpha synuclein (e.g. prasinezumab, NI-202, and MED-1341), anti- SOD1 (e.g. NI-204), anti-CGRP receptor (e.g. eptinezumab, fremanezumab, or galcanezumab), anti-VEGF (e.g., sevacizumab, ranibizumab, bevacizumab, and brolucizumab), anti-EpoR (e.g., LKA-651, ), anti-ALKl (e.g., ascrinvacumab), anti-C5 (e.g., tesidolumab, ravulizumab, and eculizumab), anti-CD105 (e.g., carotuximab), anti-CClQ (e.g., ANX-007), anti-TNFa (e.g., adalimumab, infliximab, and golimumab), anti-RGMa (e.g., elezanumab), anti-TTR (e.g., NI-301 and PRX-004), anti-CTGF (e.g., pamrevlumab), anti- IL6R (e.g., satralizumab, tocilizumab, and sarilumab), anti-IL6 (e.g. siltuximab, clazakizumab, sirukumab, olokizumab, and gerilimzumab), anti-IL4R (e.g., dupilumab), anti- IL17A (e.g., ixekizumab and secukinumab), anti-IL5R (e.g. reslizumab), anti-IL-5 (e.g., benralizumab and mepolizumab), anti-IL13 (e.g. tralokinumab), anti-IL12/IL23 (e.g., ustekinumab), anti-CD 19 (e.g., inebilizumab), anti-IL31RA (e.g. nemolizumab), anti-ITGF7 mAb (e.g., etrolizumab), anti-SOST mAb (e.g., romosozumab), anti-IgE (e.g. omalizumab), anti-TSLP (e.g. nemolizumab), anti-pKal mAb (e.g., lanadelumab), anti-ITGA4 (e.g., natalizumab), anti- ITGA4B7 (e.g., vedolizumab), anti-BLyS (e.g., belimumab), anti-PD-1 (e.g., nivolumab and pembrolizumab), anti-RANKL (e.g., denosumab), anti-PCSK9 (e.g., alirocumab and evolocumab), anti-ANGPTL3 (e.g., evinacumab*), anti-OxPL (e.g., E06), anti-fD (e.g., lampalizumab), or anti-MMP9 (e.g., andecaliximab), optionally wherein the heavy chain (Fab and Fc region) and the light chain are separated by a self-cleaving furin (F)/F2A or furin (F)/T2A, IRES site, or flexible linker, for example, ensuring expression of equal amounts of the heavy and the light chain polypeptides. In some embodiments, the payload comprises a nucleic acid encoding a gene product linked to a disorder of the eye, or a fragment thereof. Exemplary gene products linked to a disorder of the eye include, for example, ADP-ribosylation factor-like 6 (ARL6); BBSome interacting protein 1 (BBIP1); BBSome protein 1 (BBS1); BBSome protein 2 (BBS2); BBSome protein 4 (BBS4); BBSome protein 5 (BBS5); BBSome protein 7 (BBS7); BBSome protein 9 (BBS9); BBSome protein 10 (BBS10); BBSome protein 12 (BBS12); centrosomal protein 290 kDa (CEP290); intraflagellar transport protein 172 (IFT172); intraflagellar transport protein 27 (IFT27); inositol polyphosphate-5-phosphatase E (INPP5E); inwardly- rectifying potassium channel subfamily J member 13 (KCNJ13); leucine zipper transcription 170 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT factor like-1 (LZTFL1); McKusick-Kaufman syndrome protein (MKKS); Meckel syndrome type 1 protein (MKS1); nephronophthisis 3 protein (NPHP1); serologically-defined colon cancer antigen 8 (SDCCAG8); tripartite motif-containing protein 32 (TRIM32); tetratricopeptide repeat domain 8 (TTC8); Batten disease protein (CLN3); cytochrome P450 4V2 (CYP4V2); Rab escort protein 1 (CHM); PR (positive regulatory) domain-containing 13 protein (PRDM13); RPE-retinal G protein-coupled receptor (RGR); TEA domain family member 1 (TEAD1); arylhydrocarbon-interacting receptor protein-like 1 (AIPL1); cone-rod otx-like photoreceptor homeobox transcription factor (CRX); guanylate cyclase activating protein 1A (GUCA1A); retinal-specific guanylate cyclase (GUCY2D); phosphatidylinositol transfer membrane-associated family member 3 (PITPNM3); prominin 1 (PROM1); peripherin (PRPH); peripherin 2 (PRPH2); regulating synaptic membrane exocytosis protein 1 (RIMS1); semaphorin 4A (SEMA4A); human homolog of C. elegans unc119 protein (UNC119); ATP-binding cassette transporter—retinal (ABCA4); ADAM metallopeptidase domain 9 (ADAM9); activating transcription factor 6 (ATF6); chromosome 21 open reading frame 2 (C21orf2); chromosome 8 open reading frame 37 (C8orf37); calcium channel; voltage-dependent; alpha 2/delta subunit 4 (CACNA2D4); cadherin-related family member 1 (protocadherin 21) (CDHR1); ceramide kinase-like protein (CERKL); cone photoreceptor cGMP-gated cation channel alpha subunit (CNGA3); cone cyclic nucleotide-gated cation channel beta 3 subunit (CNGB3); cyclin M4 (CNNM4); guanine nucleotide binding protein (G protein); alpha transducing activity polypeptide 2 (GNAT2); potassium channel subfamily V member 2 (KCNV2); Phosphodiesterase 6C (PDE6C); Phosphodiesterase 6H (PDE6H); proteome of centriole 1 centriolar protein B (POC1B); RAB28 member of RAS oncogene family (RAB28); retina and anterior neural fold homeobox 2 transcription factor (RAX2); 11- cis retinol dehydrogenase 5 (RDH5); RP GTPase regulator-interacting protein 1 (RPGRIP1); tubulin tyrosine ligase-like family member 5 (TTLL5); L-type voltage-gated calcium channel alpha-1 subunit (CACNA1F); retinitis pigmentosa GTPase regulator (RPGR); rod transducin alpha subunit (GNAT1); rod cGMP phosphodiesterase beta subunit (PDE6B); rhodopsin (RHO); calcium binding protein 4 (CABP4); G protein-coupled receptor 179 (GPR179); rhodopsin kinase (GRK1); metabotropic glutamate receptor 6 (GRM6); leucine-rich repeat immunoglobulin-like transmembrane domains protein 3 (LRIT3); arrestin (s-antigen) (SAG); solute carrier family 24 (SLC24A1); transient receptor potential cation channel, subfamily M, member 1 (TRPM1); nyctalopin (NYX); green cone opsin (OPN1LW); red cone opsin (OPN1MW); blue cone opsin (OPN1SW); frataxin (FXN); inosine monophosphate 171 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT dehydrogenase 1 (IMPDH1); orthodenticle homeobox 2 protein (OTX2); crumbs homolog 1 (CRB1); death domain containing protein 1 (DTHD1); growth differentiation factor 6 (GDF6); intraflagellar transport 140 Chlamydomonas homolog protein (IFT140); IQ motif containing B protein (IQCB1); lebercilin (LCA5); lecithin retinol acyltransferase (LRAT); nicotinamide nucleotide adenylyltransferase 1 (NMNAT1); RD3 protein (RD3); retinol dehydrogenase 12 (RDH12); retinal pigment epithelium-specific 65 kD protein (RPE65); spermatogenesis associated protein 7 (SPATA7); tubby-like protein 1 (TULP1); mitochondrial genes (KSS, LHON, MT-ATP6, MT-TH, MT-TL1, MT-TP, MT-TS2, mitochondrially encoded NADH dehydrogenases [MT-ND]); bestrophin 1 (BEST1); C1q and tumor necrosis-related protein 5 collagen (C1QTNF5); EGF-containing fibrillin-like extracellular matrix protein 1 (EFEMP1); elongation of very long fatty acids protein (ELOVL4); retinal fascin homolog 2, actin bundling protein (FSCN2); guanylate cyclase activating protein 1B (GUCAB); hemicentin 1 (HMCN1); interphotoreceptor matrix proteoglycan 1 (IMPG1); retinitis pigmentosa 1-like protein 1 (RP1L1); tissue inhibitor of metalloproteinases-3 (TIMP3); complement factor H (CFH); complement factor D (CFD); complement component 2 (C2); complement component 3(C3); complement factor B (CFB); DNA-damage regulated autophagy modulator 2 (DRAM2); chondroitin sulfate proteoglycan 2 (VCAN); mitofusin 2 (MFN2); nuclear receptor subfamily 2 group F member 1 (NR2F1); optic atrophy 1 (OPA1); transmembrane protein 126A (TMEM126A); inner mitochondrial membrane translocase 8 homolog A (TIMM8A); carbonic anhydrase IV (CA4); hexokinase 1 (HK1); kelch-like 7 protein (KLHL7); nuclear receptor subfamily 2 group E3 (NR2E3); neural retina lucine zipper (NRL); olfactory receptor family 2 subfamily W member 3 (OR2W3); pre-mRNA processing factor 3 (PRPF3); pre-mRNA processing factor 4 (PRPF4); pre-mRNA processing factor 6 (PRPF6); pre-mRNA processing factor 8 (PRPF8); pre- mRNA processing factor 31 (PRPF31); retinal outer segment membrane protein 1 (ROM1); retinitis pigmentosa protein 1 (RP1); PIM-kinase associated protein 1 (RP9); small nuclear ribonucleoprotein 200 kDa (SNRNP200); secreted phosphoprotein 2 (SPP2); topoisomerase I binding arginine/serine rich protein (TOPORS); ADP-ribosylation factor-like 2 binding protein (ARL2BP); chromosome 2 open reading frame 71 (C2orf71); clarin-1 (CLRN1); rod cGMP-gated channel alpha subunit (CNGA1); rod cGMP-gated channel beta subunit (CNGB1); cytochrome P4504V2 (CYP4V2); dehydrodolichyl diphosphate synthetase (DHDDS); DEAH box polypeptide 38 (DHX38); ER membrane protein complex subunit 1 (EMC1); eyes shut/spacemaker homolog (EYS); family with sequence similarity 161 member 172 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT A (FAM161A); G protein-coupled receptor 125 (GPR125); heparan-alpha-glucosaminide N- acetyltransferase (HGSNAT); NAD(+)-specific isocitrate dehydrogenase 3 beta (IDH3B); interphotoreceptor matrix proteoglycan 2 (IMPG2); KIAA1549 protein (KIAA1549); kizuna centrosomal protein (KIZ); male germ-cell associated kinase (MAK); c-mer protooncogene receptor tyrosine kinase (MERTK); mevalonate kinase (MVK); NIMA (never in mitosis gene A)-related kinase 2 (NEK2); neuronal differentiation protein 1 (NEUROD1); cGMP phosphodiesterase alpha subunit (PDE6A); phosphodiesterase 6G cGMP-specific rod gamma (PDE6G); progressive rod-cone degeneration protein (PRCD); retinol binding protein 3 (RBP3); retinaldehyde-binding protein 1 (RLBP1); solute carrier family 7 member 14 (SLC7A14); usherin (USH2A); zinc finger protein 408 (ZNF408); zinc finger protein 513 (ZNF513); oral-facial-digital syndrome 1 protein (OFD1); retinitis pigmentosa 2 (RP2); retinoschisin (RS1); abhydrolase domain containing protein 12 (ABHD12); cadherin-like gene 23 (CDH23); centrosomal protein 250 kDa (CEP250); calcium and integrin binding family member 2 (CIB2); whirlin (DFNB31); monogenic audiogenic seizure susceptibility 1 homolog (GPR98); histidyl-tRNA synthetase (HARS); myosin VIIA (MYO7A); protocadherin 15 (PCDH15); harmonin (USH1C); human homolog of mouse scaffold protein containing ankyrin repeats and SAM domain (USH1G); dystrophin (DMD); norrin (NDP); phosphoglycerate kinase (PGK1); calpain 5 (CAPN5); frizzled-4 Wnt receptor homolog (FZD4); integral membrane protein 2B (ITM2B); low density lipoprotein receptor-related protein 5 (LRP5); micro RNA 204 (MIR204); retinoblastoma protein 1 (RB1); tetraspanin 12 (TSPAN12); chromosome 12 open reading frame 65 (C12orf65); cadherin 3 (CDH3); membrane-type frizzled-related protein (MFRP); ornithine aminotransferase (OAT); phospholipase A2 group V (PLA2G5); retinol-binding protein 4 (RBP4); regulator of G- protein signaling 9 (RGS9); regulator of G-protein signaling 9-binding protein (RGS9BP); ARMS2; excision repair cross-complementing rodent repair deficiency complementation group 6 protein (ERCC6); fibulin 5 (FBLN5); HtrA serine peptidase 1 (HTRA1); toll-like receptor 3 (TLR3); and toll-like receptor 4 (TLR4), opsin; rhodopsin; channel rhodopsin; halo rhodopsin, and the like. In some embodiments, the virus particle comprises a heterologous transgene encoding a genome editing system. Examples include a CRISPR genome editing system (e.g., one or more components of a CRISPR genome editing system such as, for example, a guide RNA molecule and/or a RNA-guided nuclease such as a Cas enzyme such as Cas9, Cpf1 and the like), a zinc finger nuclease genome editing system, a TALEN genome editing system or a 173 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT meganuclease genome editing system. In some embodiments, the genome editing system targets a mammalian, e.g., human, genomic target sequence. In some embodiments, the virus particle includes a heterologous transgene encoding a targetable transcription regulator. Examples include a CRISPR-based transcription regulator (for example, one or more components of a CRISPR-based transcription regulator, for example, a guide RNA molecule and/or a enzymatically-inactive RNA-guided nuclease/transcription factor (“TF”) fusion protein such as a dCas9-TF fusion, dCpf1-TF fusion and the like), a zinc finger transcription factor fusion protein, a TALEN transcription regulator or a meganuclease transcription regulator. In some embodiments, components of a therapeutic molecule or system are delivered by more than one unique virus particle (e.g., a population that includes more than one unique virus particles). In other embodiments, the therapeutic molecule or components of a therapeutic molecule or system are delivered by a single unique virus particle (e.g., a population that includes a single unique virus particle). The transgene may also encode any biologically active product or other product, e.g., a product desirable for study. Suitable transgenes may be readily selected by persons of skill in the art, such as those, but not limited to, those described herein. Other examples of proteins encoded by the transgene include, but are not limited to, colony stimulating factors (CSF); blood factors, such as β-globin, hemoglobin, tissue plasminogen activator, and coagulation factors; interleukins; soluble receptors, such as soluble TNF-α. receptors, soluble VEGF receptors, soluble interleukin receptors (e.g., soluble IL-1 receptors and soluble type II IL-1 receptors), or ligand-binding fragments of a soluble receptor; growth factors, such as keratinocyte growth factor (KGF), stem cell factor (SCF), or fibroblast growth factor (FGF, such as basic FGF and acidic FGF); enzymes; chemokines,; enzyme activators, such as tissue plasminogen activator; angiogenic agents, such as vascular endothelial growth factors, glioma-derived growth factor, angiogenin, or angiogenin-2; anti- angiogenic agents, such as a soluble VEGF receptor; a protein vaccine; neuroactive peptides, such as nerve growth factor (NGF) or oxytocin; thrombolytic agents;; tissue factors; macrophage activating factors; tissue inhibitors of metalloproteinases; or IL-1 receptor antagonists. The disclosure is further directed, in part, to a method of delivering a payload to a subject, e.g., an animal or human subject. In some embodiments, a method of delivering a payload to a subject comprises administering to the subject a virus particle, such as but not 174 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT limited to a dependoparvovirus particle, comprising a variant polypeptide (e.g., described herein) comprising the payload, e.g., in a quantity and for a time sufficient to deliver the payload. In some embodiments, the dependoparvovirus particle is a dependoparvovirus particle described herein and comprises a payload described herein. In some embodiments, the particle delivers the payload to the eye. In some embodiments, the delivery to the eye is increased as compared to a particle without the variant capsid polypeptide or as compared to a wild-type capsid polypeptide. Methods of treatment In some embodiments, the methods of the invention are not methods for treatment of the human or animal body by therapy. In other embodiments, the methods of the invention are used for therapy. The disclosure is directed, in part, to a method of treating a disease or condition in a subject, e.g., an animal or human subject. As used herein, the term “treating a disease or condition” refers to treating a manifest disease or condition, for example, where the subject is already suffering from one or more symptoms of the disease or condition, or refers to treating a pre-manifest disease or condition, for example, where the subject is identified as having a disease or condition but is not yet exhibiting one or more symptoms of the disease or condition. Pre-manifest conditions may be identified by, for example, genetic testing. In some embodiments, a method of treating a disease or condition in a subject comprises administering to the subject a virus particle, such as but not limited to a dependoparvovirus particle comprising a variant polypeptide described herein, e.g., comprising a payload described herein. In some embodiments, the dependoparvovirus particle, which comprises a variant polypeptide, comprising a payload described herein is administered in an amount and/or time effective to treat the disease or condition. In some embodiments, the payload is a therapeutic product. In some embodiments, the payload is a nucleic acid, e.g., encoding an exogenous polypeptide. The viral particles, such as but not limited to, the dependoparvovirus particles comprising a variant polypeptide described herein or produced by the methods described herein can be used to express one or more therapeutic proteins to treat various diseases or disorders. In some embodiments, the disease or disorder is a cancer, e.g., a cancer such as carcinoma, sarcoma, leukemia, lymphoma; or an autoimmune disease, e.g., multiple sclerosis. Non-limiting examples of carcinomas include esophageal carcinoma; bronchogenic 175 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT carcinoma; colon carcinoma; colorectal carcinoma; gastric carcinoma; hepatocellular carcinoma; basal cell carcinoma, squamous cell carcinoma (various tissues); bladder carcinoma, including transitional cell carcinoma; lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung; adrenocortical carcinoma; sweat gland carcinoma; sebaceous gland carcinoma; thyroid carcinoma; pancreatic carcinoma; breast carcinoma; ovarian carcinoma; prostate carcinoma; adenocarcinoma; papillary carcinoma; papillary adenocarcinoma; cystadenocarcinoma; medullary carcinoma; renal cell carcinoma; uterine carcinoma; testicular carcinoma; osteogenic carcinoma; ductal carcinoma in situ or bile duct carcinoma; choriocarcinoma; seminoma; embryonal carcinoma; Wilm's tumor; cervical carcinoma; epithelieal carcinoma; and nasopharyngeal carcinoma. Non-limiting examples of sarcomas include fibrosarcoma, myxosarcoma, liposarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. Non-limiting examples of solid tumors include ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, menangioma, melanoma, neuroblastoma, and retinoblastoma. Non-limiting examples of leukemias include chronic myeloproliferative syndromes; T-cell CLL prolymphocytic leukemia, acute myelogenous leukemias; chronic lymphocytic leukemias, including B-cell CLL, hairy cell leukemia; and acute lymphoblastic leukemias. Examples of lymphomas include, but are not limited to, B-cell lymphomas, such as Burkitt's lymphoma; and Hodgkin's lymphoma. In some embodiments, the disease or disorder is a genetic disorder. In some embodiments, the genetic disorder is sickle cell anemia, Glycogen storage diseases (GSD, e.g., GSD types I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV), cystic fibrosis, lysosomal acid lipase (LAL) deficiency 1, Tay-Sachs disease, Phenylketonuria, Mucopolysaccharidoses, Galactosemia, muscular dystrophy (e.g., Duchenne muscular dystrophy), hemophilia such as hemophilia A (classic hemophilia) or hemophilia B (Christmas Disease), Wilson's disease, Fabry Disease, Gaucher Disease hereditary angioedema (HAE), and alpha 1 antitrypsin deficiency. Examples of other diseases or disorders are provided above in the “Methods of delivering a payload” section. The viral particles, such as but not limited to, the dependoparvovirus particles comprising a variant polypeptide described herein or produced by the methods described 176 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT herein can be used to express one or more therapeutic proteins to treat various diseases or disorders. In some embodiments, the disease or disorder is a disease or disorder of the eye, for example, retinitis pigmentosa; macular degeneration (e.g.; wet age-related macular degeneration), optic neuritis; Leber’s congenital amaurosis; Leber’s hereditary optic neuropathy; achromatopsia; X-linked retinoschisis; optic neuritis; choroideremia; optic atrophy; retinal cone dystrophy; retinopathy; retinoblastoma; glaucoma; Bardet-Biedl syndrome; Usher syndrome; aniridia; Friedreich’s ataxia; vitelliform macular dystrophy; retinoblastoma; Stargardt disease; Charcot-Marie-Tooth disease; Fuch’s dystrophy; propionic acidemia; or color blindness; corneal dystrophy; keratoconus; night blindness; dry eye; Bardet-Biedl syndrome; Batten's Disease; Bietti's Crystalline Dystrophy; chorioretinal atrophy; chorioretinal degeneration; cone or cone-rod dystrophies (autosomal dominant, autosomal recessive, and X-linked), congenital stationary night blindness (autosomal dominant, autosomal recessive, and X-linked); disorders of color vision, including achromatopsia (including ACHM2, ACHM3, ACHM4, and ACHM5), protanopia, deuteranopia, and tritanopia; Friedreich's ataxia; Leber's congenital amaurosis (autosomal dominant and autosomal recessive), including, but not limited to, LCA1, LCA2, LCA3, LCA4, LCA6, LCA7, LCA8, LCA12, and LCA15; Leber's Hereditary Optic Neuropathy; macular dystrophy (autosomal dominant and autosomal recessive), including, but not limited to, acute macular degeneration, Best vitelliform macular dystrophy, pattern dystrophy, North Carolina Macular Dystrophy, inherited drusen, Sorsby's fundus dystrophy, malattia levantanese, and genetically-determined retinopathy of prematurity; ocular-retinal developmental disease; ocular albinism; optic atrophies (autosomal dominant, autosomal recessive, and X-linked); retinitis pigmentosa (autosomal dominant, autosomal recessive, X- linked, and mitochondrially-inherited traits), examples of which include RP1, RP2, RP3, RP10, RP20, RP38, RP40, and RP43; X-linked retinoschisis; Stargardt disease; and Usher syndrome, including, but not limited to, USH1B, USH1C, USH1D, USH1F, USH1G, USH2A, USH2C, USH2D, AND USH3. Examples of complex genetic diseases include, but are not limited to, glaucoma (open angle, angle-closure, low-tension, normal-tension, congenital, neovascular, pigmentary, pseudoexfoliation); age-related and other forms of macular degeneration, both exudative and non-exudative forms (autosomal dominant and autosomal recessive), such as acute macular degeneration, vitelliform macular degeneration; retinopathy of prematurity; and Vogt Koyanagi-Harada (VKH) syndrome. Examples of acquired diseases include, but are not limited to, acute macular neuroretinopathy; anterior 177 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ischemic optic neuropathy and posterior ischemic optic neuropathy; Behcet's disease; branch retinal vein occlusion; choroidal neovascularization; diabetic retinopathy, including proliferative diabetic retinopathy and associated complications; diabetic uveitis; edema, such as macular edema, cystoid macular edema and diabetic macular edema; epiretinal membrane disorders; macular telangiectasia; multifocal choroiditis; non-retinopathy diabetic retinal dysfunction; ocular tumors; optic atrophies; retinal detachment; retinal disorders, such as central retinal vein occlusion, proliferative vitreoretinopathy (PVR), retinal arterial and venous occlusive disease, vascular occlusion, uveitic retinal disease; uveal effusion; retinal infective and infiltrative disease; optic nerve diseases such as acquired optic atrophy. Examples of traumatic injuries include, but are not limited to, histoplasmosis; optic nerve trauma; ocular trauma which affects a posterior ocular site or location; retinal trauma; viral infection of the eye; viral infection of the optic nerve; a posterior ocular condition caused by or influenced by an ocular laser treatment; posterior ocular conditions caused by or influenced by a photodynamic therapy; photocoagulation, radiation retinopathy; and sympathetic ophthalmia. In some embodiments, administration of a viral particle, such as but not limited to, a dependoparvovirus particle comprising a variant polypeptide and comprising a payload (e.g., a transgene) to a subject induces expression of the payload (e.g., transgene) in a subject. In some embodiments, the expression is induced in the eye. In some embodiments, the production is increased in the eye as compared to an analogous particle with the wild-type capsid protein. The amount of a payload, e.g., transgene, e.g., heterologous protein, e.g., therapeutic polypeptide, expressed in a subject (e.g., the serum of the subject) can vary. For example, in some embodiments the payload, e.g., protein or RNA product of a transgene, can be expressed in the serum of the subject in the amount of less than about 5 μg/ml. For example, in some embodiments the payload, e.g., protein or RNA product of a transgene, can be expressed in the serum of the subject in the amount of at least about 9 μg/ml, at least about 10 μg/ml, at least about 50 μg/ml, at least about 100 μg/ml, at least about 200 μg/ml, at least about 300 μg/ml, at least about 400 μg/ml, at least about 500 μg/ml, at least about 600 μg/ml, at least about 700 μg/ml, at least about 800 μg/ml, at least about 900 μg/ml, or at least about 1000 μg/ml. In some embodiments, the payload, e.g., protein or RNA product of a transgene, is expressed in the serum of the subject in the amount of about 9 μg/ml, about 10 μg/ml, about 50 μg/ml, about 100 μg/ml, about 200 μg/ml, about 300 μg/ml, about 400 μg/ml, about 500 μg/ml, about 600 μg/ml, about 700 μg/ml, about 800 μg/ml, about 900 μg/ml, about 1000 178 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT μg/ml, about 1500 μg/ml, about 2000 μg/ml, about 2500 μg/ml, or a range between any two of these values. In some embodiments, the viral particle, such as but not limited to, the dependoparvovirus particle comprising a variant polypeptide and comprising a payload (e.g., a transgene) is administered to a subject via an injection. In some embodiments, the injection is a systemic injection, for example, intravenous, intraarterial, intramuscular, or subcutaneous injection. In some embodiments, the injection is an injection to the eye. In some embodiments, the injection is an intravitreal injection, intraorbital injection, retro-orbital injection, suprachoroidal injection, subretinal injection, subconjunctivital injection, or intracameral injection. In some embodiments, the injection is an intravitreal injection. In some embodiments, the injection is an intraorbital injection. In some embodiments, the injection is a retro-orbital injection. In some embodiments, the injection is a suprachoroidal injection. In some embodiments, the injection is a subretinal injection. In some embodiments, the injection is a subconjunctivital injection. In some embodiments, the injection is an intracameral injection. Sequences disclosed herein may be described in terms of percent identity. A person of skill will understand that such characteristics involve alignment of two or more sequences. Alignments may be performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs, such as “Clustal W”, accessible via the Internet. As another example, nucleic acid sequences may be compared using FASTA, a program in GCG Version 6.1. FASTA provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. For instance, percent identity between nucleic acid sequences may be determined using FASTA with its default parameters as provided in GCG Version 6.1, herein incorporated by reference. Similar programs are available for amino acid sequences, e.g., the “Clustal X” program. Additional sequence alignment tools that may be used are provided by (protein sequence alignment; (http://www.ebi.ac.uk/Tools/psa/emboss_needle/)) and (nucleic acid alignment; http://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html )). Generally, any of these programs may be used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. Sequences disclosed herein may further be described in terms of edit distance. The minimum number of sequence edits (i.e., additions, 179 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT substitutions, or deletions of a single base or nucleotide) which change one sequence into another sequence is the edit distance between the two sequences. In some embodiments, the distance between two sequences is calculated as the Levenshtein distance. All publications, patent applications, patents, and other publications and references (e.g., sequence database reference numbers) cited herein are incorporated by reference in their entirety. For example, all GenBank, Unigene, and Entrez sequences referred to herein, e.g., in any Table herein, are incorporated by reference. Unless otherwise specified, the sequence accession numbers specified herein, including in any Table herein, refer to the database entries current as of August 21, 2020. When one gene or protein references a plurality of sequence accession numbers, all of the sequence variants are encompassed. The invention is further illustrated by the following examples. The examples are provided for illustrative purposes only and are not to be construed as limiting the scope or content of the invention in any way. EXAMPLES Example 1 A library of 2.5E5 capsid variants of wild-type AAV2 were designed and cloned into plasmids to create a library of plasmids encoding the capsid variants (library for Library Experiment 1). Experimental results from Library Experiment 1 were assessed and machine learning models trained on this and other data, and used to design two separate libraries with 1E8 capsid variants of wild-type AAV2 each (libraries for Library Experiment 2). These libraries are significantly more diverse than the library tested in Library Experiment 1. Variants in one library were designed to maximize posterior eye transduction (including for example retina, macula, non-macular retina, neural retina and choroid/RPE) (posterior eye library) and variants in the other library were designed to maximize anterior eye transduction (including for example tissues of the trabecular meshwork and Schlemm’s canal) (anterior eye library). Both libraries were designed to include variants which would produce virus particles. A library of AAV variant genomes encoding each variant’s capsid and a unique capsid variant barcode identifier was cloned into three ITR plasmid backbones as described previously (Ogden et al.2019). Each plasmid backbone contained a unique genomic identifier enabling analysis of biodistribution and transduction efficiencies via different routes of administration. The libraries were produced via transient triple transfection of adherent HEK293T followed by iodixanol gradient purification. 180 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT In Vitro Evaluation of Library Data was prepared as described below. To measure each variant’s packaging efficiency (or “production”), barcodes from vector genomes in the plasmid and produced AAV library were prepared for illumina sequencing using two rounds of PCR. Production efficiency, normalized for presence in the input plasmid library, for each variant is expressed by comparing barcode sequencing levels for each variant in the produced vector pool to the barcode sequence levels for each variant in the input plasmid library used to create the vector pool. The measurements of variant frequency in the vector library also enable downstream normalization of biodistribution and transduction measurements by variant frequency in the input vector library. Production efficiency for variants in Library Experiment 1 is reported in Table 1A, and each reported value is reported as the log2 production relative to the production of wild-type AAV2. Production efficiency for variants in the posterior eye library and anterior eye library for Library Experiment 2 are reported in Table 1B and 1C, and each reported value is reported as the log2 production relative to the production of wild-type AAV2. In Vivo Evaluation of Library in Non-Human Primate Library Experiment 1 All NHP experiments were conducted in accordance with institutional policies and NIH guidelines. One young adult male and one young adult female cynomolgus macaque (Macaca fascicularis) weighing 2.4-2.9 kg seronegative for anti-AAV2 neutralizing antibodies (serum NAb titers <1:20 based on in vitro NAb assay) were selected for the study. Prior to test article administrations samples of blood, aqueous humor (50 μL) and vitreous humor (up to 50 μL) were collected. The animals were anesthetized with ketamine and dexmedetomidine and received intravitreal (IVT; 4.8E11 vg/eye in 50 μL), intracameral (IC; 8.5E11 vg/eye in 50 μL) and intravenous (IV; 1.8-2.5E13 vg/kg) injections of the vector libraries. During the in-life period the animals were monitored for signs of ocular inflammation via indirect ophthalmoscopy and slit-lamp biomicroscopy and treated with weekly IM injections of steroids (methylprednisolone, 40-80 mg) and topical steroids (Durezol), and atropine as needed according to the animal facility’s SOPs and recommendations from the veterinarian. Serum samples were collected at 1 h, 4 h and 24 h, and weekly after the injections. The animals were sacrificed 4 weeks after the injections and tissues were collected for biodistribution and transduction analyses. Library Experiment 2 181 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT The evaluations of anterior eye library variants and posterior eye library variants in Library Experiment 2 were carried out in Cynomolgus macaques. Both eyes of two non-naive animals with low serum anti-AAV2 NAb titers (<1:10) received intravitreal injections of the posterior eye library and intracameral injections of the anterior eye library at total doses of 7.3E11 vg/eye (3.9E11 vg for IC, 3.4E11 vg for IVT), with both libraries injected via both routes of administration in each eye. Ophthalmic examinations were performed weekly during the 4 week in-life period to monitor levels of ocular inflammation. Tissue Processing and Data Analysis for Library Experiment 1 and Library Experiment 2 Retinas and trabecular meshwork were dissected as shown in FIG.1. A list of other tissue samples collected is shown in Table 5. All samples were collected into RNAlater ^® (Sigma-Aldrich) and incubated overnight at RT, after which the RNAlater ^® was drained and samples were frozen at -80℃. In addition, samples of aqueous humor, vitreous humor, serum, and cerebrospinal fluid were collected at necropsy and stored at -80℃. Table 5. List of tissues collected. Tissue 182 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT spinal cord (cervical) spinal cord (thoracic) otal DNA and RNA was extracted from tissue samples with Trizol/chloroform and isopropanol precipitation. RNA samples were treated with TURBO DNase (Invitrogen). Reverse transcription was done with Protoscript II Reverse Transcriptase (NEB) with primers that were specific to the vector transgene and included unique molecular identifiers (UMIs). Control reactions lacking the reverse transcriptase enzyme (-RT control) were also prepared. Quantification of biodistribution and transduction was done with Luna Universal Probe qPCR Master Mix (NEB) using primers and probes specific to the transgene construct. Finally, samples were prepared for next-generation sequencing by amplifying the transgene barcode regions with primers compatible with Illumina NGS platform and sequenced with NextSeq 550 (Illumina). After sequencing, the barcode tags were extracted from reads with the expected amplicon structure, and the abundance (number of reads or number of UMIs) of each barcode was recorded. Analyses were restricted to the set of barcodes that were present in the input plasmid sample and that did not contain errors in the variant sequence, as measured by a separate sequencing assay that targeted the variant regions of the input plasmid sample. To aggregate packaging replicates, the read counts from replicate virus production samples were summed. To aggregate transduction samples, the UMI counts from samples from the same tissue were summed. Virus packaging, biodistribution and transduction of tissue were calculated using a Bayesian model with aggregated production, biodistribution and/or transduction samples as the input. Briefly, probabilistic programming and stochastic variational inference were used to model the measurement process and sources of decoupling (e.g., cross-packaging, template switching, and errors in DNA synthesis) between the actual test virus particles and their designed sequences, and to calculate virus production, biodistribution and transduction (in various tissue samples), and error rates. The output was the log2-transformed mean of the calculated distribution relative to the wild-type (WT) AAV2. Thus, positive values indicate better performance than WT for the measured property, and negative values indicate worse- 183 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT than-WT performance. Transduction and biodistribution for Library Experiment 1 is reported in Table 1A (transduction) and Table 3 (biodistribution). Transduction and biodistribution for Library Experiment 2 is reported in Tables 1B and 1C (transduction) and Tables 4A, 4B, and 4C (biodistribution). Where indicated, macula transduction and biodistribution refers to measurements taken from tissues consisting of the neural retina layer of the macula. Retina or non-macula retina transduction and biodistribution refers to measurements taken from tissues consisting of the neural retina layer of the non-macular retina areas of the eye. Measurements including the choroid and/or RPE are taken from tissues consisting of the choroid layer of the whole retina. Without being bound by theory, because the complexity of the libraries for this experiment were high relative to the total overall dose (1E8 variants with total doses of approximately 7E11 vg/eye), relative transduction and biodistribution values from Library Experiment 2 are compressed and, therefore, represent an underrepresentation of the relative transduction and biodistribution rates. The results demonstrate however, that the relative rank ordering of the variants that were included in both Library Experiment 1 and Library Experiment 2 was consistent (Spearman correlation = 0.72), confirming the top variants as having significant transduction (for example, better than wild-type AAV2) improvements. Variants from this experiment are included in a follow-on library experiment of similar complexity to Library Experiment 1 (e.g., 1-2E5 variants per library), and as described in Example 2, and properties are confirmed as described herein for Library Experiment 1 and in Example 2. Example 2 The virus particles comprising the variant capsids provided in Table 2 above and Table 9 below (sequences) are produced individually via transient triple transfection of adherent HEK293T followed by iodixanol gradient purification. Each variant capsid is produced with a genome encoding a unique barcode and a fluorescent reporter gene under the control of a ubiquitous promoter. Production efficiency is assessed as described above. Amounts (vg) of each virus particle are pooled (approximately 50-100 variants total) in approximately equimolar amounts (e.g., all variants present within a 5-fold range), and injected into AGM or other non-human primate, for example, Cynomolgus macaque at doses used in Example 1. Virus properties, including biodistribution and tissue transduction are assessed, for example, as described in Example 1. 184 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT References: Ogden PJ, Kelsic ED, Sinai S, Church GM. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science.2019 Nov 29;366(6469):1139-1143. doi: 10.1126/science.aaw2900. PMID: 31780559; PMCID: PMC7197022. The results show that variant capsid polypeptides provided for herein produce virus particles that have increased packaging, increased biodistribution, increased transduction and/or increased expression of a transgene (payload) in various regions of the eye relative to a wild-type AAV2 upon intravitreal or intracameral injection. In addition, the variant capsid polypeptides described herein provide selective biodistribution and/or expression in regions of the eye that include target cell populations for gene therapy (for example, macula- selectivity, non-macula retina selectivity, macula/retina selectivity and/or trabecular meshwork selectivity). Without limitation, the capsid polypeptides, nucleic acids and virus particles described herein are used to deliver therapeutics to the eye, e.g., to certain cell types of the eye, and are used to treat disorders of the eye as described herein, with higher efficiency. Example 3 In vivo Evaluation of Medium-Throughput Library in Non-Human Primate (Library Experiment 3) Variants in this study were selected from internal data sets acquired from ocular non- human primate (NHP) experiments based on an algorithm that optimizes capsid performance while balancing diversity and measurement uncertainty. In one arm of the experiment, variants were selected based on their transduction performance in the posterior eye (including, for example, the neural retina and choroid/RPE) and anterior eye (including, for example, tissues of the trabecular meshwork and Schlemm’s canal) via intravitreal (IVT) delivery. In the other arm of the experiment, variants were selected based on their transduction performance in the anterior eye via intracameral (IC) delivery. Without being bound by theory, capsids with specificity for one region of the eye or specific tissues and/or cell types within that region could have benefits for gene therapies by providing increased targeting to the tissue or cell type of interest and a better safety profile by de-targeting other 185 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ocular tissues or cell types. The study also included variants that contain stop codons in VP1 and VP2 as transduction negative controls (expected to produce virus but not transduce cells) and containing VP3 stop codons as production negative controls (not expected to produce virus). The study also included variants having WT AAV2 capsid polypeptides, as well as variants having the capsid polypeptides of SEQ ID NO: 72. The virus particles comprising a selection of the variant capsids provided in Table 2, (sequences) were produced individually via separate transient triple transfection of adherent HEK293T cells followed by co-purification by iodixanol gradient. The representation of each individual variant within the virus pool is calculated via NGS. Variants identified with low initial productivity yields were produced again individually in a separate production round and combined with virus from the previous productions to balance the representation of every variant to be within 10-fold range in the final test article. Final test article included each variant at an amount of 1E9vg-9E9 vg/eye for IVT, and 1E9vg-1E10vg/eye for IC test articles, as measured by ddPCR for final titer and NGS analysis for variant representation. Production efficiencies for VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR- 7, VAR-8, VAR-10, VAR-11, and VAR-12, relative to production efficiency of wild-type AAV2, are provided in Tables 1D and 1E. Each variant capsid was included in a virus particle that included a genome bearing identifying unique barcode sets of 8 as well as diverse random sequence IDs for quantification, providing a measure of biological replicates within the study. Each genome further contains a sequence encoding a fluorescent reporter gene under the control of a ubiquitous Cbh promoter. All NHP experiments were conducted in accordance with institutional policies and NIH guidelines. Four young adult male and one adult female cynomolgus macaques (Macaca fascicularis) weighing 2.2-2.9 kg, seronegative (serum NAb titers < 1:20 based on in vitro NAb assay) for anti-AAV2 neutralizing antibodies were selected for the study. Prior to test article administration, samples of blood, aqueous humor (50 μL), and vitreous humor (up to 50 μL) were collected. The animals were anesthetized with ketamine and dexmedetomidine and received bilateral (IVT; 4.27E11 vg/eye in 100uL) (IC; 2.00E11 vg/eye in 50uL) injections of vector libraries. This resulted in approximately 1E9 vg-9E9 vg of each individual variant delivered to each eye by the IVT route of administration, and 1E9 vg-1E10 vg of each individual variant delivered to each eye by the IC route of administration. During the in-life period, the animals were monitored weekly for signs of ocular inflammation via 186 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT indirect ophthalmoscopy and slit-lamp biomicroscopy and treated with weekly IM injections of steroids (methylprednisolone, 80 mg) and topical steroids (Durezol), and atropine as needed according to the animal facility’s SOPs and recommendations from the veterinarian. Confocal scanning laser ophthalmoscopy (cSLO) with green fluorescent protein (GFP) imaging using the Heidelberg Spectralis HRA/OCT system was used to take fluorescent images of each eye prior to necropsy. The animals were sacrificed four weeks after dosing, and tissues were collected for biodistribution and transduction analyses. Retinas and trabecular meshwork were dissected as shown in FIG.1. All Ocular tissues were flash-frozen on dry ice following dissection. A list of all Ocular tissues collected is shown in Tables 6A and 6B. Table 6A. Samples from Medium Throughput Study Front of the Eye Samples Sample # Region . Retinal and Choroid/RPE Samples 187 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT 15 Inferior petal (central) choroid/RPE 16 Inferior petal (peripheral) choroid/RPE tudy. Moderate ocular inflammation was observed in all 5 animals by week 2. In week 3, topical ocular medications (atropine and durezol) were applied onto the eyes of each animal in addition to weekly steroid treatment (methylprednisolone, 80mg). Inflammation was reduced by 4 weeks but was not fully resolved before termination.4 weeks following the injection, the animals were sacrificed and transduction was measured by NGS sequencing of variant associated barcodes isolated from the cDNA of bulk tissue samples and by single nuclear RNA sequencing (snRNA-seq). Through analysis of this data, we were able to determine transduction rates for the variants across major cell types within the eye by each route of administration. The data also enabled us to observe correlations and compare transduction efficiency between bulk and single-cell measurements and to identify the cell types within each tissue that were transduced by each variant. In addition to identifying highly promising capsids for improved ocular gene therapy delivery, this high-resolution dataset provides validation of our prior data measurements in other library contexts and valuable input data for future machine-guided design directed at improving cell transduction, specificity, and tissue distribution. Results from bulk tissue for variants included in this medium throughput study described in this Example 3 are shown in Tables 1D, 1E, 1F, 4D, and 4E (IVT administration). Unless otherwise noted, all values are relative to AAV2. For instance, values for trabecular transduction (IVT administration) and trabecular biodistribution (IVT administration) are relative to that of a virus particle having capsid polypeptides of SEQ ID NO: 72. This was chosen because in these tissues by these routes of administration, virus particles with WT AAV2 capsid polypeptides were not detected. Details of the tissue processing and NGS analysis for bulk tissue sample experimental workflow are described below: Tissue dissection, homogenization and nucleic acid extraction Tissue samples are dissected inside the cold chamber of a cryostat (-20°C) down to <100mg pieces using clean disposable scalpels and put into a Nuclease-free Eppendorf tube. Scalpels and forceps were changed in between tissues to avoid cross-contamination.1mL of Trizol was added into each tube along with a stainless steel bead (5mm), and tissues are homogenized using TissueLyser II (QIAGEN) according to the manufacturer’s 188 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT recommendations.200uL chloroform was added into each homogenized sample, and samples were vortexed to create phase separation. RNA was extracted from the upper aqueous phase using an RNeasy (QIAGEN) kit according to the manufacturer’s recommendations, and was further treated with Turbo™ DNase (Thermo Fisher Scientific) to remove any vector DNA contamination in the RNA sample. Reverse transcription was performed using a specific RT primer that anneals to the vector transcript to generate the targeted cDNA library. DNA was extracted from the organic layer using DNeasy Blood and Tissue Kit (QIAGEN). NGS Library Preparation Each cDNA and DNA sample was amplified using pre-indexing primers specific to the target region that contains the barcode and ID with Illumina handles (R1 and R2) as overhangs. Each sample amplification was tracked live via qPCR and terminated once the Rn of a sample reached the inflection point. Pre-indexed samples were indexed using custom Illumina indexing primers to index every tissue sample. These indexed libraries are then sequenced using an Illumina NextSeq200 Sequencer. NGS sample parsing and analysis Bulk NGS Sequencing Data Analysis After sequencing, the barcode tags were extracted from reads with the expected amplicon structure, and the abundance (number of reads or number of UMIs) of each barcode was recorded. For each route of administration, analyses were restricted to the set of designed barcodes in the corresponding test article. To aggregate biodistribution samples, read counts from samples from the same tissue were summed. To aggregate transduction samples, the number of UMIs from samples from the same tissue were summed. Biodistribution and transduction of tissue were calculated by normalizing aggregated biodistribution or transduction counts with input virus abundance. For neural retina, the rates were calculated as fold change relative to the wild-type (WT) AAV2. The neural retina measurements are reported as mean and standard deviation of eye replicates (n=8). For trabecular meshwork, the rates were calculated as fold change relative to a virus particle having capsid polypeptides of SEQ ID NO: 72, since WT AAV2 transduction was too low or dropped out, and was unable to be used to establish a reliable baseline. The trabecular meshwork measurements are reported as mean and standard error of barcode replicates (n=8). Data from different numbers of tissue samples are described herein. To generate the data shown in Tables 1D and 4D, the number of tissue samples for cDNA and vDNA that 189 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT were processed are shown in Tables 7A and 7B, respectively. Additional tissue samples were collected and used to generate the data shown in Tables 1E, 1F, and 4E, and Tables 8A and 8B show the number of tissue samples for cDNA and vDNA, respectively. Tissue samples taken from the whole retina, both the macular and non-macular regions, were used to generate the neural retina transduction and biodistribution results shown in Tables 1D, 1E, 4D, and 4E. Tissue samples taken from the macular region of the retina were used to generate the macular transduction and biodistribution results shown in Tables 1F, and 4E. Tissue samples from the trabecular meshwork and Schlemm’s canal were used to generate the trabecular transduction and biodistribution results shown in Tables 1F, and 4D. Table 7A. cDNA Number of Samples Organ Tissue NHP NHP NHP NHP NHP 1 2 3 4 5 Organ Tissue NHP NHP NHP NHP NHP . Organ Tissue NHP NHP NHP NHP NHP Table 8B. vDNA Number of Samples Organ Tissue NHP NHP NHP NHP NHP 190 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT eye trabecular meshwork; Schlemm’s 4 5 4 1 1 canal : Single-cell RNA sequencing has been previously demonstrated to allow characterization of cell-type specific tropism of barcoded rAAVs (Brown et al., Front. Immunol., 2021). However, obtaining single cell suspension from certain tissue types and/or flash frozen samples from externally-sourced NHP studies can be extremely challenging. We developed an approach that combines single-nuclei RNA sequencing (snRNA-Seq) with targeted amplicon sequencing to reliably detect cell-type specific transduction from up to 50- 100 barcoded rAAVs with minimal sequencing depth, with an initial focus on tissues of the eye, and applied these methods to the tissues collected from the experiment described in this example. To implement this approach we have: 1) developed optimized protocols for isolation of high quality single nuclei suspensions from flash frozen NHP ocular tissues (e.g. neural retina and trabecular meshwork), 2) used the 10x Genomics Chromium platform to encapsulate these nuclei and generate gene expression libraries for reliable identification of cell types, and 3) leveraged the 10x feature barcode kit to selectively amplify (for sequencing) barcoded viral transcripts that were captured using the 10x CS1 feature designed into the viral genomes. Using this approach we investigated cell-type specific tropism of multiple rAAVs in Cynomolgus macaque neural retina and the trabecular meshwork. Our snRNA-seq gene expression analysis identified all the major neural retina and trabecular meshwork cell types including therapeutically relevant cells such as rods, cones, retinal ganglion cells (RGCs), and cells responsible for draining of ocular fluids in the anterior eye, such as beam cells and juxtacanalicular (JCT) cells. Viral transduction events, as assessed from our targeted library sequencing, were detected in almost all clusters and we could successfully quantify differences in transduction rates between rAAVs and benchmarks. Overall, we demonstrate that snRNA-seq can be used to both effectively determine cell-type specific tropism of barcoded rAAVs, and quantitate relative transduction between multiple rAAVs in a single experiment. These developments open up opportunities for further designing and validating rAAVs capable of cell-type specific targeting for gene therapy. Additionally, this approach enables a medium throughput identification of rAAVs with desired properties for further study. Details of the single nuclear experimental workflow that was applied to the medium throughput study described in this example are below: 191 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Materials EZ lysis buffer + 0.2 U/μl of murine RNAse inhibitor 1X PBS + 9% BSA + 0.2 U/μl murine RNAse inhibitor 1X PBS + 5% BSA + 0.2 U/μl of murine RNAse inhibitor/Wash 1X PBS + 2% BSA + 0.2 U/μl of murine RNAse inhibitor Two 15 ml tubes pre-coated with 2% BSA+1x PBS+0.2 U/μl RNAse inhibitor Six 1.5 ml protein lobind tubes pre-coated with 2% BSA+1x PBS+0.2 U/μl RNAse inhibitor One 2 ml dounce homogenizer + Pestle A and Pestle B 2x 0.4 μm filters 2x 0.7 μm filters 1 ml wide bore pipette tips Hemocytometer 4-60.5 ml protein lobind tube with 15 μl of 1xPBS+5%BSA+ Single nuclei dissociation from Retina and Trabecular Meshwork Mincing: For the retina, the tissue sample was placed in a tube on ice and 100 μl of EZ lysis buffer + RNAse inhibitor was added. The tissue was minced with a pair of microscissors for about 1 min while holding the tube on ice.50 μl of the minced sample was transferred to a 2 ml dounce homogenizer.1-2 ml of Trizol was added to the rest of the sample for paired bulk RNA extraction and sequencing. For the trabecular meshwork, the tissue was transferred to a new 1.5 ml tube and 50 μl of EZ lysis buffer + RNAse inhibitor was added. The tissue was minced with a pair of microscissors for about 1 min while holding the tube on ice. The minced tissue was transferred to a 2 ml dounce homogenizer. Dounce homogenization: More EZ lysis buffer + RNAse inhibitor was added to the dounce homogenizer with sample to make up the volume to 2ml. A loose fitting pestle (Pestle A) was used to dounce the sample with 10 steady strokes (about 1 stroke per second). The sample was allowed to stand on ice for 20 seconds and then was dounced with a tight fitting pestle (Pestle B) with 5 steady strokes. The sample was again allowed to stand on ice for 20 seconds and dounced for another 5 strokes with Pestle B. Filtration and clean up: Post douce the sample (2 ml) was immediately transferred to a 15 ml falcon tube containing 2 ml of 9.5%+1x PBS+RNAse Inhibitor. The sample was mixed and first filtered through a 70 micron filter and then through a 40 micron filter. A small (5 μl) 192 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT aliquot of the filtered sample was diluted 1:4 in 1xPBS+2% BSA+propidium iodide (PI) for counting. The sample (about 4 ml now) was split equally into four 1.5 ml protein lobind centrifuge tubes precoated with 2% BSA+1xPBS+RNAseInhibitor. The samples were centrifuged at 200 RCF for 5 mins at 4 C. The supernatant was discarded and the pellet was resuspended in 5% BSA+1xPBS+RNAse-Inhibitor+PI. FACS cleanup: The nuclei were then sorted on a WOLF sorter. We gated for intact nuclei that were positively stained for PI. We also discarded any doublets by gating with the area under the curse for PI as a proxy for doublets. The FACS cleaned nuclei were centrifuged at 200 RFC for 5 mins at 4C. The pellet was resuspended in 2% BSA+1xPBS+RNAse-inhibitor and counted. Final nuclei concentration was adjusted as needed for 10x encapsulation. 10x Encapsulation and library preparation: We then used the 10X chromium platform for single cell encapsulation as per the manufacturer’s standard instructions. Reverse transcription was performed as per 10x protocols. cDNA amplification was performed using the 10X feature barcode cDNA amplification kit with a Dyno viral transcript specific forward primer spiked in. Post cDNA amplification a portion of the cDNA library was used to generate gene expression library as per 10x standard protocol. A small portion of the same cDNA library was used to generate targeted libraries by PCR amplifying the Dyno barcode region. Primers binding to either the Nextera Handle or the TruSeq Handle, in combination with a viral transcript specific primer, were used for the targeted amplification. When amplifying using the TruSeq-Handle primer, a gel extraction step was performed right after the targeted amplification to select out the product of interest from the larger linearly amplified background. Once the targeted amplification product was purified we performed pre-indexing and indexing PCRs and sequenced the libraries using an illumina Next Seq sequencer. Single nuclei RNA sequencing Data analysis: Gene expression libraries were demultiplexed using Illumina bcl-convert with default settings, then aligned to Macaca fascicularis reference genome (v6.0, assembly GCA_011100615.1) and quantified using the CellRanger pipeline v7.1.0 with intron mode activated. Doublet detection and filtering was performed using Scrublet package v0.2.3. Dimensionality reduction, batch effect removal, clustering, and identification of marker genes were carried out using Scanpy v1.9.3. Identification of cell types was performed with an in- house algorithm that projects cell type labels from reference datasets, which we curated from 193 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT published literature (Swamy et al., GigaScience, Vol.10, 2021; van Zyl et al., PNAS, Vol. 117, 2020, each of which is incorporated herein by reference in its entirety). Targeted libraries were processed using an in-house pipeline to obtain the identities of transducing variants and the 10X feature barcode. To completely remove chimeric molecules, we performed transcript per transcript (TPT) filtering (Dixit, bioRxiv 093237, 2021, which is incorporated herein by reference in its entirety) with a threshold of 0.5. Targeted libraries were then filtered against gene expression libraries to associate cell type information and limit the analysis to valid cell barcodes. The data was further filtered with a cut-off of 10 reads per molecule to remove any remaining sequencing artifacts. Finally, cells with more than 20 observed transduction events, which likely represent clumping artifacts, were excluded from downstream analysis. To calculate the normalized transduction rate of variant i in cell type j, the number of transduction events for variant i observed in cell type j was divided by the population count of cell type j. This value was then further normalized by the amount of virus reads for the cell type j to generate the data shown in FIGs.3A – 3E. To generate the data shown in FIGs.4A- 6B, this value was then further normalized by the amount of vector genome (vg) dosed, which is defined as the fraction of sequenced test article DNA reads belonging to variant i multiplied by total vg dosed into the eye (transduction efficiency of variant i in cell type j = (transduction events i/number of cells j)/# of dose vector genomes for variant i). The error bars were computed by bootstrapping cell barcodes (N=2000), calculating the resulting resampled rates, and identifying the 5th and 95th percentiles of the sampled distributions. Control experiments comprising a mixture of 5% HEK293 cells transduced with the library of variants and 95% untransduced NHP liver cells were performed to determine the sensitivity of the assay. After processing and data analysis, we were able to determine that 6% of all nuclei processed were HEK-293 nuclei and detected viral transcripts from the library in approximately 20% of the HEK-293 nuclei. This sensitivity is sufficient to identify and characterize viral vectors comprising variant capsid polypeptides from the medium throughput study described herein. Next, we sequenced data from nuclei isolated from NHP posterior eye and anterior eye tissue. We plotted RNA transcript data on a UMAP plot (Leiden clustering) to show major cell types when projected onto an annotated eye reference dataset using PCA (Swamy, VS et al., Gigascience 2021, incorporated herein by reference). This allowed us to annotate major cell types of the eye, including Amacrine cells, bipolar cells, cones, horizontal cells, 194 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT microglia, Muller glia, retinal ganglion cells, and rods. Using cell-type specific markers from the literature (Menon M et al., Nature Comm.2019; Peng Y et al., Cell, 2019, both incorporated herein by reference) we confirmed expected expression patterns from these cell clusters. FIGs.3A and 3E show the cell-type specific transduction for AAV2 (FIG.3A), and VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-8, VAR-10, VAR-11, and VAR-12 (FIG.3E) from tissue samples from intravitreal administration (IVT) of the medium throughput study, where the results are normalized to the amount of virus reads. The error bars show 95% confidence interval, estimated by randomly resampling the cells 2000 times. FIGs.4A-4E show the cell type specific transduction for AAV2 (FIG.4A) and variants (FIG.4B-4E) from retina tissue samples from IVT administration of the medium throughput study, where the results are normalized to the amount of vector genome (vg) dosed. FIGs. 5A-5D shows the cell type specific transduction for variants from macula tissue samples from IVT administration of the medium throughput study, where the results are normalized to the amount of vector genome (vg) dosed. The retina tissue samples used for generating the data shown in FIGs.3A, 3B, 3C, 3D, 3E, 4A, 4B, 4C, 4D, and 4E were from regions of the neural retina layer outside the macular region and, in this way, the data may be considered to show transduction of cell types in the non-macular region of the retina. In contrast, FIGs.5A-5D shows transduction of cell types in the macular region of the retina. FIGs.6A-6B shows the cell type specific transduction for variants from trabecular meshwork tissue samples from the IVT administration of the medium throughput study, where the results are normalized to the amount of vector genome (vg) dosed. No transduction of AAV2 wild-type for any of the listed cell types in FIGs.5A-5D and 6A-6B were detected in macula and trabecular meshwork tissue samples from the IVT administration of the medium throughput study. The error bars show 95% confidence interval, estimated by randomly resampling the cells 2000 times. For each of the above-described figures, lack of a data bar for a specific cell type indicates that there was no transduction of that cell type detected for AAV2 wild-type or the particular variant. For example, there is no data bar for cones in the data plot for AAV2 wild-type in FIG.4A, which means that there was zero transduction of AAV2 wild-type detected in cones as part of the IVT administration of the medium throughput study. Results Production results for the variants described herein are summarized in Tables 1D and 1E, transduction results from bulk tissue are summarized in Tables 1D, 1E, and 1F, biodistribution results from bulk tissue are summarized in Tables 4D and 4E, and single cell 195 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT results are shown in FIGs.3A-6B. VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR- 8, VAR-10, VAR-11, VAR-12, VAR-13 each display comparable or improved productivity as compared to WT AAV2. Similarly, as described herein and as shown in the Tables and Figures, variants described herein show improved biodistribution and/or transduction in the neural retina as compared to WT AAV2 by bulk and/or single-cell sequencing analyses. For example, VAR-6 shows greater than 60-fold and 400-fold improvements in transduction measured in bulk neural retina (aggregated macular and non-macular tissue samples) and macular retina, respectively. Single-cell analyses of VAR-6 in these tissues showed improved transduction in all major neural retina cell types, with highest rate of improvement in retinal ganglion cells followed by amacrine cells and cones. As yet another example, VAR-2 shows greater than 30-fold and 200-fold improvements in transduction measured in bulk neural retina (aggregated macular and non-macular tissue samples) and macular retina, respectively. Single-cell analyses of VAR-2 in these tissues showed highest rate of improved transduction in retinal ganglion cells. Biodistribution and transduction in the anterior eye samples containing trabecular meshwork and Schlemm’s canal were compared to a virus particle having capsid polypeptides of SEQ ID NO: 72. VAR-6 showed an increase in trabecular biodistribution and transduction over the virus particle comprising capsid polypeptides of SEQ ID NO: 72. VAR-3 showed an increase in trabecular biodistribution over the virus particle comprising capsid polypeptides of SEQ ID NO: 72. Single-cell analyses revealed that VAR-2 and VAR-6 have improved transduction in beam cells, a cell type responsible for proper function of the trabecular meshwork. Without being bound by theory, altogether these findings indicate that the variants described herein are suitable for gene therapies where targeting the eye is important, for example, as described herein. We next analyzed the structure of the variants described herein, for example the variants with improved transduction and/or biodistribution to one or more regions of the eye. Several variants comprise a sequence (e.g., a peptide insertion, one or more substitutions) in the surface exposed loop containing the heparin-binding domain relative to wild-type AAV2 capsid polypeptides. The insertion site originates after glutamine (Q) at position 584, glycine (G) at position 586 or asparagine (N) at position 587 (WT AAV2 VP1 numbering, SEQ ID NO:1). The insertions were between 8 and 11 amino acids in length. In addition, many of the variants described herein with insertion peptides originating at a position N-terminal to N587 (according to WT AAV2; SEQ ID NO: 1), for example those variants with an insertion peptide after G586 (according to WT AAV2; SEQ ID NO: 1) comprise a mutation at position 196 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT N587 (according to SEQ ID NO: 1) to alanine (e.g., VAR-1, VAR-3, VAR-5, VAR-6, VAR- 7, VAR-8, VAR-9, VAR-10, and VAR-13). VAR-1, VAR-4, VAR-5, VAR-8, and VAR-10 further comprise additional substitutions outside the insertion, as shown in Tables 1A-1F. VAR-4, VAR-5, VAR-6, and VAR-13 each comprise a “TRPA” motif, such as formed by an insertion having an insertion peptide C-terminal “TRP” motif followed by an alanine substitution (e.g., N587A substitution). Without being bound by theory, these results suggest that variant capsid polypeptides comprising a N587 substitution mutation, for example a N587A substitution mutation, in combination with a N-terminally juxtaposed insertion peptide (e.g., a peptide comprising at its C-terminal end threonine, arginine, proline (“TRP”)), have increased ocular retinal transduction and/or biodistribution. In some embodiments, the peptide insertion is 9 or 10 amino acids. VAR-2, VAR-7, VAR-10, and VAR-12 each comprise a “TARPA” motif, such as formed by an insertion having a C-terminal “TARP” motif followed by an alanine substitution (e.g., N587A substitution), an insertion having a C-terminal “TARPA” motif, or an insertion having a C-terminal “TA” motif followed by an arginine (e.g., R586), a proline substitution (e.g., G586P substitution), and an alanine (e.g., N587A substitution). Without being bound by theory, these results suggest that variant capsid polypeptides comprising a sequence threonine-alanine-proline-alanine (“TARPA”), including formed, for example as a combination of insertion and substitution mutations relative to WT AAV2 (SEQ ID NO: 1), have increased ocular retinal transduction and/or biodistribution. In some embodiments, the variant capsid polypeptides comprise a N587 substitution mutation, for example a N587A substitution mutation, in combination with a N-terminally juxtaposed insertion peptide (e.g., a peptide comprising at its C-terminal end threonine, alanine, arginine, and proline (“TARP”) or with a G586 substitution (e.g., G586P substitution) and an insertion peptide N-terminally juxtaposed to arginine at position 586 comprising at its C-terminal end threonine and alanine (“TA”), have increased ocular retinal transduction and/or biodistribution. In some embodiments, the variant capsid polypeptides comprise an insertion peptide comprising at its C-terminal end threonine, alanine, arginine, proline, and alanine (“TARPA”). In some embodiments, the peptide insertion is fewer than 11 amino acids. In some embodiments, the peptide insertion is 8 or more amino acids, for example, 8, 9, 10, or 11 amino acids. VAR-1 and VAR-3 each comprise a “MRPA” motif, such as formed by an insertion having a C-terminal “MRP” motif followed by an alanine substitution (e.g., N587A substitution). Without being bound by theory, these results suggest that variant capsid 197 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT polypeptides comprising a N587 substitution mutation, for example a N587A substitution mutation, in combination with a N-terminally juxtaposed insertion peptide comprising at its C-terminal end methionine, arginine, proline (“MRP”) having increased ocular retinal transduction and/or biodistribution. In some embodiments, the peptide insertion is 9 amino acids. In some embodiments, the peptide insertion comprises a sequence LAKGETMRP (SEQ ID NO: 36). Variants described herein illustrate the impact that one or more additional substitution mutations may have on increasing neural retina transduction and/or biodistribution. For example, both VAR-5 and VAR-13 each comprise an insertion peptide comprising a sequence GVRAETTRP inserted between positions G586 and N587 (according to WT AAV2; SEQ ID NO: 1) and an alanine (A) substitution at N587 (e.g., N587A substitution). VAR-5 differs from VAR-13 in that VAR-5 includes the additional mutation of an asparagine (N) at position T597 (e.g., T597N substitution). VAR-5 has increased neural retina transduction and biodistribution ~9.4-fold and ~9.0-fold relative to WT AAV2, respectively, both of which are higher than for VAR-13, which has neural retina transduction and biodistribution of ~5.7-fold and ~6.3-fold relative to WT AAV2, respectively. As another example, VAR-1 and VAR-3 each comprise an insertion peptide comprising a sequence LAKGETMRP inserted between positions G586 and N587 (according to WT AAV2; SEQ ID NO: 1) and an alanine (A) substitution at N587 (e.g., N587A substitution). Similar to VAR-5, VAR-1 comprises an asparagine (N) at position T597 (e.g., T597N substitution). VAR-1 further comprises a histidine (H) substitution at N551 (e.g., N551H substitution) and an alanine (A) substitution at Q589 (e.g., Q589A substitution). VAR-1 has increased neural retina transduction and biodistribution ~13.2-fold and ~12.1-fold relative to WT AAV2, respectively, both of which are higher than for VAR-3, which has neural retina transduction and biodistribution of ~7.8-fold and ~7.2-fold relative to WT AAV2, respectively. Neural retina transduction and biodistribution from retina tissue samples from intravitreal (“IVT”) administration of the medium throughput study (Example 3) for VAR-1, VAR-3, VAR-5, and VAR-13 are shown in FIG.7. Without being bound by theory, these results suggest that variant capsid polypeptides comprising an asparagine (N) at position T597 (according to WT AAV2; SEQ ID NO: 1) in combination with additional mutations, including, for example, a peptide insertion and one or more addition substitution mutations, have increased ocular retinal transduction and/or 198 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT biodistribution compared to variant capsid polypeptides comprising only those additional mutations. In some embodiments, the variant capsid polypeptides comprise a peptide insertion. In some embodiments, the peptide insertion is between positions G586 and N587 (according to WT AAV2; SEQ ID NO: 1). In some embodiments, the peptide insertion comprises sequence GVRAETTRP (SEQ ID NO: 38). In some embodiments, the peptide insertion comprises sequence LAKGETMRP (SEQ ID NO: 36). In some embodiments, the variant capsid polypeptide comprises an alanine (A) substitution at N587 (e.g., N587A substitution). In some embodiments, the variant capsid polypeptides comprise a histidine (H) substitution at N551 (e.g., N551H substitution). In some embodiments, the variant capsid polypeptides comprise an alanine (A) substitution at Q589 (e.g., Q589A substitution). In the neural retina, variants described herein have increased biodistribution in aggregated neural retina and macular retina relative to WT AAV2 by ~1.1-12-fold and ~4.8- 187-fold, respectively, in bulk sequencing experiments. Increased macula biodistribution may arise from the inner limiting membrane (ILM) being thinner in the macula, and thus a variant with improved ILM penetrance could therefore present with improved increase in biodistribution in the macular retina in comparison to the aggregated neural retina. Variants described herein have greater transduction in the macula (~6.1-447-fold relative to WT AAV2) than in the aggregated neural retina (~2.1-66-fold relative WT AAV2). In particular, VAR-6 has transduction in the macula greater than 400-fold relative to WT AAV2 and transduction in the aggregated neural retina greater than 60-fold relative to WT AAV2. VAR-2 has transduction in the macula greater than 200-fold relative to WT AAV2 and transduction in the aggregated neural retina greater than 30-fold relative to WT AAV2. In general, increases in relative transduction were higher than in relative biodistribution in macula and aggregated neural retina. However, for some variants described herein the opposite was observed. This may imply that improved transduction properties may not solely be caused by increased ILM penetrance, and that the designed capsid modifications may have an impact on other functional properties of the capsid. As an example, VAR-6 showed a significant increase in transduction between aggregated neural retina and macula (~6.7-fold), but relative low increase in biodistribution between aggregated neural retina and macula (~1.3-fold), particularly as compared to VAR-10, which had one of the largest increase in biodistribution between aggregated neural retina and macular retina (~17-fold) of the variants described herein included in Library Experiment 3. In addition, variants described herein 199 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT transduce macular retina more efficiently than aggregated neural retina, indicating that none of these variants specifically de-target the macular retina. Relative transduction efficiencies of the variants described herein were also measured in single-nucleus sequencing experiments. Of the variants included in Library Experiment 3, VAR-8 has the highest transduction efficiency in macular and non-macular retina cells, corresponding to bulk sequencing measurements for VAR-6. For each of VAR-2, VAR-5, VAR-6, VAR-7, VAR-10, and VAR-13 retinal ganglion cells were the most efficiently transduced cell type in both macular and non-macular retina. Some variants exhibited differences in relative transduction efficiencies for different cell types in macular and non- macular retina cells. For VAR-1, retinal ganglion cells and amacrine had similar transduction efficiencies in non-macula retina cells, but retinal ganglion cells were transduced at a higher efficiency than amacrine cells in macular cells. For VAR-3, retinal ganglion cells and cone photoreceptors had similar transduction efficiencies in non-macula retina cells, but retinal ganglion cells were transduced at a higher efficiency than cone photoreceptors in retina cells. Transduction of both cone and rod photoreceptors was observed with VAR-1, VAR-2, VAR- 3, VAR-5, VAR-6, and VAR-10 in both macular and non-macular retina cells. VAR-6 was the most efficient transducer of both cone and rod photoreceptors in non-macular retina cells. In the anterior eye, transduction was measured in samples containing the trabecular meshwork and the Schlemm’s canal by vectors delivered via intravitreal route of administration. Both biodistribution and transduction were increased over a virus particle comprising capsid polypeptides of SEQ ID NO: 72 by VAR-6 (~2.7-fold for biodistribution and ~2.7-fold for transduction). Biodistribution was increased over a virus particle comprising capsid polypeptides of SEQ ID NO: 72 by VAR-3 (~1.2-fold). Improved transduction of VAR-1, VAR-2, VAR-6, VAR-7, and VAR-11 following intravitreal delivery was also detected in single-nucleus sequencing experiments. Single-cell sequencing showed most efficient transduction by VAR-6, with highest transduction in ciliary muscle. Transduction was detected in beam cells for VAR-2 and VAR-6, and transduction was detected in juxtacanalicular cells for VAR-7. Both beam and juxtacanalicular cells are components of the trabecular meshwork. Variants described herein (e.g., VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-10 and VAR-13) are efficient in transducing several types of retinal cells via intravitreal delivery, particularly retinal ganglion cells, both in macular and non-macular retina. Therefore they have potential to be used in gene therapy applications for 200 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT neuroprotective treatments to prevent retinal ganglion cell degeneration associated with several ocular disorders, such as glaucoma, diabetic retinopathy, and retinitis pigmentosa. Transduction of both rod and cone photoreceptors was also detected by the variants described herein in non-macular retina (e.g., VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-8 and VAR-10) and in macular retina (e.g., VAR-1, VAR-2, VAR-3, VAR-5, VAR-6, VAR-7, VAR-10 and VAR-11), indicating their potential as vectors for retinal diseases where photoreceptors are affected, such as achromatopsia, retinitis pigmentosa, and forms of Leber congenital amaurosis. For ocular diseases where photoreceptors may no longer be present, transduction of the remaining retinal cells such as bipolar cells and Müller glia may enable optogenetic treatment strategies. The variants described herein (e.g., VAR-1, VAR-2, VAR- 3, VAR-5, VAR-6, VAR-8, VAR-10 and VAR-13) may be used in developing optogenetic gene therapies by transducing bipolar cells and Müller glia. Finally, overall high transduction efficiency in the retina suggests that the variants may have potential in treating wet age- related macular degeneration. Variants described herein have increased efficiency in transducing beam cells (e.g., VAR-2 and VAR-6) and juxtacanalicular cells (e.g., VAR-7) in the trabecular meshwork following intravitreal delivery. Therefore they have potential to be used in gene therapies aimed at influencing intraocular fluid balances and therefore intraocular pressure and to provide treatment options for related diseases, such as glaucoma. Example 4 To enable transduction of deeper retinal cell layers, current AAV-mediated ocular gene therapies require high doses to achieve clinically relevant efficacy which increases the risk of adverse inflammatory responses, or employ subretinal injections that must be performed by trained surgeons. More efficient cell-type targeted pan-retinal transduction via intravitreal (IVT) administration would allow for more effective therapies at lower and safer doses, broadening the reach of ocular gene therapies. Using machine-guided design we generated variant capsids with up to 80 times more efficient transduction of the neural retina in non-human primates (NHP) following IVT delivery as compared to AAV2. We then evaluated cell-type specific transduction patterns in the neural retina by single-nucleus RNA-seq. Relative to an AAV2-derived literature variant reported to have improved retinal transduction, these capsids demonstrated 2-6x improvement in retinal cell types including rods, cones, microglia and retinal ganglion cells. 201 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Extrapolating to a conservative dose of 8.0e10 vg/eye, we infer that these variants are capable of transducing a high proportion of cells across retinal cell types, for example up to 17% in retinal ganglion cells. The true proportion of transduced cells is likely even higher due to incomplete capture of transduction events in single nucleus sequencing. We selected one top capsid for further validation and injected it intravitreally into NHP eyes. Qualitative and quantitative in-life and histological readouts for transduction properties were performed based on reporter transgene expression. Histological readouts confirmed the variant’s significantly improved transduction efficiency compared to AAV2-derived literature variants. These results show the utility of single-molecule based NGS-based readouts in both library and validation contexts and demonstrate the power of applying machine learning to capsid design. Example 5 Table 10A, Table 10B, and Table 11 list information regarding exemplary variant dependoparvovirus particles comprising the variant capsids from Library Experiment 2 (Example 1), and describing the ocular transduction properties and production characteristics of said non-limiting exemplary variants. Exemplary sequences of capsid polypeptides and nucleic acid molecules encoding the same are provided in Table 9. Table 9 illustrates the VP1, VP2 and VP3 polypeptide starting amino acid sequences of each of SEQ ID NO: 48 to SEQ ID NO: 59. The exemplary nucleic acid sequences provided in Table 9 include a stop codon at the 3’-end of the sequence (e.g., the TAA stop codon). It will be understood by a skilled artisan that in some embodiments, the TAA stop codon is removed or replaced with a different stop codon (e.g., TGA or TAG). Table 9 Capsid Amino Acid Sequence of VP1 Exemplary Nucleic Acid Molecule A A T A C C C G C A IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 203 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 204 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 205 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 206 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 207 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 208 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 209 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 210 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T A T T G A C G A A T G G A A T A C C C G C A 211 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C A T A A A A C A T T C A A T A C C C G C A 212 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C A T A A A A C A T T C A A T A C C C G C A 213 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT SSQSGASNDNHYFGYSTPWGYFDFNR ACCTCTGGGCCTGGTTGAGGAACCTGTTAAGACGGCTC FHCHFSPRDWQRLINNNWGFRPKRLN CGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAG FKLFNIQVKEVTQNDGTTTIANNLTS CCAGACTCCTCCTCGGGAACCGGAAAGGCGGGCCAGCA G G T G G C A C G T G A A G G G G A G T A T G A T T A G G A A C T C C T A A A A C A T T C Table 10A and Table 10B represent data produced in the second high throughput experiment (Library Experiment 2). Transduction and virus production of exemplary variant dependoparvovirus (e.g., AVV) particles comprising variant capsid polypeptides. Injection route is as indicated in the column headings. Substitutions are notated as n###N where “N” is the final amino acid, “n” is the reference amino acid and “###” is the reference amino acid 214 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT position of SEQ ID NO: 1; deletions are notated as n###- where “-“ indicates the deletion of “n” at position “###” of the reference sequence SEQ ID NO: 1; insertions are notated as ###_Naa_###_(n)y, where “###” are the amino acid positions in the reference sequence SEQ ID NO: 1 between which the insertion occurs, “Naa” refers to the length of the insertion (having “N” amino acids) and “(n)y” providing the sequence of the insertion). Each individual Mutation Difference (e.g., within a row, each mutation in quotations (‘’) in column 4 of Table 10A, or column 8 of Table 1B) and combinations of such individual mutation differences is sometimes referred to herein as a “mutation associated with VAR-X”, where VAR-X is the variant identifier listed in the “Name column.” Choroid Transduction refers to transduction of the choroid layer of tissues in the eye. Macular Retina Transduction refers to transduction of the neural retina layer of tissues in the macula. Non-Macular Retina Transduction refers to transduction of the neural retina layer of the retina excluding the macula. Retinal Transduction refers to the aggregated measurements from Macular Retina Transduction and Non-Macular Retina Transduction. Trabecular Transduction refers to transduction of tissue samples collected from the trabecular meshwork and/or Schlemm’s canal. For purposes of Tables 10B, Neural Retina Transduction refers to transduction of tissue samples collected from the neural retina layer, including the macular region. “Not Measured” indicates the variant was not detected in the indicated sample. Unless otherwise indicated, measurements are made relative to wild-type AAV2 (SEQ ID NO: 1). Table 10A Nm SE ID Vir Prd tin Mttin Diff rn m rd t SE ID NO: ] ] IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT VAR-2559 0.53 [586_10aa_587_ANLAIEQTRP,N587A,Q598S] Name SEQ Choroid Retina Non- Macular Trabecular Mutation as 5 R 5 a , a , R , a , a , 5 R 5 a , a , a T a T _ 8 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT Table 11 lists information regarding biodistribution of variant dependoparvovirus particles comprising capsid polypeptides of the indicated variant capsid in the different layers, structures, and/or parts of the eye. In Table 11, biodistribution in choroid, retina, and trabecular meshwork is as measured following IVT injection, in each case in the Library Experiment 2. Unless otherwise indicated, measurements are made relative to wild-type AAV2 (SEQ ID NO: 1). Table 11 Name SEQ ID Biodistribution in Biodistribution in Biodistribution in s As described herein, VAR-6 comprises a peptide insertion comprising a sequence ANALAIEQTRP (SEQ ID NO: 39) inserted between positions G586 and N587 (according to WT AAV2; SEQ ID NO: 1) and has improved transduction and biodistribution for regions of the eye. VAR-23, VAR-24, and VAR-25 each comprise a peptide insertion comprising a sequence ANALAIEQTRP (SEQ ID NO: 39) inserted between positions G586 and N587 and have improved transduction and/or biodistribution for regions of the eye. For example, VAR-23, VAR-24, and VAR-25 each have greater than ~2-fold improved transduction in the macular retina relative to WT AAV2. Without being bound by theory, these results suggest that variant capsid polypeptides comprising a peptide insertion comprising a sequence 217 IPTS/124240467.1 Attorney Docket No. DYO-024WO PCT ANALAIEQTRP (SEQ ID NO: 39) inserted between positions G586 and N587 (according to WT AAV2; SEQ ID NO: 1) have increased ocular retinal transduction and/or biodistribution. In some embodiments, the variant capsid polypeptides comprise a mutation at position N587 (according to SEQ ID NO: 1) to alanine (e.g., as in VAR-6, VAR-23, VAR-24, and VAR- 25). As described herein, VAR-2 comprises a peptide insertion comprising a sequence RARLDETA (SEQ ID NO: 37) inserted between positions Q584 and G585 (according to WT AAV2; SEQ ID NO: 1) and has improved transduction and biodistribution for regions of the eye. VAR-14, VAR-15, VAR-16, VAR-17, VAR-18, VAR-19, VAR-20, VAR-21, and VAR-22 each comprise a peptide insertion comprising a sequence RARLDETA (SEQ ID NO: 37) inserted between positions Q584 and R585 and have improved transduction and/or biodistribution for regions of the eye. For example, VAR-14, VAR-15, VAR-16, VAR-17, VAR-18, VAR-19, VAR-20, VAR-21, and VAR-22 each have greater than ~2-fold improved transduction in the macular retina relative to WT AAV2. Without being bound by theory, these results suggest that variant capsid polypeptides comprising a peptide insertion comprising a sequence RARLDETA (SEQ ID NO: 37) inserted between positions Q584 and R585 (according to WT AAV2; SEQ ID NO: 1) have increased ocular retinal transduction and/or biodistribution. In some embodiments, the variant capsid polypeptides comprise a mutation at position G586 (according to SEQ ID NO: 1) to proline (e.g., as in VAR-2, VAR- 14, VAR-15, VAR-16, VAR-17, VAR-18, VAR-19, VAR-20, VAR-21, and VAR-22). In some embodiments, the variant capsid polypeptides comprise a mutation at position N587 (according to SEQ ID NO: 1) to alanine (e.g., as in VAR-2, VAR-14, VAR-15, VAR-16, VAR-17, VAR-18, VAR-19, VAR-20, VAR-21, and VAR-22). 218 IPTS/124240467.1